0000012208-24-000063.txt : 20241031 0000012208-24-000063.hdr.sgml : 20241031 20241031161435 ACCESSION NUMBER: 0000012208-24-000063 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241031 DATE AS OF CHANGE: 20241031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 241415380 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 10-Q 1 bio-20240930.htm 10-Q bio-20240930
000001220812/312024Q3false0.1xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Rate00000122082024-01-012024-09-300000012208us-gaap:CommonClassAMember2024-01-012024-09-300000012208us-gaap:CommonClassBMember2024-01-012024-09-300000012208us-gaap:CommonClassAMember2024-10-280000012208us-gaap:CommonClassBMember2024-10-2800000122082024-09-3000000122082023-12-310000012208us-gaap:CommonClassAMember2024-09-300000012208us-gaap:CommonClassAMember2023-12-310000012208us-gaap:CommonClassBMember2024-09-300000012208us-gaap:CommonClassBMember2023-12-310000012208us-gaap:TreasuryStockCommonMember2024-09-300000012208us-gaap:TreasuryStockCommonMember2023-12-3100000122082024-07-012024-09-3000000122082023-07-012023-09-3000000122082023-01-012023-09-3000000122082022-12-3100000122082023-09-300000012208us-gaap:CommonStockMember2023-12-310000012208us-gaap:AdditionalPaidInCapitalMember2023-12-310000012208us-gaap:TreasuryStockCommonMember2023-12-310000012208us-gaap:RetainedEarningsMember2023-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000012208us-gaap:CommonStockMember2024-01-012024-03-310000012208us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000012208us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000012208us-gaap:RetainedEarningsMember2024-01-012024-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-3100000122082024-01-012024-03-310000012208us-gaap:CommonStockMember2024-03-310000012208us-gaap:AdditionalPaidInCapitalMember2024-03-310000012208us-gaap:TreasuryStockCommonMember2024-03-310000012208us-gaap:RetainedEarningsMember2024-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100000122082024-03-310000012208us-gaap:CommonStockMember2024-04-012024-06-300000012208us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000012208us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000012208us-gaap:RetainedEarningsMember2024-04-012024-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-3000000122082024-04-012024-06-300000012208us-gaap:CommonStockMember2024-06-300000012208us-gaap:AdditionalPaidInCapitalMember2024-06-300000012208us-gaap:TreasuryStockCommonMember2024-06-300000012208us-gaap:RetainedEarningsMember2024-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000000122082024-06-300000012208us-gaap:CommonStockMember2024-07-012024-09-300000012208us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000012208us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000012208us-gaap:RetainedEarningsMember2024-07-012024-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000012208us-gaap:CommonStockMember2024-09-300000012208us-gaap:AdditionalPaidInCapitalMember2024-09-300000012208us-gaap:TreasuryStockCommonMember2024-09-300000012208us-gaap:RetainedEarningsMember2024-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000012208us-gaap:CommonStockMember2022-12-310000012208us-gaap:AdditionalPaidInCapitalMember2022-12-310000012208us-gaap:TreasuryStockCommonMember2022-12-310000012208us-gaap:RetainedEarningsMember2022-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000012208us-gaap:CommonStockMember2023-01-012023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000012208us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000012208us-gaap:RetainedEarningsMember2023-01-012023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100000122082023-01-012023-03-310000012208us-gaap:CommonStockMember2023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-03-310000012208us-gaap:TreasuryStockCommonMember2023-03-310000012208us-gaap:RetainedEarningsMember2023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100000122082023-03-310000012208us-gaap:CommonStockMember2023-04-012023-06-300000012208us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000012208us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000012208us-gaap:RetainedEarningsMember2023-04-012023-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000000122082023-04-012023-06-300000012208us-gaap:CommonStockMember2023-06-300000012208us-gaap:AdditionalPaidInCapitalMember2023-06-300000012208us-gaap:TreasuryStockCommonMember2023-06-300000012208us-gaap:RetainedEarningsMember2023-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000000122082023-06-300000012208us-gaap:CommonStockMember2023-07-012023-09-300000012208us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000012208us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000012208us-gaap:RetainedEarningsMember2023-07-012023-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000012208us-gaap:CommonStockMember2023-09-300000012208us-gaap:AdditionalPaidInCapitalMember2023-09-300000012208us-gaap:TreasuryStockCommonMember2023-09-300000012208us-gaap:RetainedEarningsMember2023-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000012208country:US2024-07-012024-09-300000012208country:US2023-07-012023-09-300000012208country:US2024-01-012024-09-300000012208country:US2023-01-012023-09-300000012208srt:EuropeMember2024-07-012024-09-300000012208srt:EuropeMember2023-07-012023-09-300000012208srt:EuropeMember2024-01-012024-09-300000012208srt:EuropeMember2023-01-012023-09-300000012208srt:AsiaPacificMember2024-07-012024-09-300000012208srt:AsiaPacificMember2023-07-012023-09-300000012208srt:AsiaPacificMember2024-01-012024-09-300000012208srt:AsiaPacificMember2023-01-012023-09-300000012208srt:AmericasMember2024-07-012024-09-300000012208srt:AmericasMember2023-07-012023-09-300000012208srt:AmericasMember2024-01-012024-09-300000012208srt:AmericasMember2023-01-012023-09-300000012208us-gaap:ResearchAndDevelopmentExpenseMemberbio:SaberBioAcquisitionMember2024-08-202024-08-200000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-09-300000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:BankTimeDepositsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000012208us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:FairValueMeasurementsRecurringMember2024-07-012024-09-300000012208us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300000012208bio:OrdinaryVotingSharesMember2024-09-300000012208bio:PreferenceSharesMember2024-09-300000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-09-300000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-09-300000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2024-09-300000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000012208us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-12-310000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2024-09-300000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2023-12-310000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2024-09-300000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2023-12-310000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2024-09-300000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2023-12-310000012208bio:OtherLongTermDebtMemberbio:OtherLongTermDebtMember2024-09-300000012208bio:OtherLongTermDebtMemberbio:OtherLongTermDebtMember2023-12-310000012208bio:LifeScienceMember2023-12-310000012208bio:ClinicalDiagnosticsMember2023-12-310000012208bio:LifeScienceMember2024-01-012024-09-300000012208bio:ClinicalDiagnosticsMember2024-01-012024-09-300000012208bio:LifeScienceMember2024-09-300000012208bio:ClinicalDiagnosticsMember2024-09-300000012208us-gaap:CustomerRelationshipsMember2024-09-300000012208bio:KnowHowMember2024-09-300000012208us-gaap:DevelopedTechnologyRightsMember2024-09-300000012208us-gaap:LicensingAgreementsMember2024-09-300000012208us-gaap:TradeNamesMember2024-09-300000012208us-gaap:NoncompeteAgreementsMember2024-09-300000012208us-gaap:InProcessResearchAndDevelopmentMember2024-09-300000012208us-gaap:CustomerRelationshipsMember2023-12-310000012208bio:KnowHowMember2023-12-310000012208us-gaap:DevelopedTechnologyRightsMember2023-12-310000012208us-gaap:LicensingAgreementsMember2023-12-310000012208us-gaap:TradeNamesMember2023-12-310000012208us-gaap:NoncompeteAgreementsMember2023-12-310000012208us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000012208bio:A33SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2024-09-300000012208bio:A33SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2023-12-310000012208bio:A37SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2024-09-300000012208bio:A37SeniorNotesDue2032Memberus-gaap:SeniorNotesMember2023-12-310000012208bio:FinanceLeasesandOtherDebtMemberbio:FinanceLeaseObligationsMember2024-09-300000012208bio:FinanceLeasesandOtherDebtMemberbio:FinanceLeaseObligationsMember2023-12-310000012208us-gaap:LineOfCreditMember2024-02-130000012208us-gaap:LineOfCreditMember2024-09-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000012208bio:LifeScienceMember2024-07-012024-09-300000012208bio:ClinicalDiagnosticsMember2024-07-012024-09-300000012208us-gaap:AllOtherSegmentsMember2024-07-012024-09-300000012208bio:LifeScienceMember2023-07-012023-09-300000012208bio:ClinicalDiagnosticsMember2023-07-012023-09-300000012208us-gaap:AllOtherSegmentsMember2023-07-012023-09-300000012208us-gaap:AllOtherSegmentsMember2024-01-012024-09-300000012208bio:LifeScienceMember2023-01-012023-09-300000012208bio:ClinicalDiagnosticsMember2023-01-012023-09-300000012208us-gaap:AllOtherSegmentsMember2023-01-012023-09-300000012208us-gaap:OperatingSegmentsMember2024-07-012024-09-300000012208us-gaap:OperatingSegmentsMember2023-07-012023-09-300000012208us-gaap:OperatingSegmentsMember2024-01-012024-09-300000012208us-gaap:OperatingSegmentsMember2023-01-012023-09-300000012208us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-300000012208us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000012208us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-300000012208us-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300000012208srt:MinimumMember2024-01-012024-09-300000012208srt:MaximumMember2024-01-012024-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period endedSeptember 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from______________to __________
Commission file number
001-07928
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware94-1381833
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive,Hercules,California94547
(Address of principal executive offices)(Zip Code)
(510)724-7000
(Registrant's telephone number, including area code)
No Change
(Former name, former address and former fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per shareBIONew York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share
BIO.B
New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes☒No☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).
Yes☒No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes☐No☒
.
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Shares Outstanding at October 28, 2024:
Class A - 22,921,856Class B - 5,074,909



BIO-RAD LABORATORIES, INC.

FORM 10-Q SEPTEMBER 30, 2024

TABLE OF CONTENTS

2

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this report include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our future financial performance, operating results, plans and objectives. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, the risks relating to our international operations, supply chain issues, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, reductions in government funding or capital spending of our customers, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under “Part II, Item 1A, Risk Factors” of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
3

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share data)

September 30, 2024December 31, 2023
ASSETS:(Unaudited)
Cash and cash equivalents$410,377 $403,815 
Short-term investments1,212,081 1,203,327 
Restricted investments5,560 5,560 
Accounts receivable, less allowance for credit losses of $12,139 as of September 30, 2024 and $14,926 as of December 31, 2023
461,940 489,017 
Inventory804,276 780,517 
Prepaid expenses133,228 140,040 
Other current assets28,158 26,054 
Total current assets3,055,620 3,048,330 
Property, plant and equipment, net545,304 529,007 
Operating lease right-of-use assets173,866 194,730 
Goodwill, net415,100 413,569 
Purchased intangibles, net307,325 320,514 
Other investments6,002,635 7,698,070 
Other assets103,622 94,850 
Total assets$10,603,472 $12,299,070 
























The accompanying notes are an integral part of these condensed consolidated financial statements.
4





BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(continued)
(In thousands, except share data)

September 30, 2024December 31, 2023
LIABILITIES AND STOCKHOLDERS’ EQUITY:(Unaudited) 
Accounts payable$122,185 $144,625 
Accrued payroll and employee benefits146,024 139,929 
Current maturities of long-term debt and notes payable1,262 486 
Income and other taxes payable43,625 35,759 
Current operating lease liabilities42,834 40,379 
Other current liabilities142,013 161,621 
Total current liabilities497,943 522,799 
Long-term debt, net of current maturities1,200,062 1,199,052 
Deferred income taxes1,076,058 1,475,495 
Operating lease liabilities143,919 165,478 
Other long-term liabilities197,631 195,113 
Total liabilities3,115,613 3,557,937 
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none
— — 
Class A common stock, shares issued 25,190,963 and 25,169,944 as of September 30, 2024 and December 31, 2023, respectively; shares outstanding 22,920,768 and 23,422,506 as of September 30, 2024 and December 31, 2023, respectively
2 2 
Class B common stock, shares issued and outstanding, 5,074,909 as of September 30, 2024 and 5,095,930 as of December 31, 2023, respectively
1 1 
Additional paid-in capital448,329 449,075 
Class A treasury stock at cost, 2,270,195 and 1,747,438 shares as of September 30, 2024 and December 31, 2023, respectively
(777,430)(632,536)
Retained earnings8,132,231 9,260,629 
Accumulated other comprehensive loss
(315,274)(336,038)
Total stockholders’ equity7,487,859 8,741,133 
Total liabilities and stockholders’ equity$10,603,472 $12,299,070 




The accompanying notes are an integral part of these condensed consolidated financial statements. 
5



BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income (Loss)
(In thousands, except per share data)
(Unaudited)
 Three Months EndedNine Months Ended
 September 30,September 30,
 2024202320242023
Net sales$649,729 $632,124 $1,899,025 $1,990,078 
Cost of goods sold293,826 296,441 862,037 929,495 
Gross profit355,903 335,683 1,036,988 1,060,583 
Selling, general and administrative expense200,440 201,199 610,042 634,576 
Research and development expense90,997 43,535 216,276 183,528 
Income from operations64,466 90,949 210,670 242,479 
Interest expense12,174 12,398 36,715 37,078 
Foreign currency exchange (gains) losses, net1,641 (1,680)(2,012)(5,280)
(Gains) losses from change in fair market value of equity securities and loan receivable(792,888)(36,425)1,680,290 1,576,542 
Other income, net(18,081)(20,446)(70,740)(87,365)
Income (loss) before income taxes861,620 137,102 (1,433,583)(1,278,496)
(Provision for) benefit from income taxes(208,448)(30,845)305,185 291,464 
Net income (loss)$653,172 $106,257 $(1,128,398)$(987,032)
Basic earnings (loss) loss per share:  
Net income (loss) per share$23.37 $3.65 $(39.89)$(33.63)
Weighted average common shares
27,949 29,102 28,286 29,349 
Diluted earnings (loss) per share:  
Net income (loss) per diluted share$23.34 $3.64 $(39.89)$(33.63)
Weighted average common shares - diluted27,985 29,223 28,286 29,349 




The accompanying notes are an integral part of these condensed consolidated financial statements. 
6

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Comprehensive Income (Loss)
(In thousands)
(Unaudited)
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Net income (loss)$653,172 $106,257 $(1,128,398)$(987,032)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments122,932 (126,165)6,570 (34,342)
Foreign other post-employment benefits adjustments(69)(342)815 (72)
Net unrealized holding gains on available-for-sale investments13,225 1,808 13,379 3,675 
Other comprehensive income (loss)136,088 (124,699)20,764 (30,739)
Comprehensive income (loss)$789,260 $(18,442)$(1,107,634)$(1,017,771)



The accompanying notes are an integral part of these condensed consolidated financial statements.

7

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
 Nine Months Ended
 September 30,
 20242023
Cash flows from operating activities:  
Cash received from customers$1,920,985 $2,007,482 
Cash paid to suppliers and employees(1,531,330)(1,722,173)
Interest paid, net(45,628)(46,394)
Income tax payments, net(75,710)(40,966)
Dividend proceeds and miscellaneous receipts, net
67,193 81,828 
Proceeds from (payments for) forward foreign exchange contracts, net(4,462)14,119 
Net cash provided by operating activities331,048 293,896 
Cash flows from investing activities:  
Payments for purchases of property, plant and equipment(122,686)(114,435)
Proceeds from dispositions of property, plant and equipment149 104 
Payments for acquired in-process research and development
(23,410)— 
Payments for purchases of marketable securities and investments(1,053,660)(537,540)
Proceeds from sales of marketable securities and investments900,493 339,033 
Proceeds from maturities of marketable securities and investments169,458 260,849 
Net cash used in investing activities(129,656)(51,989)
Cash flows from financing activities:  
Payments on long-term debt
(359)(349)
Payments for debt issuance costs
(617)— 
Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options15,290 14,168 
Tax payments from net share settlement(3,280)(10,118)
Payments for purchases of treasury stock(203,586)(228,728)
Net cash used in financing activities(192,552)(225,027)
Effect of foreign exchange rate changes on cash(1,021)6,891 
Net increase in cash, cash equivalents and restricted cash7,819 23,771 
Cash, cash equivalents and restricted cash at beginning of period404,369 434,544 
Cash, cash equivalents and restricted cash at end of period$412,188 $458,315 

Reconciliation of cash, cash equivalents and restricted cash (in thousands):
September 30,
20242023
Cash and cash equivalents$410,377 $457,850 
Restricted cash included in Other current assets1,376 79 
Restricted cash included in Other assets435 386 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$412,188 $458,315 

These restricted cash items are primarily related to performance guarantees and other restricted deposits.

The accompanying notes are an integral part of these condensed consolidated financial statements.

8



BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(In thousands)
(Unaudited)
Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)
Total Stockholders' Equity
Balance at December 31, 2023$3 $449,075 $(632,536)$9,260,629 $(336,038)$8,741,133 
Net income— — — 383,916 — 383,916 
Other comprehensive loss, net of tax— — — — (89,933)(89,933)
Share-based compensation expense— 15,262 — — — 15,262 
Purchase of treasury stock— — (4,702)— — (4,702)
Reissuance of treasury stock— (1,710)7,215 — — 5,505 
Excise tax on stock repurchase— — (47)— — (47)
Balance at March 31, 2024$3 $462,627 $(630,070)$9,644,545 $(425,971)$9,051,134 
Net loss— — — (2,165,486)— (2,165,486)
Other comprehensive loss, net of tax— — — — (25,391)(25,391)
Share-based compensation expense— 14,999 — — — 14,999 
Purchase of treasury stock— — (100,000)— — (100,000)
Reissuance of treasury stock— (2,745)7,428 — — 4,683 
Shares withheld related to net share settlement of equity awards— (152)— — — (152)
Excise tax on stock repurchase— — (1,000)— — $(1,000)
Balance at June 30, 2024$3 $474,729 $(723,642)$7,479,059 $(451,362)$6,778,787 
Net income— — — 653,172 — 653,172 
Other comprehensive income, net of tax— — — — 136,088 136,088 
Share-based compensation expense— 15,675 — — — 15,675 
Purchase of treasury stock— — (96,868)— — (96,868)
Reissuance of treasury stock— (38,947)44,049 — — 5,102 
Shares withheld related to net share settlement of equity awards— (3,128)— — — (3,128)
Excise tax on stock repurchase— — (969)— — $(969)
Balance at September 30, 2024$3 $448,329 $(777,430)$8,132,231 $(315,274)$7,487,859 




9

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(In thousands)
(Unaudited)
Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
Balance at December 31, 2022$3 $447,454 $(263,586)$9,898,203 $(466,822)$9,615,252 
Net income— — — 68,962 — 68,962 
Other comprehensive income, net of tax— — — — 58,470 58,470 
Share-based compensation expense— 16,608 — — — 16,608 
Reissuance of treasury stock— (660)5,290 (206)— 4,424 
Balance at March 31, 2023$3 $463,402 $(258,296)$9,966,959 $(408,352)$9,763,716 
Net loss— — — (1,162,251)— (1,162,251)
Other comprehensive income, net of tax— — — — 35,490 35,490 
Share-based compensation expense— 12,559 — — — 12,559 
Purchase of treasury stock— — (207,407)— — (207,407)
Reissuance of treasury stock— (2,089)6,919 (44)— 4,786 
Balance at June 30, 2023$3 $473,872 $(458,784)$8,804,664 $(372,862)$8,446,893 
Net income— — — 106,257 — 106,257 
Other comprehensive loss, net of tax— — — — (124,699)(124,699)
Issuance of common stock, net of shares withheld— (5,111)— — — (5,111)
Share-based compensation expense— 15,952 — — — 15,952 
Purchase of treasury stock— — (23,608)— — (23,608)
Reissuance of treasury stock— (45,258)45,772 — — 514 
Balance at September 30, 2023$3 $439,455 $(436,620)$8,910,921 $(497,561)$8,416,198 




The accompanying notes are an integral part of these condensed consolidated financial statements. 
10

BIO-RAD LABORATORIES, INC

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the loan receivable. Actual results could differ materially from those estimates.

Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is
11

allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.

We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.

We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.

Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).


12

Contract costs:

We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
United States$276.2 $275.4 $783.4 $858.8 
EMEA205.7 193.1 612.4 609.1 
APAC126.9 118.9 375.2 398.9 
Other (primarily Canada and Latin America)40.9 44.7 128.0 123.3 
Total net sales$649.7 $632.1 $1,899.0 $1,990.1 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).

Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2024 and December 31, 2023 was $64.0 million and $68.3 million, respectively. The short-term deferred revenue balance at September 30, 2024 and December 31, 2023 was $48.9 million and $51.1 million, respectively.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Changes in our warranty liability for the nine months ended September 30, 2024 and 2023 were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$8.4 $10.6 
Provision for warranty5.2 6.4 
Actual warranty costs(5.7)(9.0)
Balance at end of period$7.9 $8.0 

Accounts Receivable and Allowance for Credit Losses
We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.

13

Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.

Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$14.9 $15.0 
Provision for expected credit losses2.1 1.4 
Write-offs charged against the allowance(4.9)(1.3)
Balance at end of period$12.1 $15.1 

Saber Bio Acquisition

On July 26, 2024, the Company entered into a stock purchase agreement (the “Transaction”) to acquire all of the outstanding equity interests in Saber Bio (“Saber”). The Transaction closed on August 20, 2024. The Company accounted for the Transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single or similar in-process research and development project (“IPR&D”). The Company concluded that the acquired IPR&D does not meet the criteria for capitalization and expensed the acquired IPR&D. This amounted to $29.5 million which was recorded in Research and development expense in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024.

Recent Accounting Pronouncements Issued and to be Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, “Improvements to Reportable Segment Disclosures”. The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker ("CODM"). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.

In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However, on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures.


2. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value
14

measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•Level 1: Quoted prices in active markets for identical instruments
•Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2024 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Time deposits— 43.2 — 43.2 
Money market funds110.9 — — 110.9 
Total cash equivalents (a)110.9 43.2 — 154.1 
Restricted investments (b)7.1 — — 7.1 
Equity securities (c)5,701.4 — — 5,701.4 
Loan under the fair value option (d)— — 343.5 343.5 
Available-for-sale investments:
Corporate debt securities— 543.8 — 543.8 
U.S. government sponsored agencies— 147.0 — 147.0 
Foreign government obligations— 2.6 — 2.6 
Municipal obligations— 6.7 — 6.7 
Asset-backed securities— 433.2 — 433.2 
Total available-for-sale investments (e)— 1,133.3 — 1,133.3 
Forward foreign exchange contracts (f)— 2.2 — 2.2 
Total financial assets carried at fair value$5,819.4 $1,178.7 $343.5 $7,341.6 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $0.9 $— $0.9 
Contingent consideration (h)— — 18.3 18.3 
Total financial liabilities carried at fair value$— $0.9 $18.3 $19.2 


15

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $12.5 $— $12.5 
Time deposits— 36.6 — 36.6 
U.S. government sponsored agencies— 7.0 — 7.0 
Money market funds28.0 — — 28.0 
Total cash equivalents (a)28.0 56.1 — 84.1 
Restricted investments (b)7.1 — — 7.1 
Equity securities (c)7,399.3 — — 7,399.3 
Loan under the fair value option (d)— — 325.7 325.7 
Available-for-sale investments:
Corporate debt securities— 531.6 — 531.6 
U.S. government sponsored agencies— 255.9 — 255.9 
Foreign government obligations— 12.7 — 12.7 
Municipal obligations— 12.1 — 12.1 
Asset-backed securities— 323.7 — 323.7 
Total available-for-sale investments (e)— 1,136.0 — 1,136.0 
Forward foreign exchange contracts (f)— 4.1 — 4.1 
Total financial assets carried at fair value$7,434.4 $1,196.2 $325.7 $8,956.3 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $11.7 $— $11.7 
Contingent consideration (h)— — 17.5 17.5 
Total financial liabilities carried at fair value$— $11.7 $17.5 $29.2 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Restricted investments$5.6 $5.6 
Other investments1.5 1.5 
    Total$7.1 $7.1 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Short-term investments$78.7 $67.2 
Other investments5,622.7 7,332.1 
        Total$5,701.4 $7,399.3 

(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.
16


(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.4 million and $0.8 million in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2024.

Level 1 Fair Value Measurements

As of September 30, 2024, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG ("Sartorius"), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the outstanding ordinary shares (excluding treasury shares) and 27% of the preference shares of Sartorius as of September 30, 2024. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.

The change in fair market value of our investment in Sartorius for the three and nine months ended September 30, 2024 was a gain of $761.1 million and a loss of $1,711.0 million, respectively, and are recorded in our condensed consolidated statements of income (loss).

Level 2 Fair Value Measurements

To estimate the fair value of Level 2 debt securities as of September 30, 2024 and December 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

Available-for-sale investments consist of the following (in millions):
 September 30, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$536.6 $7.5 $(0.3)$543.8 
Municipal obligations6.6 0.1 — 6.7 
Asset-backed securities430.3 3.7 (0.8)433.2 
U.S. government sponsored agencies145.9 1.3 (0.2)147.0 
Foreign government obligations2.6 — — 2.6 
 $1,122.0 $12.6 $(1.3)$1,133.3 

17

The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2024 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$120.5 $120.4 
Mature in one to five years702.9 711.8 
Mature in more than five years298.6 301.1 
Total$1,122.0 $1,133.3 

Available-for-sale investments consist of the following (in millions):
 December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$534.1 $0.8 $(3.3)$531.6 
Municipal obligations12.2 — (0.1)12.1 
Asset-backed securities325.7 0.7 (2.7)323.7 
U.S. government sponsored agencies257.4 0.1 (1.6)255.9 
Foreign government obligations12.8 — (0.1)12.7 
Total$1,142.2 $1.6 $(7.8)$1,136.0 

As of September 30, 2024, there were no significant continuous unrealized losses greater than 12 months.

Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At September 30, 2024, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2024.
Included in Other current assets are $11.1 million and $11.9 million of interest receivable as of September 30, 2024 and December 31, 2023, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the nine months ended September 30, 2024, we have not written-off any uncollected interest receivable.

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of September 30, 2024 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was
18

derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).

The following is a summary of our forward foreign currency exchange contracts (in millions):

Contracts to sell foreign currency:
September 30, 2024December 31, 2023
Notional value$673.7 $873.5 
Unrealized gain/(loss)
$1.3 $(8.1)
Contracts to purchase foreign currency:
 
Notional value$44.4 $133.6 
Unrealized gain/(loss)
$— $0.5 

Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $8.0 million and $6.5 million as of September 30, 2024 and December 31, 2023, respectively.

Also included in Other investments in the condensed consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in Other income, net in our condensed consolidated statements of income (loss). The carrying value of these investments, net of impairments, was $26.8 million and $32.3 million as of September 30, 2024 and December 31, 2023, respectively.

The carrying value and fair value of our long-term debt were as follows (in millions):

September 30, 2024December 31, 2023
Carrying Value
Fair Value
Carrying ValueFair Value
Senior notes
$1,190.8 $1,119.9 $1,189.5 $1,102.5 
Other long-term debt
9.3 9.3 9.6 9.6 
Total
$1,200.1 $1,129.2 $1,199.1 $1,112.1 

The fair value of our long-term debt was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.

Level 3 Fair Value Investments

During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (“Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan
19

include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended September 30, 2024 was a gain of $25.2 million, which includes a $18.1 million gain from change in fair market value of the Loan and a $7.1 million gain from change in fair market value of the value appreciation right. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the nine months ended September 30, 2024 was a gain of $14.7 million, which includes a $33.1 million gain from change in fair market value of the Loan and a $18.4 million loss from change in fair market value of the value appreciation right. The increase in the fair market value of the value appreciation right was due to an increase in the value of the Sartorius ordinary shares. As of September 30, 2024, the €400 million principal amount of the loan is still due on January 31, 2029.

The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2023$325.7 
Change in estimated fair market value, net
$14.7 
Foreign currency exchange losses, net
$3.1 
September 30, 2024$343.5 

20


3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment are as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of January 1, 2024:
Goodwill$333.3 $415.5 $748.8 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net291.5 122.1 413.6 
Foreign currency adjustments— 1.5 1.5 
Period change, net
— 1.5 1.5 
Balances as of September 30, 2024:
Goodwill333.3 417.0 750.3 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$291.5 $123.6 $415.1 

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):
September 30, 2024
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists4.8$108.4 $(100.6)$7.8 
Know how1.0169.7 (165.2)4.5 
Developed product technology11.6219.3 (141.5)77.8 
Licenses4.259.3 (45.2)14.1 
Tradenames4.86.0 (4.9)1.1 
Covenants not to compete1.56.4 (5.4)1.0 
     Total finite-lived intangible assets569.1 (462.8)106.3 
In-process research and development201.0 — 201.0 
     Total purchased intangible assets $770.1 $(462.8)$307.3 

21

 December 31, 2023
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.2$108.7 $(98.9)$9.8 
Know how1.8168.9 (161.1)7.8 
Developed product technology12.0217.8 (132.9)84.9 
Licenses4.959.2 (42.4)16.8 
Tradenames5.66.1 (4.7)1.4 
Covenants not to compete2.36.4 (4.8)1.6 
     Total finite-lived intangible assets567.1 (444.8)122.3 
In-process research and development198.2 — 198.2 
     Total purchased intangible assets $765.3 $(444.8)$320.5 

Amortization expense related to purchased intangible assets is as follows (in millions):

Three Months EndedNine Months Ended
 September 30,September 30,
 2024202320242023
Amortization expense$5.3 $6.2 $16.1 $18.1 



4. INVENTORY

Following are the components of Inventory at September 30, 2024 and December 31, 2023 (in millions):

September 30, 2024December 31, 2023
Inventory:
  Raw materials$229.5 $231.6 
  Work in process255.2 246.0 
  Finished goods 319.6 302.9 
      Total Inventory$804.3 $780.5 

22


5. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):
Nine Months Ended
September 30,
20242023
Net loss$(1,128.4)$(987.0)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization112.4 108.7 
Reduction in the carrying amount of right-of-use assets31.1 30.7 
Share-based compensation45.9 45.1 
Acquired in-process research and development
29.5 — 
Losses from change in fair market value of equity securities and loan receivable1,680.3 1,576.5 
Changes in fair value of contingent consideration0.8 (18.5)
Payments for operating lease liabilities(32.2)(30.4)
Decrease in accounts receivable25.6 31.6 
Increase in inventories(16.0)(61.7)
(Increase) decrease in other current assets(4.7)15.0 
Decrease in accounts payable and other current liabilities(24.4)(72.4)
Increase in income taxes payable21.8 56.4 
Decrease in deferred income taxes(408.5)(397.4)
Increase in other long-term liabilities1.4 3.9 
Other(3.6)(6.6)
Net cash provided by operating activities$331.0 $293.9 
Non-cash investing activities:
Purchased property, plant and equipment$7.4 $2.9 
Purchased marketable securities and investments$5.7 $— 
Sold marketable securities and investments$0.2 $— 

23


6. LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):
September 30,
2024		December 31,
2023
3.3%, Senior Notes due 2027
$400.0 $400.0 
3.7%, Senior Notes due 2032
800.0 800.0 
Less unamortized discounts and debt issuance costs(9.2)(10.5)
Long-term debt less unamortized discounts and debt issuance costs1,190.8 1,189.5 
Finance leases and other debt10.6 10.1 
Less current maturities(1.3)(0.5)
Long-term debt$1,200.1 $1,199.1 

On February 13, 2024, we entered into a new $200.0 million unsecured revolving credit agreement ("Revolving Credit Agreement") with a group of financial institutions. The Revolving Credit Agreement replaced the Company's previous credit agreement, dated as of April 15, 2019. Borrowings under the Revolving Credit Agreement are on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. The Revolving Credit Agreement requires Bio-Rad to comply with certain financial ratios and other customary covenants and provisions. The Revolving Credit Agreement matures on February 13, 2029. As of September 30, 2024, no borrowings were outstanding under the Revolving Credit Agreement, although available capacity was reduced by immaterial outstanding letters of credit. As of September 30, 2024, we were in compliance with the covenants for the Revolving Credit Agreement.


7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2024:$(334.1)$(2.8)$0.9 $(336.0)
Other comprehensive income, before reclassifications6.6 0.1 19.1 25.8 
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)(1.7)(2.1)
Income tax effects(0.1)1.1 (4.0)(3.0)
Other comprehensive income, net of income taxes6.5 0.8 13.4 20.7 
Balances as of September 30, 2024:$(327.6)$(2.0)$14.3 $(315.3)
24

Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2023:$(466.5)$10.0 $(10.3)$(466.8)
Other comprehensive income (loss), before reclassifications(34.4)0.3 3.7 (30.4)
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)1.1 0.7 
Income tax effects0.1 — (1.1)(1.0)
Other comprehensive income (loss), net of income taxes(34.3)(0.1)3.7 (30.7)
Balances as of September 30, 2023:$(500.8)$9.9 $(6.6)$(497.5)

All amounts reclassified out of Accumulated other comprehensive income (loss) were reclassified into Other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.

The impact to Income (loss) before income taxes for amounts reclassified out of Accumulated other comprehensive income (loss) into Other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
Components of comprehensive income (loss)2024202320242023
Amortization of foreign other post-employment benefit items$0.1 $0.2 $0.4 $0.4 
Net holding gains (losses) on equity securities and available-for-sale investments
$2.0 $(0.1)$1.7 $(1.1)


8. EARNINGS (LOSS) PER SHARE

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock ("Class A") and Class B Common Stock ("Class B"). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one-tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.

We compute Net income (loss) per share of Class A and Class B using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the nine months ended September 30, 2024 and 2023.

25

Accordingly, Basic earnings (loss) per share is computed by dividing Net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings (loss) per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Basic weighted average shares outstanding27,949 29,102 28,286 29,349 
Effect of potentially dilutive stock options, restricted stock and performance stock awards36 121 — — 
Diluted weighted average common shares outstanding27,985 29,223 28,286 29,349 
Anti-dilutive shares257 154 411 229 


9. OTHER INCOME, NET

Other income, net includes the following components (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Interest and investment income$(15.5)$(17.3)$(66.1)$(84.1)
Net realized (gains) losses on investments
(2.0)0.1 (1.7)1.6 
Escrow receipts on prior acquisition— (2.5)— (2.5)
Other income(0.6)(0.7)(2.9)(2.4)
Other income, net$(18.1)$(20.4)$(70.7)$(87.4)



10. INCOME TAXES

Our effective income tax rate was 24.2% and 22.5% for the three months ended September 30, 2024 and 2023, respectively. Our effective income tax rate was 21.3% and 22.8% for the nine months ended September 30, 2024 and 2023, respectively.

The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of September 30, 2024, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $17.0 million for the period ended September 30, 2024 compared to the year ended December 31, 2023.

26

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our gross unrecognized tax benefits were $88.5 million and $84.7 million as of September 30, 2024 and December 31, 2023, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.

As of September 30, 2024, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $16.2 million. Substantially all such amounts will impact our effective income tax rate if recognized.

11. SEGMENT INFORMATION

Information regarding net sales and operating profit (loss) for the three months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$260.9 $388.8 $— 
 2023$263.5 $368.1 $0.5 
Operating profit (loss)2024$(9.8)$74.2 $0.1 
 2023$13.0 $78.0 $(0.1)

Information regarding Net sales and operating profit (loss) for the nine months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$753.1 $1,145.4 $0.5 
 2023$887.3 $1,100.3 $2.5 
Operating profit (loss)2024$1.1 $209.9 $(0.3)
 2023$76.7 $166.1 $(0.3)

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our CODM views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.
27


The following reconciles total operating profit to consolidated income (loss) before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Operating profit$64.5 $90.9 $210.7 $242.5 
Interest expense(12.2)(12.3)(36.7)(37.2)
Foreign currency exchange (losses) gains, net
(1.6)1.7 2.0 5.3 
Gains (losses) from change in fair market value of equity securities and loan receivable
792.8 36.4 (1,680.3)(1,576.5)
Other income, net18.1 20.4 70.7 87.4 
Consolidated income (loss) before income taxes
$861.6 $137.1 $(1,433.6)$(1,278.5)


12. LEGAL PROCEEDINGS

We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


13. LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 15 years, which includes our determination to exercise renewal options.

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt, net of current maturities in our condensed consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

The components of lease expense were as follows (in millions):
28

Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Operating lease cost$17.3 $15.7 $52.2 $47.2 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 $0.3 $0.3 
  Interest on lease liabilities0.2 0.2 0.5 0.6 
        Total finance lease cost$0.3 $0.3 $0.8 $0.9 

Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.

Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and nine months ended September 30, 2024 and 2023. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and nine months ended September 30, 2024 and 2023.

Supplemental cash flow information related to leases was as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$10.8 $10.6 $32.2 $30.4 
  Operating cash flows from finance leases$0.2 $0.2 $0.5 $0.6 
  Financing cash flows from finance leases$0.1 $0.1 $0.3 $0.3 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$0.1 $36.7 $11.3 $49.0 

Supplemental balance sheet information related to leases was as follows (in millions):
September 30, 2024December 31, 2023
Operating Leases
  Operating lease right-of-use assets$173.9 $194.7 
  Current operating lease liabilities$42.8 $40.4 
  Operating lease liabilities143.9 165.5 
     Total operating lease liabilities$186.7 $205.9 

Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt and notes payable, net of current maturities (in millions):
29

September 30, 2024December 31, 2023
Finance Leases
  Property, plant and equipment, gross$11.9 $11.9 
  Less: accumulated depreciation and amortization(6.2)(5.9)
      Property, plant and equipment, net$5.7 $6.0 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities9.3 9.6 
      Total finance lease liabilities$9.8 $10.1 

September 30, 2024December 31, 2023
Weighted Average Remaining Lease Term
  Operating leases - in years67
  Finance leases - in years1314
Weighted Average Discount Rate
  Operating leases4.0 %3.9 %
  Finance leases6.5 %6.4 %

Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2024 (excluding the nine months ended September 30, 2024)
$10.8 $0.3 
2025
49.0 1.1 
2026
37.3 1.1 
2027
28.8 1.1 
2028
22.2 1.1 
Thereafter64.1 10.8 
   Total lease payments212.2 15.5 
Less imputed interest(25.5)(5.7)
    Total$186.7 $9.8 

The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.

As of September 30, 2024, operating leases that have not commenced are not material.
30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This discussion should be read in conjunction with the information contained in both our consolidated financial statements for the year ended December 31, 2023 and the condensed consolidated financial statements for the three and nine months ended September 30, 2024.

Overview. We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and health care specialists with products needed for clinical diagnostics.

We sell more than 12,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components. As our customers require standardization for their experiments and test results, much of our revenues are recurring in nature.

We rely on the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control social spending by many governments limits opportunities for growth. Approximately 41% of our year-to-date 2024 consolidated net sales are derived from the United States and approximately 59% are derived from international locations, with Europe being our largest international region. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

We are impacted by ongoing global economic conditions and our business continued to be negatively impacted by the ongoing challenges impacting the biopharma market and small biotech companies. We expect that these conditions will continue to impact our business through the remainder of 2024 and into 2025.

Results of Operations

The following table shows Cost of goods sold, Gross profit, components of operating expense, (Gains) losses from change in fair market value of equity securities and loan receivable, and Net income (loss) as a percentage of Net sales:
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Net sales100.0 %100.0 %100.0 %100.0 %
Cost of goods sold45.2 46.9 45.4 46.7 
Gross profit54.8 53.1 54.6 53.3 
Selling, general and administrative expense30.8 31.8 32.1 31.9 
Research and development expense14.0 6.9 11.4 9.2 
(Gains) losses from change in fair market value of equity securities and loan receivable(122.0)(5.8)88.5 79.2 
Net income (loss)100.5 16.8 (59.4)(49.6)

31


Critical Accounting Policies and Estimates

An accounting policy is deemed to be critical if it affects our financial statements materially and requires subjective or complex judgements by management. An accounting estimate is deemed to be critical if it requires assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements. Management believes that there have been no significant changes during the three and nine months ended September 30, 2024 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

There have been no substantial changes in our significant accounting policies during the three and nine months ended September 30, 2024, compared with the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2023.

Three Months Ended September 30, 2024 Compared to
Three Months Ended September 30, 2023

Results of Operations -- Sales, Margins and Expenses

Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.

Net sales (sales) for the third quarter of 2024 were $649.7 million compared to $632.1 million in the third quarter of 2023, an increase of 2.8%. On a currency neutral basis, third quarter 2024 sales increased by approximately 3.4% compared to the same period in 2023. The increase in sales was driven by higher sales in our Clinical Diagnostics segment.

The Life Science segment sales for the third quarter of 2024 were $260.9 million, a decrease of 1.0% compared to the same period last year. On a currency neutral basis, sales decreased 0.6% compared to the third quarter in 2023, driven by ongoing weakness in the biotech and biopharma end-markets. Currency neutral sales decreased in the Americas, offset by an increase in EMEA.

The Clinical Diagnostics segment sales for the third quarter of 2024 were $388.8 million, an increase of 5.6% compared to the same period last year. On a currency neutral basis, sales increased 6.4% compared to the third quarter in 2023. The currency neutral sales increase was primarily driven by increased demand for quality control products and supply constraints impacting immunology products in the third quarter of 2023. Currency neutral sales increased across all regions.

Consolidated gross margin was 54.8% for the third quarter of 2024 compared to 53.1% for the third quarter of 2023. Gross margin for the Life Science segment for the third quarter of 2024 increased by approximately 2.2 percentage points from the same period last year. The increase in gross margin was primarily driven by cost control measures and product mix, partially offset by lower sales volume. Gross margin for the Clinical Diagnostics segment for the third quarter of 2024 increased by approximately 1.3 percentage points from the same period last year. The increase in gross margin was primarily driven by cost control measures, higher sales volume, and product mix.

Selling, general and administrative ("SG&A") expense for the third quarter of 2024 was $200.4 million or 30.8% of sales, compared to $201.2 million, or 31.8% of sales for the third quarter of 2023. The decrease in SG&A expense was primarily due to a reduction in discretionary spending.

Research and development ("R&D") expense for the third quarter of 2024 was $91.0 million or 14.0% of sales, compared to $43.5 million or 6.9% of sales in the third quarter of 2023. The increase in R&D expense was primarily due to a one-time acquired in-process research and development expense of $29.5 million impacting the third
32

quarter of 2024 and a decrease in the fair value of contingent consideration of $14.8 million impacting R&D expense for the third quarter of 2023.

Results of Operations – Non-operating

Interest expense for the third quarter of 2024 and 2023 was $12.2 million and $12.4 million, respectively, which primarily consisted of interest expense related to the $1.2 billion Senior Notes.

Foreign currency exchange (gains) losses, net consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Foreign currency exchange losses, net was $1.6 million for the third quarter of 2024 compared to foreign currency exchange gains, net of $1.7 million for the third quarter of 2023. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.

(Gains) losses from change in fair market value of equity securities and loan receivable was a gain of $792.9 million and $36.4 million for the third quarter of 2024 and 2023, respectively. The change in the fair market value primarily resulted from the recognition of higher holding gains of $761.1 million in the third quarter of 2024 compared to holding gains of $42.5 million in the third quarter of 2023 on our position in Sartorius AG. In addition, higher gains from the change in fair value of our loan receivable of $25.2 million in the third quarter of 2024 compared to a loss of $4.9 million in the third quarter of 2023 contributed to the change.

Other income, net for the third quarter of 2024 was $18.1 million compared to $20.4 million for the third quarter of 2023. The difference in Other income, net was primarily attributable to lower net realized gains on investments.

Our effective income tax rate was 24.2% and 22.5% for the third quarter of 2024 and 2023, respectively. The effective tax rate reported in these periods was primarily affected by the accounting treatment of our equity securities. The difference in the rate is primarily driven by geographical mix of earnings.

Nine Months Ended September 30, 2024 Compared to
Nine Months Ended September 30, 2023

Results of Operations -- Sales, Margins and Expenses

Net sales (sales) for the first nine months of 2024 were $1.90 billion compared to $1.99 billion in the first nine months of 2023, a decrease of 4.6%. On a currency neutral basis, the first nine months of 2024 sales decreased by approximately 4.0% compared to the same period in 2023. The decrease in sales was driven by lower sales in our Life Science segment.

The Life Science segment sales for the first nine months of 2024 were $753.1 million, a decrease of 15.1% compared to the same period last year. On a currency neutral basis, sales decreased 14.8% compared to the first nine months of 2023, driven by ongoing weakness in the biotech and biopharma end-markets. Currency neutral sales decreased across all regions.

The Clinical Diagnostics segment sales for the first nine months of 2024 were $1.1 billion, an increase of 4.1% compared to the same period last year. On a currency neutral basis, sales increased 4.8% compared to the first nine months of 2023. The currency neutral sales increase was primarily driven by increased demand for quality control and blood typing products. Currency neutral sales increased across all regions.

Consolidated gross margins were 54.6% for the first nine months of 2024 compared to 53.3% for the first nine months of 2023. Gross margins for the Life Science segment for the first nine months of 2024 increased by approximately 0.5 percentage points from the same period last year. The increase in gross margin was primarily driven by product mix and cost control measures partially offset by lower sales volume and higher material costs. Gross margin for the Clinical Diagnostics segment for the first nine months of 2024 increased by approximately 2.2
33

percentage points from the same period last year. The increase in gross margins was primarily driven by higher sales volume, favorable product mix, and cost control measures, partially offset by higher material costs.

SG&A expense for the first nine months of 2024 was $610.0 million or 32.1% of sales, compared to $634.6 million or 31.9% of sales for the first nine months of 2023. The decrease in SG&A expense was primarily due to lower employee-related expenses, lower restructuring costs, and a reduction in discretionary spending.

R&D expense for the first nine months of 2024 was $216.3 million or 11.4% of sales, compared to $183.5 million or 9.2% of sales in the first nine months of 2023. The increase in R&D expense was primarily due to a one-time acquired in-process research and development expense of $29.5 million impacting the first nine months of 2024 and a decrease in the fair value of contingent consideration of $14.4 million impacting R&D expense for the first nine months of 2023.

Results of Operations – Non-operating

Interest expense for the first nine months of 2024 and 2023 was $36.7 million and $37.1 million, respectively, which primarily consisted of interest expense related to the $1.2 billion Senior Notes.

Foreign currency exchange (gains) losses, net consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk. Foreign currency exchange gains, net was $2.0 million for the first nine months of 2024 compared to $5.3 million for the first nine months of 2023. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.

(Gains) losses from change in fair market value of equity securities and loan receivable was a loss of $1.68 billion and $1.58 billion for the first nine months of 2024 and 2023, respectively. The change in the fair market value primarily resulted from the recognition of higher holding losses of $1.71 billion in the first nine months of 2024 compared to holding losses of $1.56 billion in the first nine months of 2023 on our position in Sartorius AG. In addition, higher gains from the change in fair value of our loan receivable of $14.7 million in the first nine months of 2024 compared to a loss of $28.9 million in the first nine months of 2023 contributed to the change.

Other income, net for the first nine months of 2024 was $70.7 million compared to $87.4 million for the first nine months of 2023. The difference in Other income, net was primarily attributable to lower dividend income from Sartorius AG.

Our effective income tax rate was 21.3% and 22.8% for the first nine months of 2024 and 2023, respectively. The effective tax rate reported in the first nine months of both 2024 and 2023 was primarily affected by the accounting treatment of our equity securities. The difference in the rate is primarily driven by geographical mix of earnings.

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade. Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world. Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price. Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows for capital expenditures, interest and taxes. In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured Revolving Credit Agreement that we entered into in February 2024, and to a lesser extent international lines of credit. Borrowings under the Revolving Credit Agreement are available on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Revolving Credit Agreement as of September 30, 2024, however, an immaterial amount was utilized for domestic standby letters of credit that reduced our borrowing availability. As of September 30, 2024, our short-term investments include the net cash proceeds from the sale of Senior Notes of $1.186 billion. Interest is payable
34

semiannually in arrears on May 15 and September 15 of each year. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and acquisitions of reasonable proportion to our existing total available capital.

At September 30, 2024, we had available $1.63 billion in cash, cash equivalents and short-term investments, of which approximately 16% was held in our foreign subsidiaries. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as acquisitions and borrowings. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws, and there are no substantial incremental costs.

Cash Flows from Operations

Net cash provided by operations was $331.0 million and $293.9 million for the nine months ended September 30, 2024 and 2023, respectively. The increase in operating cash flows was primarily due to lower cash paid to suppliers and employees partially offset by lower cash received from customers, higher income tax paid, higher payments for foreign exchange contracts, and lower dividend proceeds.

Cash Flows from Investing Activities

Net cash used in investing activities was $129.7 million and $52.0 million for the nine months ended September 30, 2024 and 2023, respectively. The increase in cash used in investing activities was primarily due to the timing of our purchases, maturities and sales of marketable securities and investments, and higher payments for acquired in-process research and development and capital expenditures.

Cash Flows from Financing Activities

Net cash used in financing activities was $192.6 million and $225.0 million for the nine months ended September 30, 2024, and 2023, respectively. The decrease in net cash used in financing activities was primarily attributable to lower payments for purchases of treasury stock.

Treasury Shares

During the third quarter of 2024, 127,328 shares of Class A treasury stock with an aggregate total cost of $44.0 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $38.9 million from share reissuance activity during the quarter.

During the third quarter of 2024, we repurchased 330,381 shares of Class A common stock for $97 million under our 2023 Share Repurchase Program. We designated these repurchased shares as treasury stock. As of September 30, 2024, $577.1 million remained available for repurchases under the 2023 Share Repurchase Program.

In July 2024, the board of directors granted the Company authority to repurchase, on a discretionary basis, up to an additional $500 million of the outstanding shares of the Company’s common stock under the 2023 Share Repurchase Program.

During the second quarter of 2024, 21,017 shares of Class A treasury stock with an aggregate total cost of $7.4 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $2.7 million from share reissuance activity during the quarter.

35

During the second quarter of 2024, we repurchased 346,226 shares of Class A common stock for $100 million under our 2023 Share Repurchase Program. We designated these repurchased shares as treasury stock.

During the first quarter of 2024, 19,755 shares of Class A treasury stock with an aggregate total cost of $7.2 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $1.7 million from share reissuance activity during the quarter.

During the first quarter of 2024, we repurchased 14,250 shares of Class A common stock for $4.7 million under our 2023 Share Repurchase Program. We designated these repurchased shares as treasury stock.

During the third quarter of 2023, 113,908 shares of Class A treasury stock with an aggregate total cost of $45.8 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $45.3 million from share reissuance activity during the quarter.

During the third quarter of 2023, we repurchased 58,478 shares of Class A common stock for $21.3 million under our Share Repurchase Program. We designated these repurchased shares as treasury stock.

In July 2023, the board of directors authorized a new share repurchase program granting the Company authority to repurchase, on a discretionary basis, up to $500 million of the outstanding shares of the Company’s common stock.

During the second quarter of 2023, 17,428 shares of Class A treasury stock with an aggregate total cost of $6.9 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $2.1 million from share reissuance activity during the quarter.

During the second quarter of 2023, we repurchased 549,863 shares of Class A common stock for $207.4 million under our Share Repurchase Program. We designated these repurchased shares as treasury stock.

During the first quarter of 2023, 12,853 shares of Class A treasury stock with an aggregate total cost of $5.3 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $0.7 million from share reissuance activity during the quarter.

Recent Accounting Pronouncements Adopted

We did not adopt any new accounting pronouncements during the three and nine months ended September 30, 2024.


Item 3. Quantitative and Qualitative Disclosures about Market Risk

During the nine months ended September 30, 2024, there have been no material changes from the disclosures about market risk provided in our Annual Report on Form 10-K for the year ended December 31, 2023.


Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and
36

forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.

Changes to Internal Control Over Financial Reporting

We identified no changes in internal control over financial reporting that occurred during our quarter ended September 30, 2024 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.


PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are a party to various claims, legal actions and complaints arising in the ordinary course of business. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


Item 1A. Risk Factors

In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this report. We believe that any of the following risks (some of which have occurred and any of which may occur in the future) could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock. We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry, the value of our equity holdings, or the trading price of our common stock. Please carefully consider the following discussion of significant factors, events and uncertainties that make an investment in our securities risky and provide important information for the understanding of the “forward-looking” statements discussed in this report. Additional or unforeseen effects from the global economic climate may give rise to or amplify many of these risks discussed below.
37

Business, Economic, Legal and Industry Risks
Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.
We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the nine months ended September 30, 2024 our foreign entities generated 59% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements, labor relations laws, tax laws, unfair competition regulations, import and trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the Foreign Corrupt Practices Act ("FCPA") and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions.
Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. In addition, we operate in some countries in which the business environment is subject to a higher risk of corruption. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with laws and regulations, and our global policies and procedures.
Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factors regarding the COVID-19 pandemic, government regulations, and global economic conditions below.
The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.
The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts, or to source high-demand materials and components. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition.
We may not be able to grow our business because of our failure to develop new or improved products.
Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new products that integrate technological advances. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new products successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. Supply chain disruptions, including those caused by the COVID-19 pandemic, have caused some delays to our ability to develop and introduce new products. We have experienced product launch delays in the past and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.
38

Global economic and geopolitical conditions could adversely affect our operations.
In recent years, we have been faced with challenging global economic conditions. U.S. and international markets have experienced inflationary pressures, and inflation rates in the U.S. and in other countries in which we operate have been at elevated levels. Our raw material costs have increased, and we are not always able to recover these increased costs from our customers. Russia’s invasion of Ukraine and sanctions against Russia also are causing disruptions to global economic conditions and are negatively impacting our business in Russia. The recent escalation of conflicts in the Middle East also has caused some disruptions to the global business environment (including impacting international logistics), the stability of the Middle East region and our business in that region. It is unknown how long any of these disruptions will continue and whether such disruptions will become more severe. In addition, we expect moderating economic growth and changing government policies in China will continue to affect our commercial opportunities in the country. The bank failures in March 2023 and the resulting volatility in the banking sector did cause and could continue to cause disruptions to global economic conditions and may impact access to cash and other financial resources by our customers and suppliers. A deterioration in the global economic environment may result in a decrease in demand for our products, increased competition, downward pressure on prices for our products and longer sales cycles. A weakening of macroeconomic conditions is also adversely affecting our suppliers, which could continue to result in interruptions in the supply of components and raw materials necessary for our products and raw material cost increases. Additionally, the United States and other countries, such as China and India, have imposed tariffs on certain goods. Further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. See also our risk factors regarding our international operations above and regarding the COVID-19 pandemic and government regulations below.
Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.
Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and companies have a significant effect on the demand for our products. Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods. If funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.
A reduction or interruption in the supply of components and raw materials has adversely affected and could continue to adversely affect our manufacturing operations and related product sales.
The manufacture of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply, but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. The COVID-19 pandemic created delays and shortages in the supply of components and raw materials. These shortages, along with challenges in ramping up new production facilities, caused a backlog of sales orders, some of which we consider to be significant, and delays in certain new product development activities. Some of the backlog of sales orders continued into 2023 but has now moderated to a more typical level. We have experienced raw material cost increases, some of which will likely continue. In addition, due to the regulatory environment in which we operate, we may need to cease use of certain essential components and materials and be unable to establish acceptable replacement sources for such components or materials. When our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner is adversely affected, which affects our ability to sell our products. See also our risk factor regarding the COVID-19 pandemic below.
Pandemics or disease outbreaks, such as the COVID-19 pandemic, have affected and could materially adversely affect our business, operations, financial condition and results of operations.
The COVID-19 pandemic has had, and similar outbreaks could again have, an adverse effect on the United States and global economies, as well as on aspects of our business, operations and financial condition and those of third parties on whom we rely. If a new pandemic were to occur, we expect that parts of our business could again suffer
39

negative impacts, and that our customers, suppliers, logistics providers, and the global economy could also be negatively impacted.
Breaches of our information systems could have a material adverse effect on our business and results of operations.
We have experienced and expect to continue to experience attempts by individuals and organizations to attack and penetrate our layered security controls, like the December 2019 Cyberattack that was previously discussed in Item 7 of our Annual Report for the period ended December 31, 2019. Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our web site. We also acquire and retain information about suppliers and employees in the normal course of business. Such information on our systems includes personally identifiable information and, in limited instances, protected health information. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. The Company is also subject to phishing and other fraud schemes including fraudulent vendor communications with requests for payments and fraudulent attempts to redirect payments to improper bank accounts, some of which have been successful. While the Company has adopted training and process changes to limit the success of such fraudulent activity, the Company will be unable to stop all such fraudulent activity which may lead to unrecoverable payments to criminal accounts. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not recognized until launched against a target, we may not be able to anticipate all of these techniques or to implement adequate preventive measures. Computer hackers have attempted to penetrate and will likely continue to attempt to penetrate our and our vendors’ information systems and, if successful, could misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers and suppliers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted, as they were in the December 2019 Cyberattack. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our information technology systems below.
If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.
Our information technology (IT) systems are an integral part of our business, and a significant disruption of our IT systems (which increasingly include cloud-based systems provided by third party vendors) could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory, pay our vendors and collect accounts receivable. Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.
Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes. We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems or migrate to cloud-based systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our data security above and events beyond our control below.
40

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.
A significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. In addition, we hold investments and a loan receivable that are subject to foreign exchange fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.
Changes in the market value of our position in Sartorius AG materially impact our financial results.
Changes in the market value of our position in Sartorius AG will continue to materially impact our condensed consolidated statements of income (loss) and other financial statements. A decline in the market value of our position in Sartorius AG will result in decreases in net income due to write-downs in the value of the equity securities. An increase in the market value of our position in Sartorius AG will result in a favorable impact to net income independent of the actual operating performance of our business. Depending on the extent of the decline or of the increase in the market value of our position in Sartorius AG, these negative or positive impacts on us could continue to be material.
Our share price may change significantly based upon changes in the market value of our position in Sartorius AG, independent of the actual performance of our business. Additionally, non-operating income for a period may be significantly impacted by any distribution of dividends by Sartorius AG, particularly when the dividends amount varies in comparison to prior year periods.
The value of our position in Sartorius AG might cause us to be deemed an investment company under the Investment Company Act of 1940.
As a result of the market value of our position in Sartorius AG, we might be deemed to be an “investment company” under Section 3(a)(1)(C) of the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Company does not believe it is an investment company primarily in reliance on Section 3(b)(1) of the Investment Company Act because we are “primarily engaged” in a business other than that of investing, reinvesting, owning, holding or trading in securities. Rather, we are primarily engaged in the development, manufacturing and marketing of products for the life science research and clinical diagnostic markets, and we believe that our historical development, our public representations of policy, the activity of our officers and directors, the nature of our present assets, the sources of our present income, and the public perception of the nature of our business all support the conclusion that we are an operating company and not an investment company. Although we have discussed this issue with the staff of the SEC and we are comfortable with our position, if it is determined later that the Company may not rely on Section 3(b)(1) or any other exemption under the Investment Company Act and the Company were deemed to be an unregistered investment company, such determination would have a material adverse effect on our business as we would need to register as an investment company and be subject to the regulations of the Investment Company Act which are designed to restrict and regulate mutual funds rather than operating companies. It could also call into question the validity of all contracts to which the Company is a party. If it appeared likely that we would be deemed to be an investment company, we may modify our position in Sartorius AG in order to avoid such determination.
We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar investments. Financial markets are volatile and the markets for these securities can be illiquid. The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions, low trading volume of the securities, or other market considerations.
41

As discussed further in the Notes to Condensed Consolidated Financial Statements, in Note 2. Fair Value Measurements, under the heading “Level 3 Fair Value Investments”, we made a loan of 400 million Euros to Sartorius-Herbst Beteiligungen II GmbH in November 2021 that is secured by the pledge of certain trust interests which upon termination of the trust represent the right to receive Sartorius ordinary shares (the "Loan"). Prior to a termination of the trust, the trust interests, which are provided as collateral for the Loan, are not tradable on the capital markets and may, in case of an enforcement, have to be sold with a significant discount to the value of the underlying shares.
We also have positions in equity securities, including our position in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments in equity securities has resulted and could continue to result in significant losses due to write-downs in the value of the equity securities. Also, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses. In addition, significant declines in the value of the Sartorius ordinary shares have reduced the value of the collateral for the Loan discussed in the previous paragraph. The value of the collateral may be insufficient to cover the repayment of the Loan if the decline in value continues, and Sartorius-Herbst Beteiligungen II GmbH will likely have no other assets from which to repay the Loan. Furthermore, the change in the market value of Sartorius ordinary shares will have an impact on the value appreciation rights acquired in connection with the Loan discussed in the previous paragraph.
Recent and planned changes to our organizational structure could negatively impact our business.
We made significant changes to our organizational structure over the past few years, including the reorganization of aspects of our European operations that was announced in February 2021 and additional restructurings approved in 2023 and 2024. These changes may have unintended consequences, such as distraction of our management and employees, labor unrest, business disruption, disruption of supply, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.
Risks relating to intellectual property rights may negatively impact our business.
We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. Unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages or royalties to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.
Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.
There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:
•The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage. In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.
42

•Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.
To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected. If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.
We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.
Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the Food and Drug Administration ("FDA") in the United States and its foreign counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.
The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Any delay in, or failure to receive or maintain, clearance or approval for our products or changes in regulation could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.
The FDA has issued a final rule applicable to certain clinical diagnostic products referred to as laboratory developed tests. This change in the FDA approach could negatively impact our customers who use our Life Science products for laboratory developed tests.
Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. The EU in-vitro Diagnostics Regulation (the “EU IVDR”) includes broad changes regarding in vitro diagnostic devices and medical devices. The EU IVDR required us to modify or re-register some products, and we expect will continue to result in additional costs for ongoing compliance. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. The United Kingdom's withdrawal from the EU is resulting in additional regulatory requirements associated with goods
43

manufactured and sold in the United Kingdom and additional complexities and delays with respect to goods, raw materials and personnel moving between the United Kingdom and the EU. In addition, new government administrations may interpret existing regulations or practices differently. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. We may not be able to participate in certain public tenders in China, India and Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above.
We are also subject to government regulation of the use and handling of a number of materials and controlled substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.
We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or that we will be able to realize the anticipated benefits from the acquisitions.
As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. The benefits of any acquisition or investment may prove to be less than anticipated, which we have experienced in some of our acquisitions and investments, and may not outweigh the costs reported in our financial statements. Completing any potential future acquisitions could cause significant diversion of our management’s time and resources. If we acquire or invest in new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur, as they have occurred in the past. Increased antitrust enforcement and greater government scrutiny of mergers in the healthcare sector may impact our ability to consummate acquisitions. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions or investments, and any such acquisitions or investments could adversely affect our business, results of operations and financial condition.
Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.
We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. In responding to shortages, we may source components from alternative suppliers and distributors. Quality issues associated with components from these alternative sources may lead to product failures and associated costs notwithstanding our efforts to detect and remediate such quality issues. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.
Lack of key personnel could hurt our business.
Our products are very technical in nature, and we operate in a complex and competitive business environment. In general, only highly qualified and well-trained scientists, technicians and other specialized individuals have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills. In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We
44

face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business. Further, our ability to successfully execute organizational changes, including management transitions within our senior leadership team, are critical to our business success. If we are not able to fully integrate new executives, these changes could impact our ability to successfully execute our business strategy, which could adversely affect our business, results of operations and financial condition.
We may have higher than anticipated tax liabilities.
We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Determination of our tax liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.
Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. In recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.
Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.
On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) which made a number of substantial changes to how the United States imposes income tax on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies continue to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements.
On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which included an Alternative Minimum Tax based on the Adjusted Financial Statement Income of Applicable Corporations. We do not believe the Inflation Reduction Act will have a material impact on our income tax provision and cash taxes, but we continue to monitor U.S. Department of the Treasury guidance and regulations.
The tax effect of our position in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow. In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development ("OECD")’s project on “Base Erosion and Profit Shifting” ("BEPS") by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.
On October 8, 2021, the OECD announced that 136 countries have agreed on a two-pillar framework that would dramatically alter the taxation of multinational enterprises and require that all profit be subject to a global minimum tax rate of 15%. On December 15, 2022, the European Union formally adopted the Pillar Two Directive and EU member states enacted the Pillar Two Directive as of January 1, 2024. Other countries have taken similar actions. We currently believe Pillar 2 legislation will not have a material impact on our income tax provision and cash taxes.
Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.
Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, materials that we use in our products, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our
45

operations or otherwise impacting real property that we own or operate. The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.
We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.
In addition, there is an increasing focus by U.S. and international regulators, investors, customers, and other stakeholders on environmental, social and governance (ESG) matters. Complying with new laws or regulations concerning sustainability matters, climate related matters or other ESG matters will result in increased compliance costs and create additional non-compliance risks. Failure to adequately meet our stakeholder’s expectations or comply with any such laws or regulations may result in loss of business, reputational damage, an inability to attract customers, an inability to attract and retain top talent, and a negative impact on our business, results of operations and financial condition.
We also have announced certain sustainability goals, which require ongoing investment and operational changes. Our efforts may not achieve their intended outcomes, and we may not achieve such goals, which could negatively impact our reputation and business.
Our current and future debt and related covenants may restrict our future operations.
We have substantial debt and have the ability to incur additional debt. As of September 30, 2024, we had approximately $1.2 billion of outstanding long-term indebtedness, primarily consisting of the 3.3% Senior Notes due in March 2027 and the 3.7% Senior Notes due in March 2032 as further discussed in Note 6 of the condensed consolidated financial statements. In addition, we have a revolving credit facility that provides for up to $200.0 million in borrowing capacity, $0.2 million of which was utilized for domestic standby letters of credit as of September 30, 2024. Our incurrence of substantial amounts of debt may have important consequences. For instance, it could:
•make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•increase our vulnerability to general adverse economic and industry conditions;
•limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.
Our existing credit facility, our Senior Notes and agreements we may enter in the future, contain or may contain covenants imposing restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. Existing covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; enter into transactions with affiliates; sell assets; and in the case of some of our subsidiaries, guarantee debt. Our existing credit facility also requires that we comply with a maximum consolidated leverage ratio test. Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest.
46

We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.
We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:
•the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;
•U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;
•the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;
•the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and
•state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.
These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.
Risks Related to Being a Public Company
Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.
Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements. Material weaknesses in our internal control over financial reporting have adversely affected us in the past and could affect us in the future and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause the trading price of our common stock to decline.
47

General Business Risks
Natural disasters, climate related events, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.
We have significant manufacturing and distribution facilities, including in the United States, France, Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years. These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, lack of fuel resources due to geo-political instability (such as Russia’s reduction in energy resources supplied to Western Europe), electricity outages, the inability to operate our production and distribution facilities due to power grid failures or lack of fuel, and strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business. Acts of terrorism, bioterrorism, violence or war (such as Russia's invasion of Ukraine and the recent escalation of conflicts in the Middle East), weather-related events, or public health issues such as the outbreak of a contagious disease like COVID-19 could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.
Risks Related to Our Common Stock
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors. As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company. The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.
The forum selection provision in our bylaws could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees.
Our bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action arising pursuant to any provision of the General Corporation Law of the State of Delaware, the Certificate of Incorporation or the Bylaws (in each case, as may be amended from time to time) or (iv) any action asserting a claim against the Company or any of its directors, officers or other employees governed by the internal affairs doctrine of the State of Delaware. This choice of forum provision may increase costs to bring a claim, discourage claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in the Company’s bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions.
Application of the choice of forum provision may be limited in some instances by applicable law. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by
48

the Exchange Act or the rules and regulations thereunder. As a result, the choice of forum provision will not apply to actions arising under the Exchange Act or the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, subject to a limited exception for certain “covered class actions.” There is uncertainty, particularly in light of current litigation, as to whether a court would enforce the choice of forum provision with respect to claims under the Securities Act. Our stockholders will not be deemed, by operation of the Company’s choice of forum provision, to have waived claims arising under the federal securities laws and the rules and regulations thereunder.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

As of September 30, 2024, $577.1 million of stock remained available for repurchases under the Company's 2023 Share Repurchase Program, which was authorized by the Board of Directors in July 2023 and July 2024. Repurchases under the 2023 Share Repurchase Program may be made at management's discretion from time to time on the open market, through trading plans in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or through privately negotiated transactions. The authorization has no expiration.

The following table contains information on the shares of our common stock that we purchased or otherwise acquired during the three months ended September 30, 2024.

PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number (or Approximate Dollar Value) of Shares that May yet be Purchased Under the Plans or Programs (in millions)
July 1 to July 31, 2024
328,171$293.01 328,171$577.8 
August 1 to August 31, 2024
2,210$321.73 2,210$577.1 
September 1 to September 30, 2024
— $— — $577.1 



Item 3. Defaults Upon Senior Securities

None.


Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

During the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
49


Item 6. Exhibits

(a)  Exhibits

The following documents are filed as part of this report:

Exhibit
No.		 
10.1
31.1
  
31.2
  
32.1
  
32.2
  
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104.1The cover page Interactive Data File is formatted in Inline XBRL and is contained in Exhibits 101
50


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.
BIO-RAD LABORATORIES, INC.
(Registrant)
    
Date:October 31, 2024 /s/ Norman Schwartz
   
Norman Schwartz, Chairman of the Board and
   
Chief Executive Officer
    
Date:October 31, 2024 
/s/ Roop K. Lakkaraju
   
Roop K. Lakkaraju, Executive Vice President,
   Chief Financial Officer
51
 EX-10.1 2 exhibit101restrictedstocku.htm EX-10.1 Document
Exhibit 10.1
BIO-RAD LABORATORIES, INC.
2017 INCENTIVE AWARD PLAN

RESTRICTED STOCK UNIT AWARD GRANT NOTICE
(NON-EMPLOYEE DIRECTOR FORM)

Bio-Rad Laboratories, Inc., a Delaware corporation, (the “Company”), pursuant to its 2017 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Holder”), Restricted Stock Units (“RSUs”) with respect to the number of shares of the Company’s Class A common stock set forth below (the “Shares”). This Restricted Stock Unit Award is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Unit Award Agreement attached hereto as Exhibit A (the “Restricted Stock Unit Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice shall have the meanings given such terms in the Plan.
Holder:

Grant Date:

Vesting Commencement Date:

Total Number of RSUs:

Award Number:

Vesting Schedule:
100% of the RSUs shall vest on the earlier of the first anniversary of the Vesting Commencement Date or the date of the Company’s next annual meeting of stockholders, subject to Holder continuing to be a Director of the Company or one of its Subsidiaries.

By his or her acceptance of the RSUs through the Company's online acceptance procedure (or by his or her signature and the signature of the Company’s representative below), Holder agrees to be bound by the terms and conditions of the Plan, the Restricted Stock Unit Agreement, and this Grant Notice. Holder has reviewed the Plan, the Restricted Stock Unit Agreement, and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of this Grant Notice, the Restricted Stock Unit Agreement, and the Plan. Holder hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator of the Plan upon any questions arising under the Plan, this Grant Notice, the Restricted or Stock Unit Agreement.
BIO-RAD LABORATORIES, INC.:    
HOLDER:
By:___________________________By:
Print Name: ___________________________Print Name:
Title: ___________________________  



|US-DOCS\152120238.2||

EXHIBIT A TO
BIO-RAD LABORATORIES, INC.
2017 INCENTIVE AWARD PLAN
RESTRICTED STOCK UNIT AWARD GRANT NOTICE
RESTRICTED STOCK UNIT AWARD AGREEMENT
Pursuant to the Restricted Stock Unit Award Grant Notice (the “Grant Notice”) to which this Restricted Stock Unit Award Agreement (this “Agreement”) is attached, Bio-Rad Laboratories, Inc., a Delaware corporation (the “Company”), has granted to Holder the right to receive the number of Restricted Stock Units (the “RSUs”) under the 2017 Incentive Award Plan, as amended from time to time (the “Plan”), as set forth in the Grant Notice.
All capitalized terms used in this Agreement without definition shall have the meanings ascribed in the Plan and the Grant Notice.
The RSUs are subject to the terms and conditions of the Plan, which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.
1.Grant and Vesting of the RSUs. As set forth in the Grant Notice, the Company hereby grants Holder RSUs, subject to all the terms and conditions in this Agreement, the Grant Notice and the Plan. The RSUs shall vest on the Vesting Date set forth on the Grant Notice, subject to Holder's continued service as a Director with the Company or any Subsidiary through the applicable Vesting Date. In the event Holder ceases to be a Director prior to a Vesting Date, the RSUs shall cease vesting immediately upon such cessation of service and the unvested RSUs awarded by this Agreement shall be forfeited. However, no shares of Class A common stock (the “Shares”) shall be issued to Holder until the time set forth in Section 2 below. Prior to the actual issuance of any Shares, such RSUs will represent an unsecured obligation of the Company, payable only from the general assets of the Company. Only whole Shares shall be issued upon vesting of the RSUs, and the Company shall be under no obligation to issue any fractional Shares to Holder.

2.Issuance of Shares. Shares shall be issued to Holder on or as soon as administratively practicable following each vesting date as set forth in the Grant Notice (the “Vesting Date”) (and in no event later than 2 1/2 months following the end of the calendar year in which such Vesting Date or vesting event occurs. After each Vesting Date the Company shall promptly cause to be issued (either in book-entry form or otherwise) to Holder or Holder’s beneficiaries, as the case may be, Shares with respect to RSUs that became vested on such Vesting Date.

3.Dividend Equivalents. No Dividend Equivalents shall be paid to Holder prior to the Vesting Date; rather, such Dividend Equivalents, if any, will accrue, subject to forfeiture in the event Holder ceases to be a Director prior to the Vesting Date, and be notionally credited to Holder’s RSU account and paid out in the form of additional Shares at the time that the underlying RSUs are paid as set forth in Section 2 above.

4.Acceleration of Vesting. Notwithstanding Section 1 above, pursuant to Section 12.2(d) of the Plan, the RSUs shall become fully vested upon a Change in Control.

5.Taxes.

(a)    Holder acknowledges and agrees that the liability for all any or all income tax or other tax-related items related to Holder’s participation in the Plan and legally applicable to Holder (“Tax-
1


Related Items”) is Holder’s responsibility. Holder further acknowledges that the Company (i) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including, but not limited to, the grant, vesting or settlement of the RSUs, the issuance of Shares upon settlement of the RSUs, the subsequent sale of Shares acquired under the Plan and the receipt of dividends or Dividend Equivalents, if any; and (ii) does not commit to and is under no obligation to structure the terms of the RSUs or any aspect of the RSUs to reduce or eliminate Holder’s liability for Tax-Related Items or achieve any particular tax result.

(b)    This Agreement, the RSUs and payments made pursuant to this Agreement are intended to comply with or qualify for an exemption from Section 409A of the Code and the Treasury Regulations thereunder (“Section 409A”) and shall be interpreted in a manner consistent with that intention. Notwithstanding any other provision of this Agreement, the Company reserves the right, to the extent the Company deems necessary or advisable, in its sole discretion, to unilaterally amend the Plan and/or this Agreement to ensure that all RSUs are awarded in a manner that qualifies for exemption from or complies with Section 409A. This Section 5(b) does not create an obligation on the part of the Company to modify the terms of this Agreement or the Plan or to mitigate any additional tax, interest and/or penalties or other adverse tax consequences that may apply under Code Section 409A if compliance is not practical and does not guarantee that the RSUs or the delivery of Shares upon vesting/settlement of the RSU will not be subject to taxes, interest and penalties or any other adverse tax consequences under Section 409A of the Code. The Company will have no liability to Holder or any other party if the RSU that is intended to be exempt from, or compliant with, Section 409A of the Code, is not so exempt or compliant or for any action taken by the Administrator with respect thereto.

6.Award Not Transferable. This grant of RSUs and the rights and privileges conferred hereby will not be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and will not be subject to sale under execution, attachment or similar process. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of this grant, or any right or privilege conferred hereby, or upon any attempted sale under any execution, attachment or similar process, this grant and the rights and privileges conferred hereby immediately will become null and void.

7.Rights as Stockholder. Neither Holder nor any person claiming under or through Holder will have any of the rights or privileges of a stockholder of the Company with respect to any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars, and delivered to Holder (including through electronic delivery to a brokerage account). After such issuance, recordation and delivery, Holder will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.

8.Conditions to Issuance of Certificates. Notwithstanding any other provision of this Agreement, unless there is an available exemption from any registration, qualification or other legal requirement applicable to the Shares, the Company shall not be required to issue or deliver any certificate or certificates for any Shares prior to the fulfillment of all of the following conditions: (a) the admission of the Shares to listing on all stock exchanges on which such Shares are then listed, (b) the completion of any registration or other qualification of the Shares under any state, federal, or local law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or other governmental regulatory body, which the Company shall, in its sole and absolute discretion, deem necessary and advisable, (c) the obtaining of any approval or other clearance from any governmental agency that the Company shall, in its absolute discretion, determine to be necessary or advisable, and (d) the lapse of any such reasonable period of time following the date the RSUs vest as the Company may from time to time establish for reasons of administrative convenience. Holder understands that the Company is under no obligation to register or qualify the Shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares. Further, Holder agrees that the Company shall have unilateral authority to amend the Plan and this Agreement without Holder’s
2


consent to the extent necessary to facilitate compliance with securities or other laws applicable to the issuance of Shares.

9.No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Holder’s participation in the Plan, or Holder’s acquisition or sale of the underlying Shares. Holder understands and agrees he or she should consult with his or her own personal tax, legal and financial advisors regarding Holder’s participation in the Plan before taking any action related to the Plan.
10.Governing Law and Venue. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of the Grant Notice and this Agreement, regardless of the law that might be applied under conflict of laws principles.

For purposes of litigating any dispute that arises under this grant of RSUs or this Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, agree that such litigation shall be conducted in the courts of Contra Costa County, California, or the federal courts for the United States for the Northern District of California, where this grant is made and/or to be performed.

11.Conformity to Securities Laws. Holder acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act, and any and all regulations and rules promulgated thereunder by the SEC, including without limitation Rule 16b-3 under the Exchange Act. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the RSUs are granted, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by Applicable Law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.

12.Amendment, Suspension and Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator, provided, that, except as may otherwise be provided by the Plan or this Agreement, no amendment, modification, suspension or termination of this Agreement shall adversely effect the RSUs in any material way without the prior written consent of Holder.

13.Notices. Notices required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or upon deposit in the mail by certified or registered mail, with postage and fees prepaid, addressed to Holder to his or her address shown in the Company records, and to the Company at its principal executive office.

14.Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Holder and his or her heirs, executors, administrators, successors and assigns.

15.Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Holder hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

3


16.Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

17.Imposition of Other Requirements. The Company reserves the right to impose other requirements on Holder’s participation in the Plan, on the RSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Holder to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

18.Waiver. Holder acknowledges that a waiver by the Company of breach of any provision of the Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Holder or any other Holder.

19.Insider Trading/Market Abuse Laws. Holder acknowledges that he or she may be subject to insider trading restrictions and/or market abuse laws based on the exchange (if any) on which Shares are listed, and in applicable jurisdictions, including but not limited to the United States, Holder’s country and the designated broker’s country, which may affect Holder’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., RSUs) or rights linked to the value of Shares under the Plan during such times as Holder is considered to have “inside information” regarding the Company (as defined by the laws in applicable jurisdictions). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Holder placed before he or she possessed inside information. Further, Holder could be prohibited from (i) disclosing the inside information to any third party, which may include fellow directors or any employees and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Holder acknowledges he or she is responsible for complying with any applicable restrictions and is encouraged to speak to his or her personal legal advisor for further details regarding any applicable insider trading and/or market abuse laws in Holder’s country.

20.Recovery of Compensation. As an additional condition of receiving this Award, Holder agrees that the RSU and any proceeds or other benefits Holder may receive hereunder shall be subject to forfeiture and/or repayment to the Company to the extent and in the manner required (i) to comply with any requirements imposed under Applicable Law and/or the rules and regulations of the securities exchange or inter-dealer quotation system on which the Shares are listed or quoted, including, without limitation, pursuant to Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (collectively, the “Rules and Regulations”) and (ii) under the terms of any policy adopted by the Company as of the date hereof or as may be amended from time to time to comply with Applicable Law or the Rules and Regulations (and such requirements shall be deemed incorporated into this Agreement without the consent of Holder). Further, if Holder receives any amount in excess of what Holder should have received under the terms of the RSU for any reason (including without limitation by reason of a financial restatement, mistake in calculations or administrative error), all as determined by the Administrator, then Holder shall be required to promptly repay any such excess amount to the Company. For purposes of the foregoing, Holder expressly and explicitly authorizes the Company to issue instructions, on Holder’s behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold Holder’s Shares and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company. This Section 20 is not the Company’s exclusive remedy with respect to such matters.
4

 EX-31.1 3 ex31193024.htm EX-31.1 Document

Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:October 31, 2024 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board and
   Chief Executive Officer


 EX-31.2 4 ex31293024.htm EX-31.2 Document

Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Roop K. Lakkaraju, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:October 31, 2024 /s/ Roop K. Lakkaraju
   Roop K. Lakkaraju
   Executive Vice President,
   Chief Financial Officer

 EX-32.1 5 ex32193024.htm EX-32.1 Document

Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:October 31, 2024 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board and Chief Executive Officer
   


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 EX-32.2 6 ex32293024.htm EX-32.2 Document

Exhibit 32.2




Certification of Periodic Report


I, Roop K. Lakkaraju, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:October 31, 2024 /s/ Roop K. Lakkaraju
   Roop K. Lakkaraju
   Executive Vice President,
   Chief Financial Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.


 EX-101.SCH 7 bio-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets Parenthetical link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Basis of Presentation and Use of Estimates link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Goodwill and Other Purchased Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Other Income, Net link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Other Income, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Basis of Presentation and Use of Estimates Warranty Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Basis of Presentation and Use of Estimates Capitalized Cloud Computing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Basis of Presentation and Use of Estimates (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Fair Value Measurements - Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Other Income, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bio-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bio-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bio-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statistical Measurement [Domain] Statistical Measurement [Domain] Payments on long-term borrowings Repayments of Long-Term Debt Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Lease, Cost Lease, Cost [Table Text Block] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Other Nonoperating (Income) Other Nonoperating Income Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect In Process Research and Development [Member] In Process Research and Development [Member] Other current liabilities Other Liabilities, Current Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income tax payments, net Income Taxes Paid, Net Accounts receivable allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Common Class A [Member] Common Class A [Member] Common Class A [Member] Equity Method Investments Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Short-term Investments [Member] Short-Term Investments [Member] Cash Equivalents [Member] Cash Equivalents [Member] Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Net unrealized holding gains (losses) on available-for-sale investments net of tax expense OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Other Performance Measure, Amount Other Performance Measure, Amount Legal Proceedings Legal Matters and Contingencies [Text Block] Goodwill [Line Items] Goodwill [Line Items] Leases Lessee, Operating Leases [Text Block] Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Unrealized Gain (Loss) on Derivatives Foreign Currency Derivative, Unrealized Gain (Loss) Foreign Currency Derivative, Unrealized Gain (Loss) Operating Lease, Cost Operating Lease, Cost Finance Lease, Right-Of-Use Asset, before Accumulated Amortization Finance Lease, Right-of-Use Asset, before Accumulated Amortization Operating lease liabilities Operating Lease, Liability, Noncurrent Finance Lease, Interest Expense Finance Lease, Interest Expense UNITED STATES UNITED STATES Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Purchase Price Finite-Lived Intangible Assets, Gross Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Money Market Funds [Member] Money Market Funds [Member] Operating Segments Operating Segments [Member] Net cash provided by operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock, Common Treasury Stock, Common [Member] Discussion of current derivative risk management Schedule of Derivative Instruments [Table Text Block] Cash paid to suppliers and employees Payments to Suppliers and Employees Income and other taxes payable Taxes Payable, Current US Treasury Securities US Treasury Securities [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Finance Lease, Liability, Payments, Due after Year Five Finance Lease, Liability, to be Paid, after Year Five Prepaid expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Finance Lease, Liability, Payment, Due Finance Lease, Liability, to be Paid Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Debt Securities, Available-for-sale Estimated Fair Value Debt Securities, Available-for-Sale Accounts Receivable and Allowance for Credit Losses Accounts Receivable [Policy Text Block] Escrow receipts on prior acquisition Escrow Receipts for Previous Acquisition Escrow Receipts for Previous Acquisition Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Trade Names [Member] Trade Names [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Investments [Domain] Investments [Domain] Compensation Amount Outstanding Recovery Compensation Amount Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Developed Technology Rights [Member] Developed Technology Rights [Member] Company Selected Measure Amount Company Selected Measure Amount Finance Leases and Other Debt Finance Leases and Other Debt [Member] Finance Leases and Other Debt [Member] Geographical [Axis] Geographical [Axis] Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Payments for debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Life Science Life Science [Member] Life Sciences [Member] Interest and investment income Investment Income, Interest and Dividend Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Accounts Receivable, Allowance for Credit Loss [Table Text Block] Accounts Receivable, Allowance for Credit Loss [Table Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Anti-dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Asset Acquisition [Axis] Asset Acquisition [Axis] Beginning Cash, Cash Equivalents, and Restricted Cash Ending Cash, Cash Equivalents, and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Equity Securities Equity Securities, FV-NI, Current Goodwill, net Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Tax payments from net share settlement Payment, Tax Withholding, Share-Based Payment Arrangement Debt Securities Debt Securities Inventory Inventory Disclosure [Text Block] Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Treasury Stock, Shares Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Employee Stock Option Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year One Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Municipal Obligations (Member) Municipal obligations [Member] Municipal Bonds [Member] Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Security Exchange Name Security Exchange Name Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year One Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Award Type Award Type [Axis] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Goodwill, Foreign Currency Translation Gain (Loss) Goodwill, Foreign Currency Translation Gain (Loss) Investment ownership percentage Investment ownership percentage Investment ownership percentage Basic earnings per share: Earnings Per Share, Basic [Abstract] Reclassification Out Of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Noncash or Part Noncash Acquisition, Investments Acquired Noncash or Part Noncash Acquisition, Investments Acquired Fair Value, Option, Loans Held as Assets [Abstract] Fair Value, Option, Loans Held as Assets [Abstract] Work in process Inventory, Work in Process, Net of Reserves Derivative, Forward Interest Rate Derivative, Forward Interest Rate Total liabilities Liabilities Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Debt Securities, Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] Research and Development Expense Research and Development Expense Net realized (gain) loss on investments Realized Investment Gains (Losses) Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Investment Owned, Balance, Shares Investment Owned, Balance, Shares Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Subsequent Events, Policy Subsequent Events, Policy [Policy Text Block] Current operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common Stock, Shares, Issued Common Stock, Shares, Issued Increase in income taxes payable Increase (Decrease) in Income Taxes Payable Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of credit maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and Development Expense Research and Development Expense [Member] Other assets Other Assets Europe [Member] Europe [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares - diluted Diluted weighted average common shares Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholders' equity Total Stockholders' Equity Total Stockholders' Equity Total stockholders' equity Equity, Attributable to Parent Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Treasury stock Treasury Stock, Value Other Long-Term Debt Other Long-Term Debt [Member] Other Long-Term Debt Mature in less than one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Revenue from external customers [Table] Accounting Standards Update and Change in Accounting Principle [Table] Selling, general and administrative expense Selling, General and Administrative Expense Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Recurring Fair Value, Recurring [Member] Stock Repurchased During Period, Excise Tax, Amount Stock Repurchased During Period, Excise Tax, Amount Stock Repurchased During Period, Excise Tax, Amount Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash or Part Noncash Acquisition, Fixed Assets Acquired Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Sold marketable securities and investments Noncash or Part Noncash Acquisition, Accounts Receivable Acquired Accumulated Net Unrealized Investment Gain (Loss) AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS: Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Total other comprehensive income (loss) net of tax Total other comprehensive income (loss) net of tax Other Comprehensive Income (Loss), Net of Tax Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Restricted Cash, Current Restricted Cash, Current Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Commercial Paper [Member] Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Payments for acquired in-process research and development Payments to Acquire in Process Research and Development Finance Lease, Liability, Payments, Due Year Three Finance Lease, Liability, to be Paid, Year Three Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Amortized Cost Total Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization expense Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Net Carrying Amount Finite-Lived Intangible Assets, Net Accounts payable Accounts Payable, Current Investment Type [Axis] Investment Type [Axis] Restricted Investments, at Fair Value Restricted Investments, at Fair Value Current Fiscal Year End Date Current Fiscal Year End Date Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Short-term investments Short-Term Investments Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Finance Lease, Right-Of-Use Asset, Accumulated Amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization (Gains) losses from change in fair market value of equity securities and loan receivable Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Licensing Agreements [Member] Licensing Agreements [Member] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Senior Notes, Noncurrent Senior Notes, Noncurrent Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Class of Stock [Line Items] Class of Stock [Line Items] Restricted Cash, Noncurrent Restricted Cash, Noncurrent Customer Relationships [Member] Customer Relationships [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Recent Accounting Pronouncements Issued and to be Adopted New Accounting Pronouncements, Policy [Policy Text Block] Standard Product Warranty, Policy Standard Product Warranty, Policy [Policy Text Block] Long-term Debt Long-Term Debt [Text Block] Net income per share diluted attributable to Bio-Rad Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Goodwill, Period Increase (Decrease) Goodwill, Period Increase (Decrease) Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finance Lease, Liability, Payments, Due Year Four Finance Lease, Liability, to be Paid, Year Four Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares Schedule of Weighted Average Number of Shares [Table Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Reduction in the carrying amount of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Finite-lived Intangible Assets Amortization Expense [Table Text Block] Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from Sale of Debt Securities, Available-for-Sale Foreign exchange (gains) losses, net Foreign Currency Transaction Gain (Loss), before Tax Gain (Loss), Foreign Currency Transaction, before Tax Preferred Stock, Shares Issued Preferred Stock, Shares Issued Organization, Consolidation and Presentation of Financial Statements [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Asset-backed Securities [Member] Asset-Backed Securities [Member] Acquired in-process research and development Payments to Acquire in Process Research and Development, Operating Activities Payments to Acquire in Process Research and Development, Operating Activities Share-based Compensation Share-Based Payment Arrangement, Noncash Expense Accumulated Defined Benefit Plans Adjustment Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment (Provision) benefit for income taxes Income Tax Expense (Benefit) Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Derivative, Notional Amount Derivative, Notional Amount Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Reclassification Out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Increase in other long term liabilities Increase (Decrease) in Other Noncurrent Liabilities Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other Long-term Debt Other Long-Term Debt Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Segment profit (loss) Operating Income (Loss) Interest expense Interest Expense, Operating and Nonoperating Finance Lease, Liability, Payments, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total liabilities and stockholders' equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued payroll and employee benefits Employee-related Liabilities, Current Additional paid-in capital Additional paid-in-capital Additional Paid in Capital Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Finance Lease, Liability, Payments, Due Year Two Finance Lease, Liability, to be Paid, Year Two Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Maturities Of Lease Liabilities For Operating and Finance Leases Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Debt Securities, Trading, and Equity Securities, FV-NI Debt Securities, Trading, and Equity Securities, FV-NI Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Inventory Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, Country Entity Address, State or Province Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Clinical Diagnostics Clinical Diagnostics [Member] Clinical Diagnostics [Member] Restricted investment [Member] Restricted investment [Member] Restricted investment LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Asia Pacific [Member] Asia Pacific [Member] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Mature in more than five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Restricted investments Restricted Investments, Current Line of Credit, Current Line of Credit, Current Other Long-Term Debt, Current Other Long-Term Debt, Current Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Earnings (Loss) Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Goodwill and Other Purchased Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Other investments Long-Term Investments Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Finance Lease, Liability Finance Lease, Liability All Individuals All Individuals [Member] Depreciation and amortization Other Depreciation and Amortization Fair Value, Option, Changes in Fair Value, Gain (Loss) Fair Value, Option, Changes in Fair Value, Gain (Loss) PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other Nonoperating Income (Expense) Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Goodwill Goodwill, Gross Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Ordinary voting shares [Member] Ordinary voting shares [Member] Ordinary voting shares Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other Operating Segment Other Operating Segment [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Deferred Revenue Deferred Revenue Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Deferred income taxes Deferred Income Tax Liabilities, Net Americas [Member] Americas [Member] PEO Total Compensation Amount PEO Total Compensation Amount Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Stock Issued During Period, Value, Treasury Stock Reissued Stock Issued During Period, Value, Treasury Stock Reissued Common Stock [Member] Common Stock [Member] Measure: Measure [Axis] Noncompete Agreements [Member] Noncompete Agreements [Member] Cash received from customers Proceeds from Customers Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure Segment Reporting [Abstract] Segment Reporting [Abstract] Other Investments [Member] Other Investments [Member] Entity Central Index Key Entity Central Index Key Statement, Scenario [Axis] Statement, Scenario [Axis] Scenario [Axis] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Decrease in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Accumulated Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Segment Information Segment Reporting Disclosure [Text Block] Interest Receivable, Current Interest Receivable, Current Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability APIC, Share-based Payment Arrangement, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Common Class B [Member] Common Class B [Member] Common Class B [Member] Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Finance Lease Obligations Finance Lease Obligations [Member] Finance Lease Obligations [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Unrecognized Tax Benefits Unrecognized Tax Benefits Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Interest paid, net Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Payments for purchases of treasury stock Payments for Repurchase of Common Stock Preference shares [Member] Preference shares [Member] Preference shares Proceeds from forward foreign exchange contracts, net Payments for (proceeds from) derivative instruments, operating activities Payments for (proceeds from) derivative instruments, operating activities Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, net of current maturities Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Securities without Readily Determinable Fair Value, Amount Equity Securities without Readily Determinable Fair Value, Amount Mature in more than five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Time Deposits [Member] Bank Time Deposits [Member] Income Taxes Income Tax Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Earnings Per Share [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Retained earnings Retained earnings Retained Earnings (Accumulated Deficit) Reclassification Out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Finance Lease Cost Finance Lease Cost Finance Lease Cost Decrease (increase) in inventories Increase (Decrease) in Inventories Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Foreign Government Obligations [Member] Debt Security, Government, Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Election Percentage for Board of Directors Election Percentage for Board of Directors Election Percentage for Board of Directors Operating Lease, Liability Operating Lease, Liability Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Deferred Revenue, Current Deferred Revenue, Current Reissuance of treasury stock Treasury Stock Reissued at Lower than Repurchase Price Lessee Supplemental Balance Sheet Information Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Current maturities of long-term debt and notes payable Notes and Loans Payable, Current Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Amendment Flag Amendment Flag Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Total long-term debt, excluding leases and current maturities Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Marketable Securities, Unrealized (Gain) Loss Marketable Securities, Unrealized Gain (Loss) Marketable Security, Unrealized Gain (Loss) Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Gross profit Gross Profit Reclassification Out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Schedule of Product Warranty Liability [Table Text Block] Schedule of Product Warranty Liability [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization 3.3%, Senior Notes due 2027 3.3%, Senior Notes due 2027 [Member] 3.3%, Senior Notes due 2027 Other Income, Net Other Income and Other Expense Disclosure [Text Block] Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Mature in less than one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Warranty accrual, beginning of period Warranty accrual, end of period Standard and Extended Product Warranty Accrual Entity Address, Postal Zip Code Entity Address, Postal Zip Code Equity Securities, FV-NI, Unrealized Loss Equity Securities, FV-NI, Unrealized Loss Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock Common Stock, Value, Issued Finance Lease, Interest Payment on Liability Finance Lease, Interest Payment on Liability Allowance for Loan and Lease Losses, Write-offs Allowance for Loan and Lease Losses, Writeoff Know How [Member] Know How [Member] Know how [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Unrealized Gain on Securities Equity Securities, FV-NI, Unrealized Gain Preferred Stock, Value, Issued Preferred Stock, Value, Issued Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Net income per share basic attributable to Bio-Rad Earnings Per Share, Basic Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Operating Lease, Payments Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Foreign exchange (gains) losses, net Realized Gain (Loss), Foreign Currency Transaction, before Tax Finance Lease, Principal Payments Finance Lease, Principal Payments Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Goodwill [Table] Goodwill [Table] 3.7%, Senior Notes due 2032 3.7%, Senior Notes due 2032 [Member] 3.7%, Senior Notes due 2032 Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Assets Assets Payments of operating lease liabilities Increase (Decrease) in Deferred Liabilities Cost of goods sold Cost of Goods and Services Sold Schedule of identifiable purchased intangible assets with definite lives Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Capital expenditures Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Foreign Government Debt [Member] Foreign Government Debt [Member] Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, to be Paid, Year Two Asset Acquisition, Consideration Transferred Asset Acquisition, Consideration Transferred Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Mature in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Net income attributable to Bio-Rad Net Income (Loss) Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net Sartorius Loan value appreciation rights - Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Assets, Fair Value Disclosure Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Finance Lease, Liability, Current Finance Lease, Liability, Current Increase in deferred income taxes Increase (Decrease) in Deferred Income Taxes Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, to be Paid Insider Trading Arrangements [Line Items] Common Stock, Voting Rights Common Stock, Voting Rights Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Increase in other current assets Increase (Decrease) in Other Current Assets Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Saber Bio Acquisition Saber Bio Acquisition [Member] Saber Bio Acquisition Adjustment to Compensation: Adjustment to Compensation [Axis] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Mature in one to five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Beginning balance, Accumulated other comprehensive income Ending balance, Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings [Member] Retained Earnings [Member] Amortization [Abstract] Amortization [Abstract] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Weighted average common shares - basic Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Lessee Supplemental Cash Flow Information Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Payments for purchases of marketable securities and investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 11 bio-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2024
Oct. 28, 2024
Document Transition Report false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Shell Company false  
City Area Code (510)  
Document Quarterly Report true  
Entity Incorporation, State or Country Code DE  
Entity File Number 001-07928  
Entity Registrant Name BIO-RAD LABORATORIES, INC.  
Entity Central Index Key 0000012208  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Small Business false  
Entity Tax Identification Number 94-1381833  
Entity Address, Address Line One 1000 Alfred Nobel Drive,  
Entity Address, City or Town Hercules,  
Entity Address, Country CA  
Entity Address, Postal Zip Code 94547  
Local Phone Number 724-7000  
Entity Emerging Growth Company false  
Common Class A [Member]    
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 per share  
Trading Symbol BIO  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   22,921,856
Common Class B [Member]    
Title of 12(b) Security Class B Common Stock, Par Value $0.0001 per share  
Trading Symbol BIO.B  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   5,074,909
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
ASSETS:    
Cash and cash equivalents $ 410,377 $ 403,815
Short-term investments 1,212,081 1,203,327
Restricted investments 5,560 5,560
Accounts receivable, net 461,940 489,017
Inventory 804,276 780,517
Prepaid expenses 133,228 140,040
Other current assets 28,158 26,054
Total current assets 3,055,620 3,048,330
Property, plant and equipment, net 545,304 529,007
Operating lease right-of-use assets 173,866 194,730
Goodwill, net 415,100 413,569
Purchased intangibles, net 307,325 320,514
Other investments 6,002,635 7,698,070
Other assets 103,622 94,850
Assets 10,603,472 12,299,070
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable 122,185 144,625
Accrued payroll and employee benefits 146,024 139,929
Current maturities of long-term debt and notes payable 1,262 486
Income and other taxes payable 43,625 35,759
Current operating lease liabilities 42,834 40,379
Other current liabilities 142,013 161,621
Total current liabilities 497,943 522,799
Long-term debt, net of current maturities 1,200,062 1,199,052
Deferred income taxes 1,076,058 1,475,495
Operating lease liabilities 143,919 165,478
Other long-term liabilities 197,631 195,113
Total liabilities 3,115,613 3,557,937
Preferred Stock, Value, Issued 0 0
Stockholders' equity:    
Additional paid-in capital 448,329 449,075
Retained earnings 8,132,231 9,260,629
Accumulated other comprehensive loss (315,274) (336,038)
Total stockholders' equity 7,487,859 8,741,133
Total liabilities and stockholders' equity 10,603,472 12,299,070
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Stock, Common    
Stockholders' equity:    
Treasury stock $ (777,430) $ (632,536)
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets Parenthetical - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Accounts receivable allowance for doubtful accounts $ 12,139 $ 14,926
Preferred Stock, Par or Stated Value Per Share $ 0.0001  
Preferred Stock, Shares Authorized 7,500,000  
Preferred Stock, Shares Issued 0  
Common Class A [Member]    
Common Stock, Shares, Issued 25,190,963 25,169,944
Common Stock, Shares, Outstanding 22,920,768 23,422,506
Common Class B [Member]    
Common Stock, Shares, Issued 5,074,909 5,095,930
Common Stock, Shares, Outstanding 5,074,909 5,095,930
Treasury Stock, Common    
Treasury Stock, Shares 2,270,195 1,747,438
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Net sales $ 649,729 $ 632,124 $ 1,899,025 $ 1,990,078
Cost of goods sold 293,826 296,441 862,037 929,495
Gross profit 355,903 335,683 1,036,988 1,060,583
Selling, general and administrative expense 200,440 201,199 610,042 634,576
Research and Development Expense 90,997 43,535 216,276 183,528
Segment profit (loss) 64,466 90,949 210,670 242,479
Interest expense 12,174 12,398 36,715 37,078
Foreign exchange (gains) losses, net 1,641 (1,680) (2,012) (5,280)
Marketable Securities, Unrealized (Gain) Loss (792,888) (36,425) 1,680,290 1,576,542
Other Nonoperating Income (Expense) 18,081 20,446 70,740 87,365
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 861,620 137,102 (1,433,583) (1,278,496)
(Provision) benefit for income taxes (208,448) (30,845) 305,185 291,464
Net income attributable to Bio-Rad $ 653,172 $ 106,257 $ (1,128,398) $ (987,032)
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 23.37 $ 3.65 $ (39.89) $ (33.63)
Weighted average common shares - basic 27,949 29,102 28,286 29,349
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 23.34 $ 3.64 $ (39.89) $ (33.63)
Weighted average common shares - diluted 27,985 29,223 28,286 29,349
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Net Income (Loss) Attributable to Parent $ 653,172 $ 106,257 $ (1,128,398) $ (987,032)
Foreign currency translation adjustments 122,932 (126,165) 6,570 (34,342)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent (69) (342) 815 (72)
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense 13,225 1,808 13,379 3,675
Total other comprehensive income (loss) net of tax 136,088 (124,699) 20,764 (30,739)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ 789,260 $ (18,442) $ (1,107,634) $ (1,017,771)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Cash flows from operating activities:    
Cash received from customers $ 1,920,985 $ 2,007,482
Cash paid to suppliers and employees (1,531,330) (1,722,173)
Interest paid, net (45,628) (46,394)
Income tax payments, net (75,710) (40,966)
Investment proceeds and miscellaneous receipts, net 67,193 81,828
Proceeds from forward foreign exchange contracts, net (4,462) 14,119
Net cash provided by operating activities 331,048 293,896
Cash flows from investing activities:    
Capital expenditures (122,686) (114,435)
Proceeds from dispositions of property, plant and equipment 149 104
Payments for acquired in-process research and development (23,410) 0
Payments for purchases of marketable securities and investments (1,053,660) (537,540)
Proceeds from maturities of marketable securities and investments 169,458 260,849
Proceeds from Sale of Debt Securities, Available-for-sale 900,493 339,033
Net cash used in investing activities (129,656) (51,989)
Cash flows from financing activities:    
Payments on long-term borrowings (359) (349)
Payments for debt issuance costs (617) 0
Proceeds from Issuance of Common Stock 15,290 14,168
Tax payments from net share settlement (3,280) (10,118)
Payments for purchases of treasury stock (203,586) (228,728)
Net cash used in financing activities (192,552) (225,027)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (1,021) 6,891
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7,819 23,771
Beginning Cash, Cash Equivalents, and Restricted Cash 404,369 434,544
Cash and cash equivalents 410,377 457,850
Restricted Cash, Current 1,376 79
Restricted Cash, Noncurrent 435 386
Ending Cash, Cash Equivalents, and Restricted Cash $ 412,188 $ 458,315
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock, Common
Retained Earnings [Member]
AOCI Attributable to Parent
Total Stockholders' Equity at Dec. 31, 2022 $ 9,615,252 $ 3 $ 447,454 $ (263,586) $ 9,898,203 $ (466,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 68,962 0 0 0 68,962 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 58,470 0 0 0 0 58,470
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 16,608 0 16,608 0 0 0
Stock Issued During Period, Value, Treasury Stock Reissued 4,424 0 (660) 5,290 (206) 0
Total Stockholders' Equity at Mar. 31, 2023 9,763,716 3 463,402 (258,296) 9,966,959 (408,352)
Total Stockholders' Equity at Dec. 31, 2022 9,615,252 3 447,454 (263,586) 9,898,203 (466,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (987,032)          
Proceeds from Issuance of Common Stock (14,168)          
Total Stockholders' Equity at Sep. 30, 2023 8,416,198 3 439,455 (436,620) 8,910,921 (497,561)
Total Stockholders' Equity at Mar. 31, 2023 9,763,716 3 463,402 (258,296) 9,966,959 (408,352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (1,162,251) 0 0 0 (1,162,251) 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 35,490 0 0 0 0 35,490
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12,559 0 12,559 0 0 0
Treasury Stock, Value, Acquired, Cost Method (207,407) 0 0 (207,407) 0 0
Stock Issued During Period, Value, Treasury Stock Reissued 4,786 0 (2,089) 6,919 (44) 0
Total Stockholders' Equity at Jun. 30, 2023 8,446,893 3 473,872 (458,784) 8,804,664 (372,862)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 106,257 0 0 0 106,257 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (124,699) 0 0 0 0 (124,699)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 15,952 0 15,952 0 0 0
Proceeds from Issuance of Common Stock (5,111) 0 (5,111) 0 0 0
Treasury Stock, Value, Acquired, Cost Method (23,608) 0 0 (23,608) 0 0
Reissuance of treasury stock 514 0 (45,258) 45,772 0 0
Total Stockholders' Equity at Sep. 30, 2023 8,416,198 3 439,455 (436,620) 8,910,921 (497,561)
Total Stockholders' Equity at Dec. 31, 2023 8,741,133 3 449,075 (632,536) 9,260,629 (336,038)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 383,916 0 0 0 383,916 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (89,933) 0 0 0 0 (89,933)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 15,262 0 15,262 0 0 0
Treasury Stock, Value, Acquired, Cost Method (4,702) 0 0 (4,702) 0 0
Stock Issued During Period, Value, Treasury Stock Reissued 5,505 0 (1,710) 7,215 0 0
Stock Repurchased During Period, Excise Tax, Amount (47) 0 0 (47) 0 0
Total Stockholders' Equity at Mar. 31, 2024 9,051,134 3 462,627 (630,070) 9,644,545 (425,971)
Total Stockholders' Equity at Dec. 31, 2023 8,741,133 3 449,075 (632,536) 9,260,629 (336,038)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (1,128,398)          
Proceeds from Issuance of Common Stock (15,290)          
Total Stockholders' Equity at Sep. 30, 2024 7,487,859 3 448,329 (777,430) 8,132,231 (315,274)
Total Stockholders' Equity at Mar. 31, 2024 9,051,134 3 462,627 (630,070) 9,644,545 (425,971)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (2,165,486) 0 0 0 (2,165,486) 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (25,391) 0 0 0 0 (25,391)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 14,999 0 14,999 0 0 0
Treasury Stock, Value, Acquired, Cost Method (100,000) 0 0 (100,000) 0 0
Stock Issued During Period, Value, Treasury Stock Reissued 4,683 0 (2,745) 7,428 0 0
Stock Repurchased During Period, Excise Tax, Amount (1,000) 0 0 (1,000) 0 0
Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount (152) 0 (152) 0 0 0
Total Stockholders' Equity at Jun. 30, 2024 6,778,787 3 474,729 (723,642) 7,479,059 (451,362)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 653,172 0 0 0 653,172 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 136,088 0 0 0 0 136,088
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 15,675 0 15,675 0 0 0
Treasury Stock, Value, Acquired, Cost Method (96,868) 0 0 (96,868) 0 0
Stock Repurchased During Period, Excise Tax, Amount (969) 0 0 (969) 0 0
Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount (3,128) 0 (3,128) 0 0 0
Reissuance of treasury stock (5,102) 0 38,947 (44,049) 0 0
Total Stockholders' Equity at Sep. 30, 2024 $ 7,487,859 $ 3 $ 448,329 $ (777,430) $ 8,132,231 $ (315,274)
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Use of Estimates
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Use of Estimates
1. BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the loan receivable. Actual results could differ materially from those estimates.

Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is
allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.

We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.

We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.

Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).
Contract costs:

We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
United States$276.2 $275.4 $783.4 $858.8 
EMEA205.7 193.1 612.4 609.1 
APAC126.9 118.9 375.2 398.9 
Other (primarily Canada and Latin America)40.9 44.7 128.0 123.3 
Total net sales$649.7 $632.1 $1,899.0 $1,990.1 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).

Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2024 and December 31, 2023 was $64.0 million and $68.3 million, respectively. The short-term deferred revenue balance at September 30, 2024 and December 31, 2023 was $48.9 million and $51.1 million, respectively.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Changes in our warranty liability for the nine months ended September 30, 2024 and 2023 were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$8.4 $10.6 
Provision for warranty5.2 6.4 
Actual warranty costs(5.7)(9.0)
Balance at end of period$7.9 $8.0 

Accounts Receivable and Allowance for Credit Losses
We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.
Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.

Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$14.9 $15.0 
Provision for expected credit losses2.1 1.4 
Write-offs charged against the allowance(4.9)(1.3)
Balance at end of period$12.1 $15.1 

Saber Bio Acquisition

On July 26, 2024, the Company entered into a stock purchase agreement (the “Transaction”) to acquire all of the outstanding equity interests in Saber Bio (“Saber”). The Transaction closed on August 20, 2024. The Company accounted for the Transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single or similar in-process research and development project (“IPR&D”). The Company concluded that the acquired IPR&D does not meet the criteria for capitalization and expensed the acquired IPR&D. This amounted to $29.5 million which was recorded in Research and development expense in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024.

Recent Accounting Pronouncements Issued and to be Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, “Improvements to Reportable Segment Disclosures”. The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker ("CODM"). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.

In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However, on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements
 3 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements
2. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value
measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•Level 1: Quoted prices in active markets for identical instruments
•Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2024 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Time deposits— 43.2 — 43.2 
Money market funds110.9 — — 110.9 
Total cash equivalents (a)110.9 43.2 — 154.1 
Restricted investments (b)7.1 — — 7.1 
Equity securities (c)5,701.4 — — 5,701.4 
Loan under the fair value option (d)— — 343.5 343.5 
Available-for-sale investments:
Corporate debt securities— 543.8 — 543.8 
U.S. government sponsored agencies— 147.0 — 147.0 
Foreign government obligations— 2.6 — 2.6 
Municipal obligations— 6.7 — 6.7 
Asset-backed securities— 433.2 — 433.2 
Total available-for-sale investments (e)— 1,133.3 — 1,133.3 
Forward foreign exchange contracts (f)— 2.2 — 2.2 
Total financial assets carried at fair value$5,819.4 $1,178.7 $343.5 $7,341.6 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $0.9 $— $0.9 
Contingent consideration (h)— — 18.3 18.3 
Total financial liabilities carried at fair value$— $0.9 $18.3 $19.2 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $12.5 $— $12.5 
Time deposits— 36.6 — 36.6 
U.S. government sponsored agencies— 7.0 — 7.0 
Money market funds28.0 — — 28.0 
Total cash equivalents (a)28.0 56.1 — 84.1 
Restricted investments (b)7.1 — — 7.1 
Equity securities (c)7,399.3 — — 7,399.3 
Loan under the fair value option (d)— — 325.7 325.7 
Available-for-sale investments:
Corporate debt securities— 531.6 — 531.6 
U.S. government sponsored agencies— 255.9 — 255.9 
Foreign government obligations— 12.7 — 12.7 
Municipal obligations— 12.1 — 12.1 
Asset-backed securities— 323.7 — 323.7 
Total available-for-sale investments (e)— 1,136.0 — 1,136.0 
Forward foreign exchange contracts (f)— 4.1 — 4.1 
Total financial assets carried at fair value$7,434.4 $1,196.2 $325.7 $8,956.3 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $11.7 $— $11.7 
Contingent consideration (h)— — 17.5 17.5 
Total financial liabilities carried at fair value$— $11.7 $17.5 $29.2 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Restricted investments$5.6 $5.6 
Other investments1.5 1.5 
    Total$7.1 $7.1 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Short-term investments$78.7 $67.2 
Other investments5,622.7 7,332.1 
        Total$5,701.4 $7,399.3 

(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.
(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.4 million and $0.8 million in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2024.

Level 1 Fair Value Measurements

As of September 30, 2024, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG ("Sartorius"), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the outstanding ordinary shares (excluding treasury shares) and 27% of the preference shares of Sartorius as of September 30, 2024. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.

The change in fair market value of our investment in Sartorius for the three and nine months ended September 30, 2024 was a gain of $761.1 million and a loss of $1,711.0 million, respectively, and are recorded in our condensed consolidated statements of income (loss).

Level 2 Fair Value Measurements

To estimate the fair value of Level 2 debt securities as of September 30, 2024 and December 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

Available-for-sale investments consist of the following (in millions):
 September 30, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$536.6 $7.5 $(0.3)$543.8 
Municipal obligations6.6 0.1 — 6.7 
Asset-backed securities430.3 3.7 (0.8)433.2 
U.S. government sponsored agencies145.9 1.3 (0.2)147.0 
Foreign government obligations2.6 — — 2.6 
 $1,122.0 $12.6 $(1.3)$1,133.3 
The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2024 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$120.5 $120.4 
Mature in one to five years702.9 711.8 
Mature in more than five years298.6 301.1 
Total$1,122.0 $1,133.3 

Available-for-sale investments consist of the following (in millions):
 December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$534.1 $0.8 $(3.3)$531.6 
Municipal obligations12.2 — (0.1)12.1 
Asset-backed securities325.7 0.7 (2.7)323.7 
U.S. government sponsored agencies257.4 0.1 (1.6)255.9 
Foreign government obligations12.8 — (0.1)12.7 
Total$1,142.2 $1.6 $(7.8)$1,136.0 

As of September 30, 2024, there were no significant continuous unrealized losses greater than 12 months.

Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At September 30, 2024, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2024.
Included in Other current assets are $11.1 million and $11.9 million of interest receivable as of September 30, 2024 and December 31, 2023, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the nine months ended September 30, 2024, we have not written-off any uncollected interest receivable.

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of September 30, 2024 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was
derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).

The following is a summary of our forward foreign currency exchange contracts (in millions):

Contracts to sell foreign currency:
September 30, 2024December 31, 2023
Notional value$673.7 $873.5 
Unrealized gain/(loss)
$1.3 $(8.1)
Contracts to purchase foreign currency:
 
Notional value$44.4 $133.6 
Unrealized gain/(loss)
$— $0.5 

Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $8.0 million and $6.5 million as of September 30, 2024 and December 31, 2023, respectively.

Also included in Other investments in the condensed consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in Other income, net in our condensed consolidated statements of income (loss). The carrying value of these investments, net of impairments, was $26.8 million and $32.3 million as of September 30, 2024 and December 31, 2023, respectively.

The carrying value and fair value of our long-term debt were as follows (in millions):

September 30, 2024December 31, 2023
Carrying Value
Fair Value
Carrying ValueFair Value
Senior notes
$1,190.8 $1,119.9 $1,189.5 $1,102.5 
Other long-term debt
9.3 9.3 9.6 9.6 
Total
$1,200.1 $1,129.2 $1,199.1 $1,112.1 

The fair value of our long-term debt was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.

Level 3 Fair Value Investments

During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (“Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan
include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended September 30, 2024 was a gain of $25.2 million, which includes a $18.1 million gain from change in fair market value of the Loan and a $7.1 million gain from change in fair market value of the value appreciation right. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the nine months ended September 30, 2024 was a gain of $14.7 million, which includes a $33.1 million gain from change in fair market value of the Loan and a $18.4 million loss from change in fair market value of the value appreciation right. The increase in the fair market value of the value appreciation right was due to an increase in the value of the Sartorius ordinary shares. As of September 30, 2024, the €400 million principal amount of the loan is still due on January 31, 2029.

The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2023$325.7 
Change in estimated fair market value, net
$14.7 
Foreign currency exchange losses, net
$3.1 
September 30, 2024$343.5 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Purchased Intangible Assets
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Purchased Intangible Assets
3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment are as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of January 1, 2024:
Goodwill$333.3 $415.5 $748.8 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net291.5 122.1 413.6 
Foreign currency adjustments— 1.5 1.5 
Period change, net
— 1.5 1.5 
Balances as of September 30, 2024:
Goodwill333.3 417.0 750.3 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$291.5 $123.6 $415.1 

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):
September 30, 2024
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists4.8$108.4 $(100.6)$7.8 
Know how1.0169.7 (165.2)4.5 
Developed product technology11.6219.3 (141.5)77.8 
Licenses4.259.3 (45.2)14.1 
Tradenames4.86.0 (4.9)1.1 
Covenants not to compete1.56.4 (5.4)1.0 
     Total finite-lived intangible assets569.1 (462.8)106.3 
In-process research and development201.0 — 201.0 
     Total purchased intangible assets $770.1 $(462.8)$307.3 
 December 31, 2023
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.2$108.7 $(98.9)$9.8 
Know how1.8168.9 (161.1)7.8 
Developed product technology12.0217.8 (132.9)84.9 
Licenses4.959.2 (42.4)16.8 
Tradenames5.66.1 (4.7)1.4 
Covenants not to compete2.36.4 (4.8)1.6 
     Total finite-lived intangible assets567.1 (444.8)122.3 
In-process research and development198.2 — 198.2 
     Total purchased intangible assets $765.3 $(444.8)$320.5 

Amortization expense related to purchased intangible assets is as follows (in millions):

Three Months EndedNine Months Ended
 September 30,September 30,
 2024202320242023
Amortization expense$5.3 $6.2 $16.1 $18.1 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Inventory
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventory
4. INVENTORY

Following are the components of Inventory at September 30, 2024 and December 31, 2023 (in millions):

September 30, 2024December 31, 2023
Inventory:
  Raw materials$229.5 $231.6 
  Work in process255.2 246.0 
  Finished goods 319.6 302.9 
      Total Inventory$804.3 $780.5 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Supplemental Cash Flow Information
 9 Months Ended
Sep. 30, 2024
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information
5. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):
Nine Months Ended
September 30,
20242023
Net loss$(1,128.4)$(987.0)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization112.4 108.7 
Reduction in the carrying amount of right-of-use assets31.1 30.7 
Share-based compensation45.9 45.1 
Acquired in-process research and development
29.5 — 
Losses from change in fair market value of equity securities and loan receivable1,680.3 1,576.5 
Changes in fair value of contingent consideration0.8 (18.5)
Payments for operating lease liabilities(32.2)(30.4)
Decrease in accounts receivable25.6 31.6 
Increase in inventories(16.0)(61.7)
(Increase) decrease in other current assets(4.7)15.0 
Decrease in accounts payable and other current liabilities(24.4)(72.4)
Increase in income taxes payable21.8 56.4 
Decrease in deferred income taxes(408.5)(397.4)
Increase in other long-term liabilities1.4 3.9 
Other(3.6)(6.6)
Net cash provided by operating activities$331.0 $293.9 
Non-cash investing activities:
Purchased property, plant and equipment$7.4 $2.9 
Purchased marketable securities and investments$5.7 $— 
Sold marketable securities and investments$0.2 $— 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Long-Term Debt
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Long-term Debt
6. LONG-TERM DEBT

The principal components of long-term debt are as follows (in millions):
September 30,
2024		December 31,
2023
3.3%, Senior Notes due 2027
$400.0 $400.0 
3.7%, Senior Notes due 2032
800.0 800.0 
Less unamortized discounts and debt issuance costs(9.2)(10.5)
Long-term debt less unamortized discounts and debt issuance costs1,190.8 1,189.5 
Finance leases and other debt10.6 10.1 
Less current maturities(1.3)(0.5)
Long-term debt$1,200.1 $1,199.1 

On February 13, 2024, we entered into a new $200.0 million unsecured revolving credit agreement ("Revolving Credit Agreement") with a group of financial institutions. The Revolving Credit Agreement replaced the Company's previous credit agreement, dated as of April 15, 2019. Borrowings under the Revolving Credit Agreement are on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. The Revolving Credit Agreement requires Bio-Rad to comply with certain financial ratios and other customary covenants and provisions. The Revolving Credit Agreement matures on February 13, 2029. As of September 30, 2024, no borrowings were outstanding under the Revolving Credit Agreement, although available capacity was reduced by immaterial outstanding letters of credit. As of September 30, 2024, we were in compliance with the covenants for the Revolving Credit Agreement.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive Income (Loss)
7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2024:$(334.1)$(2.8)$0.9 $(336.0)
Other comprehensive income, before reclassifications6.6 0.1 19.1 25.8 
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)(1.7)(2.1)
Income tax effects(0.1)1.1 (4.0)(3.0)
Other comprehensive income, net of income taxes6.5 0.8 13.4 20.7 
Balances as of September 30, 2024:$(327.6)$(2.0)$14.3 $(315.3)
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2023:$(466.5)$10.0 $(10.3)$(466.8)
Other comprehensive income (loss), before reclassifications(34.4)0.3 3.7 (30.4)
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)1.1 0.7 
Income tax effects0.1 — (1.1)(1.0)
Other comprehensive income (loss), net of income taxes(34.3)(0.1)3.7 (30.7)
Balances as of September 30, 2023:$(500.8)$9.9 $(6.6)$(497.5)

All amounts reclassified out of Accumulated other comprehensive income (loss) were reclassified into Other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.

The impact to Income (loss) before income taxes for amounts reclassified out of Accumulated other comprehensive income (loss) into Other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
Components of comprehensive income (loss)2024202320242023
Amortization of foreign other post-employment benefit items$0.1 $0.2 $0.4 $0.4 
Net holding gains (losses) on equity securities and available-for-sale investments
$2.0 $(0.1)$1.7 $(1.1)
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Earnings (Loss) Per Share
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share
8. EARNINGS (LOSS) PER SHARE

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock ("Class A") and Class B Common Stock ("Class B"). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one-tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.

We compute Net income (loss) per share of Class A and Class B using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the nine months ended September 30, 2024 and 2023.
Accordingly, Basic earnings (loss) per share is computed by dividing Net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings (loss) per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Basic weighted average shares outstanding27,949 29,102 28,286 29,349 
Effect of potentially dilutive stock options, restricted stock and performance stock awards36 121 — — 
Diluted weighted average common shares outstanding27,985 29,223 28,286 29,349 
Anti-dilutive shares257 154 411 229 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Other Income, Net
 9 Months Ended
Sep. 30, 2024
Other Income and Expenses [Abstract]  
Other Income, Net
9. OTHER INCOME, NET

Other income, net includes the following components (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Interest and investment income$(15.5)$(17.3)$(66.1)$(84.1)
Net realized (gains) losses on investments
(2.0)0.1 (1.7)1.6 
Escrow receipts on prior acquisition— (2.5)— (2.5)
Other income(0.6)(0.7)(2.9)(2.4)
Other income, net$(18.1)$(20.4)$(70.7)$(87.4)
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes
 9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes
10. INCOME TAXES

Our effective income tax rate was 24.2% and 22.5% for the three months ended September 30, 2024 and 2023, respectively. Our effective income tax rate was 21.3% and 22.8% for the nine months ended September 30, 2024 and 2023, respectively.

The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of September 30, 2024, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $17.0 million for the period ended September 30, 2024 compared to the year ended December 31, 2023.
Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our gross unrecognized tax benefits were $88.5 million and $84.7 million as of September 30, 2024 and December 31, 2023, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.

As of September 30, 2024, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $16.2 million. Substantially all such amounts will impact our effective income tax rate if recognized.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment Information
11. SEGMENT INFORMATION

Information regarding net sales and operating profit (loss) for the three months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$260.9 $388.8 $— 
 2023$263.5 $368.1 $0.5 
Operating profit (loss)2024$(9.8)$74.2 $0.1 
 2023$13.0 $78.0 $(0.1)

Information regarding Net sales and operating profit (loss) for the nine months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$753.1 $1,145.4 $0.5 
 2023$887.3 $1,100.3 $2.5 
Operating profit (loss)2024$1.1 $209.9 $(0.3)
 2023$76.7 $166.1 $(0.3)

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our CODM views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.
The following reconciles total operating profit to consolidated income (loss) before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Operating profit$64.5 $90.9 $210.7 $242.5 
Interest expense(12.2)(12.3)(36.7)(37.2)
Foreign currency exchange (losses) gains, net
(1.6)1.7 2.0 5.3 
Gains (losses) from change in fair market value of equity securities and loan receivable
792.8 36.4 (1,680.3)(1,576.5)
Other income, net18.1 20.4 70.7 87.4 
Consolidated income (loss) before income taxes
$861.6 $137.1 $(1,433.6)$(1,278.5)
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Legal Proceedings
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings
12. LEGAL PROCEEDINGS
We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Leases
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Leases
13. LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 15 years, which includes our determination to exercise renewal options.

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt, net of current maturities in our condensed consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

The components of lease expense were as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Operating lease cost$17.3 $15.7 $52.2 $47.2 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 $0.3 $0.3 
  Interest on lease liabilities0.2 0.2 0.5 0.6 
        Total finance lease cost$0.3 $0.3 $0.8 $0.9 

Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.

Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and nine months ended September 30, 2024 and 2023. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and nine months ended September 30, 2024 and 2023.

Supplemental cash flow information related to leases was as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$10.8 $10.6 $32.2 $30.4 
  Operating cash flows from finance leases$0.2 $0.2 $0.5 $0.6 
  Financing cash flows from finance leases$0.1 $0.1 $0.3 $0.3 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$0.1 $36.7 $11.3 $49.0 

Supplemental balance sheet information related to leases was as follows (in millions):
September 30, 2024December 31, 2023
Operating Leases
  Operating lease right-of-use assets$173.9 $194.7 
  Current operating lease liabilities$42.8 $40.4 
  Operating lease liabilities143.9 165.5 
     Total operating lease liabilities$186.7 $205.9 

Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt and notes payable, net of current maturities (in millions):
September 30, 2024December 31, 2023
Finance Leases
  Property, plant and equipment, gross$11.9 $11.9 
  Less: accumulated depreciation and amortization(6.2)(5.9)
      Property, plant and equipment, net$5.7 $6.0 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities9.3 9.6 
      Total finance lease liabilities$9.8 $10.1 

September 30, 2024December 31, 2023
Weighted Average Remaining Lease Term
  Operating leases - in years67
  Finance leases - in years1314
Weighted Average Discount Rate
  Operating leases4.0 %3.9 %
  Finance leases6.5 %6.4 %

Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2024 (excluding the nine months ended September 30, 2024)
$10.8 $0.3 
2025
49.0 1.1 
2026
37.3 1.1 
2027
28.8 1.1 
2028
22.2 1.1 
Thereafter64.1 10.8 
   Total lease payments212.2 15.5 
Less imputed interest(25.5)(5.7)
    Total$186.7 $9.8 

The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.

As of September 30, 2024, operating leases that have not commenced are not material.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure                
Net Income (Loss) Attributable to Parent $ 653,172 $ (2,165,486) $ 383,916 $ 106,257 $ (1,162,251) $ 68,962 $ (1,128,398) $ (987,032)
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Use of Estimates (Policies)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023.
Subsequent Events, Policy
We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.
Use of Estimates
Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the loan receivable. Actual results could differ materially from those estimates.
Revenue Recognition
Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is
allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.

We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.

We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.

Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).
Contract costs:

We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
United States$276.2 $275.4 $783.4 $858.8 
EMEA205.7 193.1 612.4 609.1 
APAC126.9 118.9 375.2 398.9 
Other (primarily Canada and Latin America)40.9 44.7 128.0 123.3 
Total net sales$649.7 $632.1 $1,899.0 $1,990.1 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).

Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2024 and December 31, 2023 was $64.0 million and $68.3 million, respectively. The short-term deferred revenue balance at September 30, 2024 and December 31, 2023 was $48.9 million and $51.1 million, respectively.
Standard Product Warranty, Policy
We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Changes in our warranty liability for the nine months ended September 30, 2024 and 2023 were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$8.4 $10.6 
Provision for warranty5.2 6.4 
Actual warranty costs(5.7)(9.0)
Balance at end of period$7.9 $8.0 
Accounts Receivable and Allowance for Credit Losses
Accounts Receivable and Allowance for Credit Losses
We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.
Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.

Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$14.9 $15.0 
Provision for expected credit losses2.1 1.4 
Write-offs charged against the allowance(4.9)(1.3)
Balance at end of period$12.1 $15.1 
Recent Accounting Pronouncements Issued and to be Adopted
Recent Accounting Pronouncements Issued and to be Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, “Improvements to Reportable Segment Disclosures”. The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker ("CODM"). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.

In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However, on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
United States$276.2 $275.4 $783.4 $858.8 
EMEA205.7 193.1 612.4 609.1 
APAC126.9 118.9 375.2 398.9 
Other (primarily Canada and Latin America)40.9 44.7 128.0 123.3 
Total net sales$649.7 $632.1 $1,899.0 $1,990.1 
Schedule of Product Warranty Liability [Table Text Block]
Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Changes in our warranty liability for the nine months ended September 30, 2024 and 2023 were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$8.4 $10.6 
Provision for warranty5.2 6.4 
Actual warranty costs(5.7)(9.0)
Balance at end of period$7.9 $8.0 
Accounts Receivable, Allowance for Credit Loss [Table Text Block]
Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20242023
Balance at beginning of period$14.9 $15.0 
Provision for expected credit losses2.1 1.4 
Write-offs charged against the allowance(4.9)(1.3)
Balance at end of period$12.1 $15.1 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements, Recurring and Nonrecurring
Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2024 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Time deposits— 43.2 — 43.2 
Money market funds110.9 — — 110.9 
Total cash equivalents (a)110.9 43.2 — 154.1 
Restricted investments (b)7.1 — — 7.1 
Equity securities (c)5,701.4 — — 5,701.4 
Loan under the fair value option (d)— — 343.5 343.5 
Available-for-sale investments:
Corporate debt securities— 543.8 — 543.8 
U.S. government sponsored agencies— 147.0 — 147.0 
Foreign government obligations— 2.6 — 2.6 
Municipal obligations— 6.7 — 6.7 
Asset-backed securities— 433.2 — 433.2 
Total available-for-sale investments (e)— 1,133.3 — 1,133.3 
Forward foreign exchange contracts (f)— 2.2 — 2.2 
Total financial assets carried at fair value$5,819.4 $1,178.7 $343.5 $7,341.6 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $0.9 $— $0.9 
Contingent consideration (h)— — 18.3 18.3 
Total financial liabilities carried at fair value$— $0.9 $18.3 $19.2 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $12.5 $— $12.5 
Time deposits— 36.6 — 36.6 
U.S. government sponsored agencies— 7.0 — 7.0 
Money market funds28.0 — — 28.0 
Total cash equivalents (a)28.0 56.1 — 84.1 
Restricted investments (b)7.1 — — 7.1 
Equity securities (c)7,399.3 — — 7,399.3 
Loan under the fair value option (d)— — 325.7 325.7 
Available-for-sale investments:
Corporate debt securities— 531.6 — 531.6 
U.S. government sponsored agencies— 255.9 — 255.9 
Foreign government obligations— 12.7 — 12.7 
Municipal obligations— 12.1 — 12.1 
Asset-backed securities— 323.7 — 323.7 
Total available-for-sale investments (e)— 1,136.0 — 1,136.0 
Forward foreign exchange contracts (f)— 4.1 — 4.1 
Total financial assets carried at fair value$7,434.4 $1,196.2 $325.7 $8,956.3 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $11.7 $— $11.7 
Contingent consideration (h)— — 17.5 17.5 
Total financial liabilities carried at fair value$— $11.7 $17.5 $29.2 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Restricted investments$5.6 $5.6 
Other investments1.5 1.5 
    Total$7.1 $7.1 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Short-term investments$78.7 $67.2 
Other investments5,622.7 7,332.1 
        Total$5,701.4 $7,399.3 

(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.
(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.4 million and $0.8 million in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2024.
Debt Securities, Available-for-sale
Available-for-sale investments consist of the following (in millions):
 September 30, 2024
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$536.6 $7.5 $(0.3)$543.8 
Municipal obligations6.6 0.1 — 6.7 
Asset-backed securities430.3 3.7 (0.8)433.2 
U.S. government sponsored agencies145.9 1.3 (0.2)147.0 
Foreign government obligations2.6 — — 2.6 
 $1,122.0 $12.6 $(1.3)$1,133.3 
Available-for-sale investments consist of the following (in millions):
 December 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$534.1 $0.8 $(3.3)$531.6 
Municipal obligations12.2 — (0.1)12.1 
Asset-backed securities325.7 0.7 (2.7)323.7 
U.S. government sponsored agencies257.4 0.1 (1.6)255.9 
Foreign government obligations12.8 — (0.1)12.7 
Total$1,142.2 $1.6 $(7.8)$1,136.0 
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date
The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2024 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$120.5 $120.4 
Mature in one to five years702.9 711.8 
Mature in more than five years298.6 301.1 
Total$1,122.0 $1,133.3 
Discussion of current derivative risk management
The following is a summary of our forward foreign currency exchange contracts (in millions):

Contracts to sell foreign currency:
September 30, 2024December 31, 2023
Notional value$673.7 $873.5 
Unrealized gain/(loss)
$1.3 $(8.1)
Contracts to purchase foreign currency:
 
Notional value$44.4 $133.6 
Unrealized gain/(loss)
$— $0.5 
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments
The carrying value and fair value of our long-term debt were as follows (in millions):

September 30, 2024December 31, 2023
Carrying Value
Fair Value
Carrying ValueFair Value
Senior notes
$1,190.8 $1,119.9 $1,189.5 $1,102.5 
Other long-term debt
9.3 9.3 9.6 9.6 
Total
$1,200.1 $1,129.2 $1,199.1 $1,112.1 
Fair Value Measurement Inputs and Valuation Techniques
The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2023$325.7 
Change in estimated fair market value, net
$14.7 
Foreign currency exchange losses, net
$3.1 
September 30, 2024$343.5 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Purchased Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment
Changes to goodwill by segment are as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of January 1, 2024:
Goodwill$333.3 $415.5 $748.8 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net291.5 122.1 413.6 
Foreign currency adjustments— 1.5 1.5 
Period change, net
— 1.5 1.5 
Balances as of September 30, 2024:
Goodwill333.3 417.0 750.3 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$291.5 $123.6 $415.1 
Schedule of identifiable purchased intangible assets with definite lives
Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):
September 30, 2024
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists4.8$108.4 $(100.6)$7.8 
Know how1.0169.7 (165.2)4.5 
Developed product technology11.6219.3 (141.5)77.8 
Licenses4.259.3 (45.2)14.1 
Tradenames4.86.0 (4.9)1.1 
Covenants not to compete1.56.4 (5.4)1.0 
     Total finite-lived intangible assets569.1 (462.8)106.3 
In-process research and development201.0 — 201.0 
     Total purchased intangible assets $770.1 $(462.8)$307.3 
 December 31, 2023
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.2$108.7 $(98.9)$9.8 
Know how1.8168.9 (161.1)7.8 
Developed product technology12.0217.8 (132.9)84.9 
Licenses4.959.2 (42.4)16.8 
Tradenames5.66.1 (4.7)1.4 
Covenants not to compete2.36.4 (4.8)1.6 
     Total finite-lived intangible assets567.1 (444.8)122.3 
In-process research and development198.2 — 198.2 
     Total purchased intangible assets $765.3 $(444.8)$320.5 
Finite-lived Intangible Assets Amortization Expense [Table Text Block]
Amortization expense related to purchased intangible assets is as follows (in millions):

Three Months EndedNine Months Ended
 September 30,September 30,
 2024202320242023
Amortization expense$5.3 $6.2 $16.1 $18.1 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Inventory (Tables)
 9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Following are the components of Inventory at September 30, 2024 and December 31, 2023 (in millions):

September 30, 2024December 31, 2023
Inventory:
  Raw materials$229.5 $231.6 
  Work in process255.2 246.0 
  Finished goods 319.6 302.9 
      Total Inventory$804.3 $780.5 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Supplemental Cash Flow Information (Tables)
 9 Months Ended
Sep. 30, 2024
Supplemental Cash Flow Elements [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures
The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):
Nine Months Ended
September 30,
20242023
Net loss$(1,128.4)$(987.0)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization112.4 108.7 
Reduction in the carrying amount of right-of-use assets31.1 30.7 
Share-based compensation45.9 45.1 
Acquired in-process research and development
29.5 — 
Losses from change in fair market value of equity securities and loan receivable1,680.3 1,576.5 
Changes in fair value of contingent consideration0.8 (18.5)
Payments for operating lease liabilities(32.2)(30.4)
Decrease in accounts receivable25.6 31.6 
Increase in inventories(16.0)(61.7)
(Increase) decrease in other current assets(4.7)15.0 
Decrease in accounts payable and other current liabilities(24.4)(72.4)
Increase in income taxes payable21.8 56.4 
Decrease in deferred income taxes(408.5)(397.4)
Increase in other long-term liabilities1.4 3.9 
Other(3.6)(6.6)
Net cash provided by operating activities$331.0 $293.9 
Non-cash investing activities:
Purchased property, plant and equipment$7.4 $2.9 
Purchased marketable securities and investments$5.7 $— 
Sold marketable securities and investments$0.2 $— 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Long-Term Debt (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
The principal components of long-term debt are as follows (in millions):
September 30,
2024		December 31,
2023
3.3%, Senior Notes due 2027
$400.0 $400.0 
3.7%, Senior Notes due 2032
800.0 800.0 
Less unamortized discounts and debt issuance costs(9.2)(10.5)
Long-term debt less unamortized discounts and debt issuance costs1,190.8 1,189.5 
Finance leases and other debt10.6 10.1 
Less current maturities(1.3)(0.5)
Long-term debt$1,200.1 $1,199.1 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2024:$(334.1)$(2.8)$0.9 $(336.0)
Other comprehensive income, before reclassifications6.6 0.1 19.1 25.8 
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)(1.7)(2.1)
Income tax effects(0.1)1.1 (4.0)(3.0)
Other comprehensive income, net of income taxes6.5 0.8 13.4 20.7 
Balances as of September 30, 2024:$(327.6)$(2.0)$14.3 $(315.3)
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of January 1, 2023:$(466.5)$10.0 $(10.3)$(466.8)
Other comprehensive income (loss), before reclassifications(34.4)0.3 3.7 (30.4)
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)1.1 0.7 
Income tax effects0.1 — (1.1)(1.0)
Other comprehensive income (loss), net of income taxes(34.3)(0.1)3.7 (30.7)
Balances as of September 30, 2023:$(500.8)$9.9 $(6.6)$(497.5)
Reclassification Out of Accumulated Other Comprehensive Income
The impact to Income (loss) before income taxes for amounts reclassified out of Accumulated other comprehensive income (loss) into Other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
Components of comprehensive income (loss)2024202320242023
Amortization of foreign other post-employment benefit items$0.1 $0.2 $0.4 $0.4 
Net holding gains (losses) on equity securities and available-for-sale investments
$2.0 $(0.1)$1.7 $(1.1)
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Earnings (Loss) Per Share (Tables)
 9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares
The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Basic weighted average shares outstanding27,949 29,102 28,286 29,349 
Effect of potentially dilutive stock options, restricted stock and performance stock awards36 121 — — 
Diluted weighted average common shares outstanding27,985 29,223 28,286 29,349 
Anti-dilutive shares257 154 411 229 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Other Income, Net (Tables)
 9 Months Ended
Sep. 30, 2024
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net
Other income, net includes the following components (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Interest and investment income$(15.5)$(17.3)$(66.1)$(84.1)
Net realized (gains) losses on investments
(2.0)0.1 (1.7)1.6 
Escrow receipts on prior acquisition— (2.5)— (2.5)
Other income(0.6)(0.7)(2.9)(2.4)
Other income, net$(18.1)$(20.4)$(70.7)$(87.4)
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Information regarding net sales and operating profit (loss) for the three months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$260.9 $388.8 $— 
 2023$263.5 $368.1 $0.5 
Operating profit (loss)2024$(9.8)$74.2 $0.1 
 2023$13.0 $78.0 $(0.1)

Information regarding Net sales and operating profit (loss) for the nine months ended September 30, 2024 and 2023 are as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2024$753.1 $1,145.4 $0.5 
 2023$887.3 $1,100.3 $2.5 
Operating profit (loss)2024$1.1 $209.9 $(0.3)
 2023$76.7 $166.1 $(0.3)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following reconciles total operating profit to consolidated income (loss) before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2024202320242023
Operating profit$64.5 $90.9 $210.7 $242.5 
Interest expense(12.2)(12.3)(36.7)(37.2)
Foreign currency exchange (losses) gains, net
(1.6)1.7 2.0 5.3 
Gains (losses) from change in fair market value of equity securities and loan receivable
792.8 36.4 (1,680.3)(1,576.5)
Other income, net18.1 20.4 70.7 87.4 
Consolidated income (loss) before income taxes
$861.6 $137.1 $(1,433.6)$(1,278.5)
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Leases (Tables)
 9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Lease, Cost
The components of lease expense were as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Operating lease cost$17.3 $15.7 $52.2 $47.2 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 $0.3 $0.3 
  Interest on lease liabilities0.2 0.2 0.5 0.6 
        Total finance lease cost$0.3 $0.3 $0.8 $0.9 
Lessee Supplemental Cash Flow Information
Supplemental cash flow information related to leases was as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$10.8 $10.6 $32.2 $30.4 
  Operating cash flows from finance leases$0.2 $0.2 $0.5 $0.6 
  Financing cash flows from finance leases$0.1 $0.1 $0.3 $0.3 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$0.1 $36.7 $11.3 $49.0 
Lessee Supplemental Balance Sheet Information
Supplemental balance sheet information related to leases was as follows (in millions):
September 30, 2024December 31, 2023
Operating Leases
  Operating lease right-of-use assets$173.9 $194.7 
  Current operating lease liabilities$42.8 $40.4 
  Operating lease liabilities143.9 165.5 
     Total operating lease liabilities$186.7 $205.9 

Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt and notes payable, net of current maturities (in millions):
September 30, 2024December 31, 2023
Finance Leases
  Property, plant and equipment, gross$11.9 $11.9 
  Less: accumulated depreciation and amortization(6.2)(5.9)
      Property, plant and equipment, net$5.7 $6.0 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities9.3 9.6 
      Total finance lease liabilities$9.8 $10.1 

September 30, 2024December 31, 2023
Weighted Average Remaining Lease Term
  Operating leases - in years67
  Finance leases - in years1314
Weighted Average Discount Rate
  Operating leases4.0 %3.9 %
  Finance leases6.5 %6.4 %
Maturities Of Lease Liabilities For Operating and Finance Leases
Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2024 (excluding the nine months ended September 30, 2024)
$10.8 $0.3 
2025
49.0 1.1 
2026
37.3 1.1 
2027
28.8 1.1 
2028
22.2 1.1 
Thereafter64.1 10.8 
   Total lease payments212.2 15.5 
Less imputed interest(25.5)(5.7)
    Total$186.7 $9.8 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Aug. 20, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Line Items]                      
Net sales   $ 649,729 $ 632,124 $ 1,899,025 $ 1,990,078            
Cost of goods sold   293,826 296,441 862,037 929,495            
Deferred Revenue   64,000   64,000       $ 68,300      
Retained earnings   8,132,231   8,132,231       9,260,629      
Accumulated other comprehensive loss   (315,274)   (315,274)       (336,038)      
Total stockholders' equity   $ 7,487,859 8,416,198 $ 7,487,859 8,416,198 $ 6,778,787 $ 9,051,134 8,741,133 $ 8,446,893 $ 9,763,716 $ 9,615,252
Revenue Allocation Percent To Lease Elements   3.00%   3.00%              
Additional paid-in-capital   $ 448,329   $ 448,329       449,075      
Selling, general and administrative expense   200,440 201,199 610,042 634,576            
Interest expense   12,174 12,398 36,715 37,078            
Other Nonoperating Income (Expense)   18,081 20,446 70,740 87,365            
Deferred Revenue, Current   48,900   48,900       $ 51,100      
Saber Bio Acquisition | Research and Development Expense                      
Organization, Consolidation and Presentation of Financial Statements [Line Items]                      
Asset Acquisition, Consideration Transferred $ 29,500                    
Europe [Member]                      
Organization, Consolidation and Presentation of Financial Statements [Line Items]                      
Net sales   205,700 193,100 612,400 609,100            
Asia Pacific [Member]                      
Organization, Consolidation and Presentation of Financial Statements [Line Items]                      
Net sales   126,900 118,900 375,200 398,900            
UNITED STATES                      
Organization, Consolidation and Presentation of Financial Statements [Line Items]                      
Net sales   276,200 275,400 783,400 858,800            
Americas [Member]                      
Organization, Consolidation and Presentation of Financial Statements [Line Items]                      
Net sales   $ 40,900 $ 44,700 $ 128,000 $ 123,300            
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Warranty accrual, beginning of period $ 8.4 $ 10.6
Provision for warranty 5.2 6.4
Actual warranty costs (5.7) (9.0)
Warranty accrual, end of period $ 7.9 $ 8.0
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Accounts Receivable, Allowance for Credit Loss $ 12.1 $ 15.1 $ 14.9 $ 15.0
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 2.1 1.4    
Allowance for Loan and Lease Losses, Write-offs $ (4.9) $ (1.3)    
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Basis of Presentation and Use of Estimates (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Revenue Allocation Percent To Lease Elements 3.00% 3.00%
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Trading, and Equity Securities, FV-NI $ 343.5 $ 343.5   $ 325.7  
Debt Securities, Available-for-sale [1] 1,133.3 1,133.3      
Fair Value, Option, Changes in Fair Value, Gain (Loss) 25.2 14.7      
Foreign exchange (gains) losses, net   3.1      
Fair Value, Option, Loans Held as Assets [Abstract]          
Debt Securities [2]         $ 400.0
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions (18.1) (33.1)      
Derivative, Forward Interest Rate         1.50%
Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net (7.1) 18.4      
Changes in fair value of contingent consideration   $ 0.8 $ (18.5)    
Unrealized Gain on Securities $ 761.1        
Ordinary voting shares [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment ownership percentage 38.00% 38.00%      
Preference shares [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment ownership percentage 27.00% 27.00%      
Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] $ 7.1 $ 7.1   7.1  
Equity Securities [4] 5,701.4 5,701.4   7,399.3  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 343.5 343.5   325.7  
Debt Securities, Available-for-sale [1] 1,133.3 1,133.3   1,136.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 2.2 2.2   4.1  
Assets, Fair Value Disclosure 7,341.6 7,341.6   8,956.3  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.9 0.9   11.7  
Business Combination, Contingent Consideration, Liability [7] 18.3 18.3   17.5  
Liabilities, Fair Value Disclosure 19.2 19.2   29.2  
Fair Value, Recurring | Research and Development Expense          
Fair Value, Option, Loans Held as Assets [Abstract]          
Changes in fair value of contingent consideration 0.4 0.8      
Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 7.1 7.1   7.1  
Equity Securities [4] 5,701.4 5,701.4   7,399.3  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 0.0 0.0   0.0  
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.0 0.0   0.0  
Assets, Fair Value Disclosure 5,819.4 5,819.4   7,434.4  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.0 0.0   0.0  
Business Combination, Contingent Consideration, Liability [7] 0.0 0.0   0.0  
Liabilities, Fair Value Disclosure 0.0 0.0   0.0  
Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 0.0 0.0   0.0  
Equity Securities [4] 0.0 0.0   0.0  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 0.0 0.0   0.0  
Debt Securities, Available-for-sale 1,133.3 1,133.3   1,136.0 [1]  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 2.2 2.2   4.1  
Assets, Fair Value Disclosure 1,178.7 1,178.7   1,196.2  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.9 0.9   11.7  
Business Combination, Contingent Consideration, Liability [7] 0.0 0.0   0.0  
Liabilities, Fair Value Disclosure 0.9 0.9   11.7  
Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 0.0 0.0   0.0  
Equity Securities [4] 0.0 0.0   0.0  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 343.5 343.5   325.7  
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.0 0.0   0.0  
Assets, Fair Value Disclosure 343.5 343.5   325.7  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.0 0.0   0.0  
Business Combination, Contingent Consideration, Liability [7] 18.3 18.3   17.5  
Liabilities, Fair Value Disclosure 18.3 18.3   17.5  
Commercial Paper [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       12.5  
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       12.5  
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Time Deposits [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 43.2 43.2   36.6  
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 43.2 43.2   36.6  
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Money Market Funds [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 110.9 110.9   28.0  
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 110.9 110.9   28.0  
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Cash Equivalents [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 154.1 154.1   84.1  
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 110.9 110.9   28.0  
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 43.2 43.2   56.1  
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
US Treasury Securities | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       7.0  
US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       7.0  
US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Foreign Government Debt [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Municipal Obligations (Member) | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 6.7 6.7   12.1  
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 6.7 6.7   12.1  
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Foreign Government Obligations [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 2.6 2.6   12.7  
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 2.6 2.6   12.7  
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Corporate Debt Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 543.8 543.8   531.6  
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 543.8 543.8   531.6  
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
US Government Sponsored Agencies [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 147.0 147.0   255.9  
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 147.0 147.0   255.9  
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Asset-backed Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 433.2 433.2   323.7  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 433.2 433.2   323.7  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Short-term Investments [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Equity Securities [4] 78.7 78.7   67.2  
Debt Securities, Available-for-sale [1] 1,133.3 1,133.3   1,136.0  
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 6.7 6.7   12.1  
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 2.6 2.6   12.7  
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 543.8 543.8   531.6  
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 147.0 147.0   255.9  
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 433.2 433.2   323.7  
Other Investments [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 1.5 1.5   1.5  
Equity Securities [4] 5,622.7 5,622.7   7,332.1  
Restricted investment [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] $ 5.6 $ 5.6   $ 5.6  
[1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
[2] The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.
[3] Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Restricted investments$5.6 $5.6 
Other investments1.5 1.5 
    Total$7.1 $7.1 
[4] Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2024December 31, 2023
Short-term investments$78.7 $67.2 
Other investments5,622.7 7,332.1 
        Total$5,701.4 $7,399.3 
[5] Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.
[6] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.
[7] Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.4 million and $0.8 million in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2024.
[8] Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Forward foreign exchange contract to sell foreign currency [Member]    
Derivatives, Fair Value [Line Items]    
Derivative, Notional Amount $ 673.7 $ 873.5
Unrealized Gain (Loss) on Derivatives 1.3 (8.1)
Forward foreign exchange contract to purchase foreign currency [Member]    
Derivatives, Fair Value [Line Items]    
Derivative, Notional Amount 44.4 133.6
Unrealized Gain (Loss) on Derivatives $ 0.0 $ 0.5
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] $ 1,122.0  
Debt Securities, Available-for-sale [1] 1,133.3  
Equity Securities, FV-NI, Unrealized Loss (1,711.0)  
Equity Securities without Readily Determinable Fair Value, Amount 8.0 $ 8.0
Equity Method Investments 26.8 32.3
Fair Value, Recurring    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 1,133.3 1,136.0
Fair Value, Recurring | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 543.8 531.6
Fair Value, Recurring | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 6.7 12.1
Fair Value, Recurring | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 147.0 255.9
Fair Value, Recurring | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 2.6 12.7
Fair Value, Recurring | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 433.2 323.7
Fair Value, Recurring | Short-term Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 1,122.0 1,142.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 12.6 1.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (1.3) (7.8)
Debt Securities, Available-for-sale [1] 1,133.3 1,136.0
Fair Value, Recurring | Short-term Investments [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 536.6 534.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 7.5 0.8
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (0.3) (3.3)
Debt Securities, Available-for-sale [1] 543.8 531.6
Fair Value, Recurring | Short-term Investments [Member] | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 6.6 12.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.1 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] 0.0 (0.1)
Debt Securities, Available-for-sale [1] 6.7 12.1
Fair Value, Recurring | Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 145.9 257.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 1.3 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (0.2) (1.6)
Debt Securities, Available-for-sale [1] 147.0 255.9
Fair Value, Recurring | Short-term Investments [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 2.6 12.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] 0.0 (0.1)
Debt Securities, Available-for-sale [1] 2.6 12.7
Fair Value, Recurring | Short-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 430.3 325.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 3.7 0.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (0.8) (2.7)
Debt Securities, Available-for-sale [1] $ 433.2 $ 323.7
[1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Sep. 30, 2024
USD ($)
 [1]
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 120.5
Mature in one to five years 702.9
Mature in more than five years 298.6
Total Amortized Cost 1,122.0
Mature in less than one year 120.4
Mature in one to five years 711.8
Mature in more than five years 301.1
Estimated Fair Value $ 1,133.3
[1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Long-term debt, net of current maturities $ 1,200,062 $ 1,199,052
Total long-term debt, excluding leases and current maturities 1,129,200 1,112,100
Senior Notes | Senior Notes    
Debt Instrument [Line Items]    
Long-term debt 1,190,800 1,189,500
Total long-term debt, excluding leases and current maturities 1,119,900 1,102,500
Other Long-Term Debt | Other Long-Term Debt    
Debt Instrument [Line Items]    
Long-term debt 9,300 9,600
Total long-term debt, excluding leases and current maturities $ 9,300 $ 9,600
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Receivable, Current $ 11.1 $ 11.9
Ordinary voting shares [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Investment ownership percentage 38.00%  
Investment Owned, Balance, Shares 12,987,900  
Preference shares [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Investment ownership percentage 27.00%  
Investment Owned, Balance, Shares 9,588,908  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Purchased Intangible Assets (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Goodwill [Line Items]    
Goodwill $ 750,300 $ 748,800
Accumulated impairment loss (335,200) (335,200)
Goodwill, net 415,100 413,569
Goodwill, Foreign Currency Translation Gain (Loss) 1,500  
Goodwill, Period Increase (Decrease) 1,500  
Clinical Diagnostics    
Goodwill [Line Items]    
Goodwill 417,000 415,500
Accumulated impairment loss (293,400) (293,400)
Goodwill, net 123,600 122,100
Goodwill, Foreign Currency Translation Gain (Loss) 1,500  
Goodwill, Period Increase (Decrease) 1,500  
Life Science    
Goodwill [Line Items]    
Goodwill 333,300 333,300
Accumulated impairment loss (41,800) (41,800)
Goodwill, net 291,500 $ 291,500
Goodwill, Foreign Currency Translation Gain (Loss) 0  
Goodwill, Period Increase (Decrease) $ 0  
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3
Goodwill and Other Purchased Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 569,100   $ 569,100   $ 567,100
Accumulated Amortization (462,800)   (462,800)   (444,800)
Net Carrying Amount 106,300   106,300   122,300
Amortization [Abstract]          
Amortization expense 5,300 $ 6,200 16,100 $ 18,100  
Purchased intangibles, net 307,325   307,325   320,514
Intangible Assets, Gross (Excluding Goodwill) $ 770,100   $ 770,100   $ 765,300
Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 4 years 9 months 18 days   4 years 9 months 18 days   5 years 2 months 12 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 108,400   $ 108,400   $ 108,700
Accumulated Amortization (100,600)   (100,600)   (98,900)
Net Carrying Amount $ 7,800   $ 7,800   $ 9,800
Know How [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 1 year   1 year   1 year 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 169,700   $ 169,700   $ 168,900
Accumulated Amortization (165,200)   (165,200)   (161,100)
Net Carrying Amount $ 4,500   $ 4,500   $ 7,800
Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 11 years 7 months 6 days   11 years 7 months 6 days   12 years
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 219,300   $ 219,300   $ 217,800
Accumulated Amortization (141,500)   (141,500)   (132,900)
Net Carrying Amount $ 77,800   $ 77,800   $ 84,900
Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 4 years 2 months 12 days   4 years 2 months 12 days   4 years 10 months 24 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 59,300   $ 59,300   $ 59,200
Accumulated Amortization (45,200)   (45,200)   (42,400)
Net Carrying Amount $ 14,100   $ 14,100   $ 16,800
Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 4 years 9 months 18 days   4 years 9 months 18 days   5 years 7 months 6 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 6,000   $ 6,000   $ 6,100
Accumulated Amortization (4,900)   (4,900)   (4,700)
Net Carrying Amount $ 1,100   $ 1,100   $ 1,400
Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 1 year 6 months   1 year 6 months   2 years 3 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 6,400   $ 6,400   $ 6,400
Accumulated Amortization (5,400)   (5,400)   (4,800)
Net Carrying Amount 1,000   1,000   1,600
In Process Research and Development [Member]          
Amortization [Abstract]          
Indefinite-lived Intangible Assets (Excluding Goodwill) $ 201,000   $ 201,000   $ 198,200
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 229,500 $ 231,600
Work in process 255,200 246,000
Finished goods 319,600 302,900
Inventory $ 804,276 $ 780,517
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3
Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]                
Net loss $ 653,172 $ (2,165,486) $ 383,916 $ 106,257 $ (1,162,251) $ 68,962 $ (1,128,398) $ (987,032)
Depreciation and amortization             112,400 108,700
Reduction in the carrying amount of right-of-use assets             31,100 30,700
Share-based Compensation             45,900 45,100
Acquired in-process research and development             29,500 0
(Gains) losses from change in fair market value of equity securities and loan receivable             1,680,300 1,576,500
Changes in fair value of contingent consideration             800 (18,500)
Payments of operating lease liabilities             (32,200) (30,400)
Decrease in accounts receivable             25,600 31,600
Decrease (increase) in inventories             (16,000) (61,700)
Increase in other current assets             (4,700) 15,000
Decrease in accounts payable and other current liabilities             (24,400) (72,400)
Increase in income taxes payable             21,800 56,400
Increase in deferred income taxes             (408,500) (397,400)
Increase in other long term liabilities             1,400 3,900
Other             (3,600) (6,600)
Net cash provided by operating activities             331,048 293,896
Noncash or Part Noncash Acquisition, Fixed Assets Acquired             7,400 2,900
Noncash or Part Noncash Acquisition, Investments Acquired             5,700 0
Sold marketable securities and investments             $ 200 $ 0
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3
Long-Term Debt (Details) - USD ($)
Sep. 30, 2024
Feb. 13, 2024
Dec. 31, 2023
Debt Instrument [Line Items]      
Other Long-Term Debt, Current $ (1,300,000)   $ (500,000)
Long-term debt, net of current maturities 1,200,062,000   1,199,052,000
Line of Credit      
Debt Instrument [Line Items]      
Line of credit maximum borrowing capacity   $ 200,000,000  
Line of Credit, Current $ 0    
Senior Notes | 3.3%, Senior Notes due 2027      
Debt Instrument [Line Items]      
Debt Instrument, Interest Rate, Stated Percentage 3.30%    
Senior Notes, Noncurrent $ 400,000,000.0   400,000,000.0
Senior Notes | 3.7%, Senior Notes due 2032      
Debt Instrument [Line Items]      
Debt Instrument, Interest Rate, Stated Percentage 3.70%    
Senior Notes, Noncurrent $ 800,000,000.0   800,000,000.0
Senior Notes | Senior Notes      
Debt Instrument [Line Items]      
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net (9,200,000)   (10,500,000)
Long-term debt 1,190,800,000   1,189,500,000
Finance Lease Obligations | Finance Leases and Other Debt      
Debt Instrument [Line Items]      
Other Long-term Debt $ 10,600,000   $ 10,100,000
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     $ (336,038)  
Total other comprehensive income (loss) net of tax $ 136,088 $ (124,699) 20,764 $ (30,739)
Ending balance, Accumulated other comprehensive income (315,274)   (315,274)  
Other (income) expense, net (18,081) (20,446) (70,740) (87,365)
Accumulated Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     (334,100) (466,500)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     6,600 (34,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     0 0
Other Comprehensive Income (Loss), Tax     (100) 100
Total other comprehensive income (loss) net of tax     6,500 (34,300)
Ending balance, Accumulated other comprehensive income (327,600) (500,800) (327,600) (500,800)
Accumulated Defined Benefit Plans Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     (2,800) 10,000
Other Comprehensive Income (Loss), before Reclassifications, before Tax     100 300
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     400 400
Other Comprehensive Income (Loss), Tax     1,100 0
Total other comprehensive income (loss) net of tax     800 (100)
Ending balance, Accumulated other comprehensive income (2,000) 9,900 (2,000) 9,900
Accumulated Defined Benefit Plans Adjustment | Reclassification Out Of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other (income) expense, net 100 200 400 400
Accumulated Net Unrealized Investment Gain (Loss)        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     900 (10,300)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     19,100 3,700
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     1,700 (1,100)
Other Comprehensive Income (Loss), Tax     (4,000) (1,100)
Total other comprehensive income (loss) net of tax     13,400 3,700
Ending balance, Accumulated other comprehensive income 14,300 (6,600) 14,300 (6,600)
Accumulated Net Unrealized Investment Gain (Loss) | Reclassification Out Of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other (income) expense, net (2,000) 100 (1,700) 1,100
AOCI Attributable to Parent        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     (336,000) (466,800)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     25,800 (30,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     2,100 (700)
Other Comprehensive Income (Loss), Tax     (3,000) (1,000)
Total other comprehensive income (loss) net of tax     20,700 (30,700)
Ending balance, Accumulated other comprehensive income $ (315,300) $ (497,500) $ (315,300) $ (497,500)
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3
Earnings (Loss) Per Share (Details)
 9 Months Ended
Sep. 30, 2024
Common Class A [Member]  
Class of Stock [Line Items]  
Common Stock, Voting Rights 0.1
Election Percentage for Board of Directors 25.00%
Common Class B [Member]  
Class of Stock [Line Items]  
Common Stock, Voting Rights one
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3
Earnings (Loss) Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Basic weighted average shares outstanding 27,949 29,102 28,286 29,349
Effect of potentially dilutive stock options and restricted stock awards 36 121 0 0
Diluted weighted average common shares 27,985 29,223 28,286 29,349
Anti-dilutive shares 257 154 411 229
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3
Other Income, Net (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Interest and investment income $ (15,500) $ (17,300) $ (66,100) $ (84,100)
Net realized (gain) loss on investments (2,000) 100 (1,700) 1,600
Escrow receipts on prior acquisition 0 (2,500) 0 (2,500)
Other Nonoperating (Income) (600) (700) (2,900) (2,400)
Other (income) expense, net $ (18,081) $ (20,446) $ (70,740) $ (87,365)
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Income Tax Disclosure [Abstract]          
Effective tax rate 24.20% 22.50% 21.30% 22.80%  
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $ 16.2   $ 16.2    
Unrecognized Tax Benefits $ 88.5   88.5   $ 84.7
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount     $ 17.0    
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Net sales $ 649,729 $ 632,124 $ 1,899,025 $ 1,990,078
Life Science        
Segment Reporting Information [Line Items]        
Net sales 260,900 263,500 753,100 887,300
Income before income taxes (9,800) 13,000 1,100 76,700
Clinical Diagnostics        
Segment Reporting Information [Line Items]        
Net sales 388,800 368,100 1,145,400 1,100,300
Income before income taxes 74,200 78,000 209,900 166,100
Other Operating Segment        
Segment Reporting Information [Line Items]        
Net sales 0 500 500 2,500
Income before income taxes $ 100 $ (100) $ (300) $ (300)
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Interest expense $ 12,174 $ 12,398 $ 36,715 $ 37,078
Foreign Currency Transaction Gain (Loss), before Tax (1,641) 1,680 2,012 5,280
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 861,620 137,102 (1,433,583) (1,278,496)
Marketable Securities, Unrealized Gain (Loss) 792,888 36,425 (1,680,290) (1,576,542)
Other Nonoperating Income (Expense) 18,081 20,446 70,740 87,365
Net sales 649,729 632,124 1,899,025 1,990,078
Life Science        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes (9,800) 13,000 1,100 76,700
Net sales 260,900 263,500 753,100 887,300
Other Operating Segment        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 100 (100) (300) (300)
Net sales 0 500 500 2,500
Clinical Diagnostics        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 74,200 78,000 209,900 166,100
Net sales 388,800 368,100 1,145,400 1,100,300
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 64,500 90,900 210,700 242,500
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Interest expense (12,200) (12,300) (36,700) (37,200)
Foreign Currency Transaction Gain (Loss), before Tax (1,600) 1,700 2,000 5,300
Marketable Securities, Unrealized Gain (Loss) 792,800 36,400 (1,680,300) (1,576,500)
Other Nonoperating Income (Expense) $ 18,100 $ 20,400 $ 70,700 $ 87,400
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.3
Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Lessee, Lease, Description [Line Items]          
Operating Lease, Cost $ 17,300 $ 15,700 $ 52,200 $ 47,200  
Finance Lease, Right-of-Use Asset, Amortization 100 100 300 300  
Finance Lease, Interest Expense 200 200 500 600  
Finance Lease Cost 300 300 800 900  
Operating Lease, Payments 10,800 10,600 32,200 30,400  
Finance Lease, Interest Payment on Liability 200 200 500 600  
Finance Lease, Principal Payments 100 100 300 300  
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 100 $ 36,700 11,300 $ 49,000  
Operating lease right-of-use assets 173,866   173,866   $ 194,730
Current operating lease liabilities 42,834   42,834   40,379
Operating lease liabilities 143,919   143,919   165,478
Operating Lease, Liability 186,700   186,700   205,900
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization 11,900   11,900   11,900
Finance Lease, Right-Of-Use Asset, Accumulated Amortization 6,200   6,200   5,900
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization 5,700   5,700   6,000
Finance Lease, Liability, Current 500   500   500
Finance Lease, Liability, Noncurrent 9,300   9,300   9,600
Finance Lease, Liability $ 9,800   $ 9,800   $ 10,100
Operating Lease, Weighted Average Remaining Lease Term 6 years   6 years   7 years
Finance Lease, Weighted Average Remaining Lease Term 13 years   13 years   14 years
Operating Lease, Weighted Average Discount Rate, Percent 4.00%   4.00%   3.90%
Finance Lease, Weighted Average Discount Rate, Percent 6.50%   6.50%   6.40%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year $ 10,800   $ 10,800    
Finance Lease, Liability, Payments, Remainder of Fiscal Year 300   300    
Lessee, Operating Lease, Liability, to be Paid, Year One 49,000   49,000    
Finance Lease, Liability, to be Paid, Year One 1,100   1,100    
Lessee, Operating Lease, Liability, Payments, Due Year Two 37,300   37,300    
Finance Lease, Liability, Payments, Due Year Two 1,100   1,100    
Lessee, Operating Lease, Liability, Payments, Due Year Three 28,800   28,800    
Finance Lease, Liability, Payments, Due Year Three 1,100   1,100    
Lessee, Operating Lease, Liability, Payments, Due Year Four 22,200   22,200    
Finance Lease, Liability, Payments, Due Year Four 1,100   1,100    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 64,100   64,100    
Finance Lease, Liability, Payments, Due after Year Five 10,800   10,800    
Lessee, Operating Lease, Liability, Payments, Due 212,200   212,200    
Finance Lease, Liability, Payment, Due 15,500   15,500    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (25,500)   (25,500)    
Finance Lease, Liability, Undiscounted Excess Amount $ (5,700)   $ (5,700)    
Minimum          
Lessee, Lease, Description [Line Items]          
Lessee Operating And Finance Leases Remaining Lease Term     1 year    
Maximum          
Lessee, Lease, Description [Line Items]          
Lessee Operating And Finance Leases Remaining Lease Term     15 years    
EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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bio-20240930_htm.xml IDEA: XBRL DOCUMENT 0000012208 2024-01-01 2024-09-30 0000012208 us-gaap:CommonClassAMember 2024-01-01 2024-09-30 0000012208 us-gaap:CommonClassBMember 2024-01-01 2024-09-30 0000012208 us-gaap:CommonClassAMember 2024-10-28 0000012208 us-gaap:CommonClassBMember 2024-10-28 0000012208 2024-09-30 0000012208 2023-12-31 0000012208 us-gaap:CommonClassAMember 2024-09-30 0000012208 us-gaap:CommonClassAMember 2023-12-31 0000012208 us-gaap:CommonClassBMember 2024-09-30 0000012208 us-gaap:CommonClassBMember 2023-12-31 0000012208 us-gaap:TreasuryStockCommonMember 2024-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012208 2024-07-01 2024-09-30 0000012208 2023-07-01 2023-09-30 0000012208 2023-01-01 2023-09-30 0000012208 2022-12-31 0000012208 2023-09-30 0000012208 us-gaap:CommonStockMember 2023-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000012208 us-gaap:TreasuryStockCommonMember 2023-12-31 0000012208 us-gaap:RetainedEarningsMember 2023-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000012208 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000012208 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000012208 2024-01-01 2024-03-31 0000012208 us-gaap:CommonStockMember 2024-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2024-03-31 0000012208 us-gaap:RetainedEarningsMember 2024-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000012208 2024-03-31 0000012208 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0000012208 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000012208 2024-04-01 2024-06-30 0000012208 us-gaap:CommonStockMember 2024-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2024-06-30 0000012208 us-gaap:RetainedEarningsMember 2024-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000012208 2024-06-30 0000012208 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0000012208 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000012208 us-gaap:CommonStockMember 2024-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2024-09-30 0000012208 us-gaap:RetainedEarningsMember 2024-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000012208 us-gaap:CommonStockMember 2022-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012208 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012208 us-gaap:RetainedEarningsMember 2022-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000012208 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000012208 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000012208 2023-01-01 2023-03-31 0000012208 us-gaap:CommonStockMember 2023-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2023-03-31 0000012208 us-gaap:RetainedEarningsMember 2023-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000012208 2023-03-31 0000012208 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000012208 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000012208 2023-04-01 2023-06-30 0000012208 us-gaap:CommonStockMember 2023-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-06-30 0000012208 us-gaap:RetainedEarningsMember 2023-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000012208 2023-06-30 0000012208 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000012208 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000012208 us-gaap:CommonStockMember 2023-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-09-30 0000012208 us-gaap:RetainedEarningsMember 2023-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000012208 country:US 2024-07-01 2024-09-30 0000012208 country:US 2023-07-01 2023-09-30 0000012208 country:US 2024-01-01 2024-09-30 0000012208 country:US 2023-01-01 2023-09-30 0000012208 srt:EuropeMember 2024-07-01 2024-09-30 0000012208 srt:EuropeMember 2023-07-01 2023-09-30 0000012208 srt:EuropeMember 2024-01-01 2024-09-30 0000012208 srt:EuropeMember 2023-01-01 2023-09-30 0000012208 srt:AsiaPacificMember 2024-07-01 2024-09-30 0000012208 srt:AsiaPacificMember 2023-07-01 2023-09-30 0000012208 srt:AsiaPacificMember 2024-01-01 2024-09-30 0000012208 srt:AsiaPacificMember 2023-01-01 2023-09-30 0000012208 srt:AmericasMember 2024-07-01 2024-09-30 0000012208 srt:AmericasMember 2023-07-01 2023-09-30 0000012208 srt:AmericasMember 2024-01-01 2024-09-30 0000012208 srt:AmericasMember 2023-01-01 2023-09-30 0000012208 bio:SaberBioAcquisitionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-08-20 2024-08-20 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:ForeignGovernmentDebtMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0000012208 bio:OrdinaryVotingSharesMember 2024-09-30 0000012208 bio:PreferenceSharesMember 2024-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2024-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2024-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2024-09-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2023-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2024-09-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2023-12-31 0000012208 us-gaap:SeniorNotesMember us-gaap:SeniorNotesMember 2024-09-30 0000012208 us-gaap:SeniorNotesMember us-gaap:SeniorNotesMember 2023-12-31 0000012208 bio:OtherLongTermDebtMember bio:OtherLongTermDebtMember 2024-09-30 0000012208 bio:OtherLongTermDebtMember bio:OtherLongTermDebtMember 2023-12-31 0000012208 bio:LifeScienceMember 2023-12-31 0000012208 bio:ClinicalDiagnosticsMember 2023-12-31 0000012208 bio:LifeScienceMember 2024-01-01 2024-09-30 0000012208 bio:ClinicalDiagnosticsMember 2024-01-01 2024-09-30 0000012208 bio:LifeScienceMember 2024-09-30 0000012208 bio:ClinicalDiagnosticsMember 2024-09-30 0000012208 us-gaap:CustomerRelationshipsMember 2024-09-30 0000012208 bio:KnowHowMember 2024-09-30 0000012208 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000012208 us-gaap:LicensingAgreementsMember 2024-09-30 0000012208 us-gaap:TradeNamesMember 2024-09-30 0000012208 us-gaap:NoncompeteAgreementsMember 2024-09-30 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000012208 us-gaap:CustomerRelationshipsMember 2023-12-31 0000012208 bio:KnowHowMember 2023-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000012208 us-gaap:LicensingAgreementsMember 2023-12-31 0000012208 us-gaap:TradeNamesMember 2023-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2023-12-31 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000012208 bio:A33SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2024-09-30 0000012208 bio:A33SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2023-12-31 0000012208 bio:A37SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2024-09-30 0000012208 bio:A37SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2023-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2024-09-30 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2023-12-31 0000012208 us-gaap:LineOfCreditMember 2024-02-13 0000012208 us-gaap:LineOfCreditMember 2024-09-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-09-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-07-01 2024-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-07-01 2024-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-01 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0000012208 bio:LifeScienceMember 2024-07-01 2024-09-30 0000012208 bio:ClinicalDiagnosticsMember 2024-07-01 2024-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2024-07-01 2024-09-30 0000012208 bio:LifeScienceMember 2023-07-01 2023-09-30 0000012208 bio:ClinicalDiagnosticsMember 2023-07-01 2023-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-09-30 0000012208 bio:LifeScienceMember 2023-01-01 2023-09-30 0000012208 bio:ClinicalDiagnosticsMember 2023-01-01 2023-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0000012208 us-gaap:OperatingSegmentsMember 2024-07-01 2024-09-30 0000012208 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0000012208 us-gaap:OperatingSegmentsMember 2024-01-01 2024-09-30 0000012208 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2024-07-01 2024-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2023-07-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-09-30 0000012208 srt:MinimumMember 2024-01-01 2024-09-30 0000012208 srt:MaximumMember 2024-01-01 2024-09-30 shares iso4217:USD iso4217:USD shares pure utr:Rate 0000012208 --12-31 2024 Q3 false 0.1 10-Q true 2024-09-30 false 001-07928 BIO-RAD LABORATORIES, INC. DE 94-1381833 1000 Alfred Nobel Drive, Hercules, CA 94547 (510) 724-7000 Class A Common Stock, Par Value $0.0001 per share BIO NYSE Class B Common Stock, Par Value $0.0001 per share BIO.B NYSE Yes Yes Large Accelerated Filer false false false false 22921856 5074909 410377000 403815000 1212081000 1203327000 5560000 5560000 12139000 14926000 461940000 489017000 804276000 780517000 133228000 140040000 28158000 26054000 3055620000 3048330000 545304000 529007000 173866000 194730000 415100000 413569000 307325000 320514000 6002635000 7698070000 103622000 94850000 10603472000 12299070000 122185000 144625000 146024000 139929000 1262000 486000 43625000 35759000 42834000 40379000 142013000 161621000 497943000 522799000 1200062000 1199052000 1076058000 1475495000 143919000 165478000 197631000 195113000 3115613000 3557937000 0.0001 7500000 0 0 0 25190963 25169944 22920768 23422506 2000 2000 5074909 5074909 5095930 5095930 1000 1000 448329000 449075000 2270195 1747438 777430000 632536000 8132231000 9260629000 -315274000 -336038000 7487859000 8741133000 10603472000 12299070000 649729000 632124000 1899025000 1990078000 293826000 296441000 862037000 929495000 355903000 335683000 1036988000 1060583000 200440000 201199000 610042000 634576000 90997000 43535000 216276000 183528000 64466000 90949000 210670000 242479000 12174000 12398000 36715000 37078000 -1641000 1680000 2012000 5280000 792888000 36425000 -1680290000 -1576542000 18081000 20446000 70740000 87365000 861620000 137102000 -1433583000 -1278496000 208448000 30845000 -305185000 -291464000 653172000 106257000 -1128398000 -987032000 23.37 3.65 -39.89 -33.63 27949000 29102000 28286000 29349000 23.34 3.64 -39.89 -33.63 27985000 29223000 28286000 29349000 653172000 106257000 -1128398000 -987032000 122932000 -126165000 6570000 -34342000 69000 342000 -815000 72000 13225000 1808000 13379000 3675000 136088000 -124699000 20764000 -30739000 789260000 -18442000 -1107634000 -1017771000 1920985000 2007482000 1531330000 1722173000 45628000 46394000 75710000 40966000 67193000 81828000 4462000 -14119000 331048000 293896000 122686000 114435000 149000 104000 23410000 0 1053660000 537540000 900493000 339033000 169458000 260849000 -129656000 -51989000 359000 349000 617000 0 15290000 14168000 3280000 10118000 203586000 228728000 -192552000 -225027000 -1021000 6891000 7819000 23771000 404369000 434544000 412188000 458315000 410377000 457850000 1376000 79000 435000 386000 412188000 458315000 3000 449075000 -632536000 9260629000 -336038000 8741133000 0 0 0 383916000 0 383916000 0 0 0 0 -89933000 -89933000 0 15262000 0 0 0 15262000 0 0 4702000 0 0 4702000 0 -1710000 7215000 0 0 5505000 0 0 47000 0 0 47000 3000 462627000 -630070000 9644545000 -425971000 9051134000 0 0 0 -2165486000 0 -2165486000 0 0 0 0 -25391000 -25391000 0 14999000 0 0 0 14999000 0 0 100000000 0 0 100000000 0 -2745000 7428000 0 0 4683000 0 152000 0 0 0 152000 0 0 1000000 0 0 1000000 3000 474729000 -723642000 7479059000 -451362000 6778787000 0 0 0 653172000 0 653172000 0 0 0 0 136088000 136088000 0 15675000 0 0 0 15675000 0 0 96868000 0 0 96868000 0 -38947000 44049000 0 0 5102000 0 3128000 0 0 0 3128000 0 0 969000 0 0 969000 3000 448329000 -777430000 8132231000 -315274000 7487859000 3000 447454000 -263586000 9898203000 -466822000 9615252000 0 0 0 68962000 0 68962000 0 0 0 0 58470000 58470000 0 16608000 0 0 0 16608000 0 -660000 5290000 -206000 0 4424000 3000 463402000 -258296000 9966959000 -408352000 9763716000 0 0 0 -1162251000 0 -1162251000 0 0 0 0 35490000 35490000 0 12559000 0 0 0 12559000 0 0 207407000 0 0 207407000 0 -2089000 6919000 -44000 0 4786000 3000 473872000 -458784000 8804664000 -372862000 8446893000 0 0 0 106257000 0 106257000 0 0 0 0 -124699000 -124699000 0 5111000 0 0 0 5111000 0 15952000 0 0 0 15952000 0 0 23608000 0 0 23608000 0 45258000 -45772000 0 0 -514000 3000 439455000 -436620000 8910921000 -497561000 8416198000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">1. BASIS OF PRESENTATION AND USE OF ESTIMATES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the loan receivable. Actual results could differ materially from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue attributed to the lease elements of our reagent rental arrangements represented approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3% of total revenue for both the three and nine months ended September 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Contract costs:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">783.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">858.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">205.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">612.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">609.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">126.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">118.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">375.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">398.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">128.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">649.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">632.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,899.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2024 and December 31, 2023 was $64.0 million and $68.3 million, respectively. The short-term deferred revenue balance at September 30, 2024 and December 31, 2023 was $48.9 million and $51.1 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Changes in our warranty liability for the nine months ended September 30, 2024 and 2023 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Accounts Receivable and Allowance for Credit Losses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for credit losses were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Saber Bio Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 26, 2024, the Company entered into a stock purchase agreement (the “Transaction”) to acquire all of the outstanding equity interests in Saber Bio (“Saber”). The Transaction closed on August 20, 2024. The Company accounted for the Transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single or similar in-process research and development project (“IPR&amp;D”). The Company concluded that the acquired IPR&amp;D does not meet the criteria for capitalization and expensed the acquired IPR&amp;D. This amounted to $29.5 million which was recorded in Research and development expense in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Issued and to be Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, “Improvements to Reportable Segment Disclosures”. The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker ("CODM"). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However, on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2023.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the loan receivable. Actual results could differ materially from those estimates.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">allocated between separate performance obligations of an arrangement based on the stand-alone selling price ("SSP") for each distinct product or service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, we offer a reagent rental program which provides our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Maintenance services and reagent sales are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue attributed to the lease elements of our reagent rental arrangements represented approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3% of total revenue for both the three and nine months ended September 30, 2024 and 2023. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Contract costs:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We elected a practical expedient and expense costs to obtain contracts as incurred as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">783.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">858.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">205.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">612.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">609.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">126.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">118.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">375.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">398.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">128.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">649.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">632.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,899.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2024 and December 31, 2023 was $64.0 million and $68.3 million, respectively. The short-term deferred revenue balance at September 30, 2024 and December 31, 2023 was $48.9 million and $51.1 million, respectively.</span></div> 0.03 0.03 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">276.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">783.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">858.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">205.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">612.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">609.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">126.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">118.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">375.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">398.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">128.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">649.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">632.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,899.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 276200000 275400000 783400000 858800000 205700000 193100000 612400000 609100000 126900000 118900000 375200000 398900000 40900000 44700000 128000000.0 123300000 649700000 632100000 1899000000 1990100000 64000000.0 68300000 48900000 51100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Changes in our warranty liability for the nine months ended September 30, 2024 and 2023 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Changes in our warranty liability for the nine months ended September 30, 2024 and 2023 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8400000 10600000 5200000 6400000 5700000 9000000.0 7900000 8000000.0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Accounts Receivable and Allowance for Credit Losses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for credit losses were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for credit losses were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14900000 15000000.0 2100000 1400000 4900000 1300000 12100000 15100000 29500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Issued and to be Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, “Improvements to Reportable Segment Disclosures”. The ASU includes enhanced disclosure requirements, primarily related to significant segment expenses that are regularly provided to and used by the chief operating decision maker ("CODM"). The amendments are to be applied retrospectively to all prior periods presented in the financial statements. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". The ASU includes enhanced disclosure requirements, primarily related to the rate reconciliation and income taxes paid information. The amendments are to be applied prospectively in the financial statements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the effect of adopting this pronouncement on our disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In March 2024, the U.S. Securities and Exchange Commission ("SEC") adopted the final rule under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. This rule will require registrants to disclose certain climate-related information in registration statements and annual reports. The disclosure requirements will not apply before the Company's fiscal year beginning January 1, 2025. However, on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. We are monitoring SEC developments and evaluating the final rule to determine its impact on our disclosures.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2. FAIR VALUE MEASUREMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Level 1: Quoted prices in active markets for identical instruments</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2024 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">110.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">110.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">110.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,701.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,701.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">543.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">543.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">147.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">147.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,819.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,178.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,341.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,399.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,399.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">531.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">531.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,136.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,136.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,434.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,196.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,956.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt">Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:68.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67.2 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,622.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,332.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,701.4 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,399.3 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.4 million and $0.8 million in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Level 1 Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As of September 30, 2024, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shares of Sartorius AG ("Sartorius"), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the outstanding ordinary shares (excluding treasury shares) and 27% of the preference shares of Sartorius as of September 30, 2024. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The change in fair market value of our investment in Sartorius for the three and nine months ended September 30, 2024 was a gain of $761.1 million and a loss of $1,711.0 million, respectively, and are recorded in our condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Level 2 Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To estimate the fair value of Level 2 debt securities as of September 30, 2024 and December 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">536.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">543.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">430.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">145.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">147.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,122.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2024 by contractual maturity date (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">702.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">711.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in more than five years</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">298.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">301.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,122.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">534.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">531.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">257.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,142.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,136.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September 30, 2024, there were no significant continuous unrealized losses greater than 12 months.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our evaluation of credit losses for available-for-sale investments included t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At September 30, 2024, we have concluded that all payments related to our available-for-sale investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are expected to be made in full and on time at </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Included in Other current assets are $11.1 million and $11.9 million of interest receivable as of September 30, 2024 and December 31, 2023, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the nine months ended September 30, 2024, we have not written-off any uncollected interest receivable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of September 30, 2024 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of our forward foreign currency exchange contracts (in millions): </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts to sell foreign currency:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">673.7 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">873.5 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain/(loss)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts to purchase foreign currency:</span></div></td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain/(loss)</span></div></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $8.0 million and $6.5 million as of September 30, 2024 and December 31, 2023, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Also included in Other investments in the condensed consolidated balance sheet are our equity method investments, for which our share of the equity method investees earnings is included in Other income, net in our condensed consolidated statements of income (loss). The carrying value of these investments, net of impairments, was $26.8 million and $32.3 million as of September 30, 2024 and December 31, 2023, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The carrying value and fair value of our long-term debt were as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Senior notes</span></div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,190.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,119.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,189.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,102.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other long-term debt</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,200.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,129.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,199.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,112.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The fair value of our long-term debt was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Level 3 Fair Value Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (“Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended September 30, 2024 was a gain of $25.2 million, which includes a $18.1 million gain from change in fair market value of the Loan and a $7.1 million gain from change in fair market value of the value appreciation right. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the nine months ended September 30, 2024 was a gain of $14.7 million, which includes a $33.1 million gain from change in fair market value of the Loan and a $18.4 million loss from change in fair market value of the value appreciation right. The increase in the fair market value of the value appreciation right was due to an increase in the value of the Sartorius ordinary shares. As of September 30, 2024, the €400 million principal amount of the loan is still due on January 31, 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:75.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in estimated fair market value, net</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange losses, net</span></div></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2024 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">110.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">110.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">110.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,701.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,701.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">543.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">543.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">147.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">147.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,819.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,178.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,341.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2023 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,399.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,399.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">531.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">531.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,136.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,136.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,434.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,196.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,956.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt">Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:68.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67.2 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,622.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,332.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5,701.4 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,399.3 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.4 million and $0.8 million in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2024.</span></div> 0 43200000 0 43200000 110900000 0 0 110900000 110900000 43200000 0 154100000 7100000 0 0 7100000 5701400000 0 0 5701400000 0 0 343500000 343500000 0 543800000 0 543800000 0 147000000.0 0 147000000.0 0 2600000 0 2600000 0 6700000 0 6700000 0 433200000 0 433200000 0 1133300000 0 1133300000 0 2200000 0 2200000 5819400000 1178700000 343500000 7341600000 0 900000 0 900000 0 0 18300000 18300000 0 900000 18300000 19200000 0 12500000 0 12500000 0 36600000 0 36600000 0 7000000.0 0 7000000.0 28000000.0 0 0 28000000.0 28000000.0 56100000 0 84100000 7100000 0 0 7100000 7399300000 0 0 7399300000 0 0 325700000 325700000 0 531600000 0 531600000 0 255900000 0 255900000 0 12700000 0 12700000 0 12100000 0 12100000 0 323700000 0 323700000 0 1136000000 0 1136000000 0 4100000 0 4100000 7434400000 1196200000 325700000 8956300000 0 11700000 0 11700000 0 0 17500000 17500000 0 11700000 17500000 29200000 5600000 5600000 1500000 1500000 7100000 7100000 78700000 67200000 5622700000 7332100000 5701400000 7399300000 400000 800000 12987900 9588908 0.38 0.27 761100000 1711000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">536.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">543.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">430.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">433.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">145.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">147.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,122.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">534.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">531.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">323.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">257.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,142.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,136.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 536600000 7500000 300000 543800000 6600000 100000 0 6700000 430300000 3700000 800000 433200000 145900000 1300000 200000 147000000.0 2600000 0 0 2600000 1122000000 12600000 1300000 1133300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2024 by contractual maturity date (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.4 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">702.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">711.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in more than five years</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">298.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">301.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,122.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,133.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 120500000 120400000 702900000 711800000 298600000 301100000 1122000000 1133300000 534100000 800000 3300000 531600000 12200000 0 100000 12100000 325700000 700000 2700000 323700000 257400000 100000 1600000 255900000 12800000 0 100000 12700000 1142200000 1600000 7800000 1136000000 11100000 11900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of our forward foreign currency exchange contracts (in millions): </span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts to sell foreign currency:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">673.7 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">873.5 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain/(loss)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts to purchase foreign currency:</span></div></td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">133.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain/(loss)</span></div></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;padding:0 1pt"></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 673700000 873500000 1300000 -8100000 44400000 133600000 0 500000 8000000.0 8000000.0 26800000 32300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The carrying value and fair value of our long-term debt were as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Carrying Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Senior notes</span></div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,190.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,119.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,189.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,102.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other long-term debt</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,200.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,129.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,199.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,112.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1190800000 1119900000 1189500000 1102500000 9300000 9300000 9600000 9600000 1200100000 1129200000 1199100000 1112100000 400000000 0.015 25200000 18100000 -7100000 14700000 33100000 18400000 400000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:75.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">325.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in estimated fair market value, net</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange losses, net</span></div></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">343.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 325700000 14700000 -3100000 343500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes to goodwill by segment are as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of January 1, 2024:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">415.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">748.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">413.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Period change, net</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2024:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">417.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">750.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.6 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">415.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(100.6)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">169.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(165.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">219.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(141.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(45.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">569.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(462.8)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">106.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">770.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(462.8)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">307.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(98.9)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">168.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(161.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.0</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">217.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(132.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(42.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">567.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(444.8)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">198.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">198.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">765.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(444.8)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">320.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes to goodwill by segment are as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of January 1, 2024:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">415.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">748.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">413.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Period change, net</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2024:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">417.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">750.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.6 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">415.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 333300000 415500000 748800000 41800000 293400000 335200000 291500000 122100000 413600000 0 1500000 1500000 0 1500000 1500000 333300000 417000000.0 750300000 41800000 293400000 335200000 291500000 123600000 415100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(100.6)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">169.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(165.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">219.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(141.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">77.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(45.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">569.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(462.8)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">106.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">201.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">770.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(462.8)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">307.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(98.9)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">168.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(161.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.0</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">217.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(132.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">84.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(42.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">567.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(444.8)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">198.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">198.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">765.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(444.8)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">320.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P4Y9M18D 108400000 100600000 7800000 P1Y 169700000 165200000 4500000 P11Y7M6D 219300000 141500000 77800000 P4Y2M12D 59300000 45200000 14100000 P4Y9M18D 6000000.0 4900000 1100000 P1Y6M 6400000 5400000 1000000.0 569100000 462800000 106300000 201000000.0 201000000.0 770100000 462800000 307300000 P5Y2M12D 108700000 98900000 9800000 P1Y9M18D 168900000 161100000 7800000 P12Y 217800000 132900000 84900000 P4Y10M24D 59200000 42400000 16800000 P5Y7M6D 6100000 4700000 1400000 P2Y3M18D 6400000 4800000 1600000 567100000 444800000 122300000 198200000 198200000 765300000 444800000 320500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5300000 6200000 16100000 18100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">4. INVENTORY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following are the components of Inventory at September 30, 2024 and December 31, 2023 (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Raw materials</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">246.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finished goods </span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">319.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">302.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">804.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">780.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following are the components of Inventory at September 30, 2024 and December 31, 2023 (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventory:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Raw materials</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">255.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">246.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finished goods </span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">319.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">302.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">804.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">780.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 229500000 231600000 255200000 246000000.0 319600000 302900000 804300000 780500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">5. SUPPLEMENTAL CASH FLOW INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,128.4)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(987.0)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">112.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduction in the carrying amount of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Losses from change in fair market value of equity securities and loan receivable</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,680.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,576.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments for operating lease liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(32.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Increase) decrease in other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(72.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in deferred income taxes</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(408.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(397.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">331.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased property, plant and equipment</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased marketable securities and investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sold marketable securities and investments</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,128.4)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(987.0)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">112.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduction in the carrying amount of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Losses from change in fair market value of equity securities and loan receivable</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,680.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,576.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments for operating lease liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(32.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Increase) decrease in other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(72.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in deferred income taxes</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(408.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(397.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">331.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased property, plant and equipment</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased marketable securities and investments</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sold marketable securities and investments</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -1128400000 -987000000.0 112400000 108700000 31100000 30700000 45900000 45100000 29500000 0 -1680300000 -1576500000 800000 -18500000 -32200000 -30400000 -25600000 -31600000 16000000.0 61700000 4700000 -15000000.0 -24400000 -72400000 21800000 56400000 408500000 397400000 1400000 3900000 3600000 6600000 331000000.0 293900000 7400000 2900000 5700000 0 200000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">6. LONG-TERM DEBT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The principal components of long-term debt are as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3%, Senior Notes due 2027</span></div></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7%, Senior Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,190.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,189.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance leases and other debt</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,200.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,199.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 13, 2024, we entered into a new $200.0 million unsecured revolving credit agreement ("Revolving Credit Agreement") with a group of financial institutions. The Revolving Credit Agreement replaced the Company's previous credit agreement, dated as of April 15, 2019. Borrowings under the Revolving Credit Agreement are on a revolving basis and can be used to make acquisitions, for working capital and for other general corporate purposes. The Revolving Credit Agreement requires Bio-Rad to comply with certain financial ratios and other customary covenants and provisions. The Revolving Credit Agreement matures on February 13, 2029. As of September 30, 2024, no borrowings were outstanding under the Revolving Credit Agreement, although available capacity was reduced by immaterial outstanding letters of credit. As of September 30, 2024, we were in compliance with the covenants for the Revolving Credit Agreement.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The principal components of long-term debt are as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3%, Senior Notes due 2027</span></div></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7%, Senior Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,190.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,189.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance leases and other debt</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,200.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,199.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.033 400000000.0 400000000.0 0.037 800000000.0 800000000.0 -9200000 -10500000 1190800000 1189500000 10600000 10100000 1300000 500000 1200100000 1199100000 200000000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of January 1, 2024:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(334.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(336.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income, net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2024:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(327.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(315.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of January 1, 2023:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(500.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All amounts reclassified out of Accumulated other comprehensive income (loss) were reclassified into Other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The impact to Income (loss) before income taxes for amounts reclassified out of Accumulated other comprehensive income (loss) into Other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Components of comprehensive income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization of foreign other post-employment benefit items</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net holding gains (losses) on equity securities and available-for-sale investments</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of January 1, 2024:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(334.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(336.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income, net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2024:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(327.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(315.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of January 1, 2023:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(500.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -334100000 -2800000 900000 -336000000.0 6600000 100000 19100000 25800000 0 400000 1700000 2100000 100000 -1100000 4000000.0 3000000.0 6500000 800000 13400000 20700000 -327600000 -2000000.0 14300000 -315300000 -466500000 10000000.0 -10300000 -466800000 -34400000 300000 3700000 -30400000 0 400000 -1100000 -700000 -100000 0 1100000 1000000.0 -34300000 -100000 3700000 -30700000 -500800000 9900000 -6600000 -497500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The impact to Income (loss) before income taxes for amounts reclassified out of Accumulated other comprehensive income (loss) into Other income, net in the condensed consolidated statements of income (loss) were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Components of comprehensive income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization of foreign other post-employment benefit items</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net holding gains (losses) on equity securities and available-for-sale investments</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -100000 -200000 -400000 -400000 2000000.0 -100000 1700000 -1100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">8. EARNINGS (LOSS) PER SHARE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bio-Rad’s issued and outstanding stock consists of Class A Common Stock ("Class A") and Class B Common Stock ("Class B"). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one-tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We compute Net income (loss) per share of Class A and Class B using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the nine months ended September 30, 2024 and 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accordingly, Basic earnings (loss) per share is computed by dividing Net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings (loss) per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,949 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,102 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,286 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options, restricted stock and performance stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,985 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,223 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,286 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> one 0.25 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,949 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,102 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,286 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options, restricted stock and performance stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27,985 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,223 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28,286 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 27949000 29102000 28286000 29349000 36000 121000 0 0 27985000 29223000 28286000 29349000 257000 154000 411000 229000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">9. OTHER INCOME, NET</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income, net includes the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest and investment income</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(84.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net realized (gains) losses on investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Escrow receipts on prior acquisition</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(70.7)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income, net includes the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest and investment income</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(66.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(84.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net realized (gains) losses on investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Escrow receipts on prior acquisition</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(70.7)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 15500000 17300000 66100000 84100000 2000000.0 -100000 1700000 -1600000 0 2500000 0 2500000 600000 700000 2900000 2400000 18100000 20400000 70700000 87400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">10. INCOME TAXES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our effective income tax rate was 24.2% and 22.5% for the three months ended September 30, 2024 and 2023, respectively. Our effective income tax rate was 21.3% and 22.8% for the nine months ended September 30, 2024 and 2023, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of September 30, 2024, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $17.0 million for the period ended September 30, 2024 compared to the year ended December 31, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our income tax returns are audited by U.S. federal, state and foreign tax authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Our gross unrecognized tax benefits were $88.5 million and $84.7 million as of September 30, 2024 and December 31, 2023, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As of September 30, 2024, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $16.2 million. Substantially all such amounts will impact our effective income tax rate if recognized.</span></div> 0.242 0.225 0.213 0.228 17000000 88500000 84700000 16200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">11. SEGMENT INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding net sales and operating profit (loss) for the three months ended September 30, 2024 and 2023 are as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">260.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">388.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">368.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">74.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding Net sales and operating profit (loss) for the nine months ended September 30, 2024 and 2023 are as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">753.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,145.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">887.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,100.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">209.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">166.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our CODM views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The following reconciles total operating profit to consolidated income (loss) before income taxes (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:48.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.136%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">210.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">242.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(36.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange (losses) gains, net</span></div></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gains (losses) from change in fair market value of equity securities and loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">792.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,680.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,576.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">87.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated income (loss) before income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">861.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,433.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,278.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding net sales and operating profit (loss) for the three months ended September 30, 2024 and 2023 are as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">260.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">388.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">368.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">74.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding Net sales and operating profit (loss) for the nine months ended September 30, 2024 and 2023 are as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">753.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,145.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">887.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,100.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">209.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">166.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 260900000 388800000 0 263500000 368100000 500000 -9800000 74200000 100000 13000000.0 78000000.0 -100000 753100000 1145400000 500000 887300000 1100300000 2500000 1100000 209900000 -300000 76700000 166100000 -300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The following reconciles total operating profit to consolidated income (loss) before income taxes (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:48.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.136%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">210.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">242.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(36.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange (losses) gains, net</span></div></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gains (losses) from change in fair market value of equity securities and loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">792.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,680.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,576.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">87.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated income (loss) before income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">861.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,433.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,278.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 64500000 90900000 210700000 242500000 -12200000 -12300000 -36700000 -37200000 -1600000 1700000 2000000.0 5300000 792800000 36400000 -1680300000 -1576500000 18100000 20400000 70700000 87400000 861600000 137100000 -1433600000 -1278500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">12. LEGAL PROCEEDINGS</span></div>We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">13. LEASES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 15 years, which includes our determination to exercise renewal options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt, net of current maturities in our condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:49.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="9" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total finance lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and nine months ended September 30, 2024 and 2023. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and nine months ended September 30, 2024 and 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from operating leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Financing cash flows from finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">173.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">194.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">143.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">165.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">205.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt and notes payable, net of current maturities (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Finance Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Property, plant and equipment, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current maturities of long-term debt and notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Long-term debt, net of current maturities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:60.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases - in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases - in years</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maturities of lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance Leases</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024 (excluding the nine months ended September 30, 2024)</span></div></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2028</span></div></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total lease payments</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">212.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September 30, 2024, operating leases that have not commenced are not material.</span></div> P1Y P15Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:49.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="9" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total finance lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17300000 15700000 52200000 47200000 100000 100000 300000 300000 200000 200000 500000 600000 300000 300000 800000 900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from operating leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Financing cash flows from finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 10800000 10600000 32200000 30400000 200000 200000 500000 600000 100000 100000 300000 300000 100000 36700000 11300000 49000000.0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">173.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">194.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">143.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">165.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">205.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finance leases are included in Property, plant and equipment, net, Current maturities of long-term debt and notes payable, and Long-term debt and notes payable, net of current maturities (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Finance Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Property, plant and equipment, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current maturities of long-term debt and notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Long-term debt, net of current maturities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:60.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases - in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases - in years</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 173900000 194700000 42800000 40400000 143900000 165500000 186700000 205900000 11900000 11900000 6200000 5900000 5700000 6000000.0 500000 500000 9300000 9600000 9800000 10100000 P6Y P7Y P13Y P14Y 0.040 0.039 0.065 0.064 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maturities of lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance Leases</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024 (excluding the nine months ended September 30, 2024)</span></div></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></div></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2028</span></div></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total lease payments</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">212.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.7 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.8 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10800000 300000 49000000.0 1100000 37300000 1100000 28800000 1100000 22200000 1100000 64100000 10800000 212200000 15500000 25500000 5700000 186700000 9800000 false false false false Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):September 30, 2024December 31, 2023Restricted investments$5.6 $5.6 Other investments1.5 1.5     Total$7.1 $7.1  Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):September 30, 2024December 31, 2023Short-term investments$78.7 $67.2 Other investments5,622.7 7,332.1         Total$5,701.4 $7,399.3  The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense amounted to $0.4 million and $0.8 million in the condensed consolidated statements of income (loss) for the three and nine months ended September 30, 2024, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2024.

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�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end XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 297 311 1 true 63 0 false 5 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets Parenthetical Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets Parenthetical Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement Condensed Consolidated Statements of Stockholders' Equity Statement Statements 7 false false R8.htm 9952157 - Disclosure - Basis of Presentation and Use of Estimates Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates Basis of Presentation and Use of Estimates Notes 8 false false R9.htm 9952158 - Disclosure - Fair Value Measurements Sheet http://www.bio-rad.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 9952159 - Disclosure - Goodwill and Other Purchased Intangible Assets Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets Goodwill and Other Purchased Intangible Assets Notes 10 false false R11.htm 9952160 - Disclosure - Inventory Sheet http://www.bio-rad.com/role/Inventory Inventory Notes 11 false false R12.htm 9952161 - Disclosure - Supplemental Cash Flow Information Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 12 false false R13.htm 9952162 - Disclosure - Long-Term Debt Sheet http://www.bio-rad.com/role/LongTermDebt Long-Term Debt Notes 13 false false R14.htm 9952163 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 9952164 - Disclosure - Earnings (Loss) Per Share Sheet http://www.bio-rad.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 15 false false R16.htm 9952165 - Disclosure - Other Income, Net Sheet http://www.bio-rad.com/role/OtherIncomeNet Other Income, Net Notes 16 false false R17.htm 9952166 - Disclosure - Income Taxes Sheet http://www.bio-rad.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 9952167 - Disclosure - Segment Information Sheet http://www.bio-rad.com/role/SegmentInformation Segment Information Notes 18 false false R19.htm 9952168 - Disclosure - Legal Proceedings Sheet http://www.bio-rad.com/role/LegalProceedings Legal Proceedings Notes 19 false false R20.htm 9952169 - Disclosure - Leases Sheet http://www.bio-rad.com/role/Leases Leases Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies Basis of Presentation and Use of Estimates (Policies) Policies 23 false false R24.htm 9954472 - Disclosure - Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Tables 24 false false R25.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/FairValueMeasurements 25 false false R26.htm 9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables Goodwill and Other Purchased Intangible Assets (Tables) Tables http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets 26 false false R27.htm 9954475 - Disclosure - Inventory (Tables) Sheet http://www.bio-rad.com/role/InventoryTables Inventory (Tables) Tables http://www.bio-rad.com/role/Inventory 27 false false R28.htm 9954476 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.bio-rad.com/role/SupplementalCashFlowInformation 28 false false R29.htm 9954477 - Disclosure - Long-Term Debt (Tables) Sheet http://www.bio-rad.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/LongTermDebt 29 false false R30.htm 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss 30 false false R31.htm 9954479 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.bio-rad.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.bio-rad.com/role/EarningsLossPerShare 31 false false R32.htm 9954480 - Disclosure - Other Income, Net (Tables) Sheet http://www.bio-rad.com/role/OtherIncomeNetTables Other Income, Net (Tables) Tables http://www.bio-rad.com/role/OtherIncomeNet 32 false false R33.htm 9954481 - Disclosure - Segment Information (Tables) Sheet http://www.bio-rad.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.bio-rad.com/role/SegmentInformation 33 false false R34.htm 9954482 - Disclosure - Leases (Tables) Sheet http://www.bio-rad.com/role/LeasesTables Leases (Tables) Tables http://www.bio-rad.com/role/Leases 34 false false R35.htm 9954483 - Disclosure - Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Details 35 false false R36.htm 9954484 - Disclosure - Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Details 36 false false R37.htm 9954486 - Disclosure - Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Details 37 false false R38.htm 9954487 - Disclosure - Basis of Presentation and Use of Estimates (Details) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesDetails Basis of Presentation and Use of Estimates (Details) Details http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables 38 false false R39.htm 9954488 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 39 false false R40.htm 9954489 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_1 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 40 false false R41.htm 9954490 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_2 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 41 false false R42.htm 9954491 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) Details 42 false false R43.htm 9954493 - Disclosure - Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details) Details 43 false false R44.htm 9954494 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_3 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 44 false false R45.htm 9954495 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails Goodwill and Other Purchased Intangible Assets (Details) Details http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables 45 false false R46.htm 9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1 Goodwill and Other Purchased Intangible Assets (Details) Details http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables 46 false false R47.htm 9954497 - Disclosure - Inventory (Details) Sheet http://www.bio-rad.com/role/InventoryDetails Inventory (Details) Details http://www.bio-rad.com/role/InventoryTables 47 false false R48.htm 9954498 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/SupplementalCashFlowInformationTables 48 false false R49.htm 9954499 - Disclosure - Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/LongTermDebtDetails Long-Term Debt (Details) Details http://www.bio-rad.com/role/LongTermDebtTables 49 false false R50.htm 9954500 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables 50 false false R51.htm 9954501 - Disclosure - Earnings (Loss) Per Share (Details) Sheet http://www.bio-rad.com/role/EarningsLossPerShareDetails Earnings (Loss) Per Share (Details) Details http://www.bio-rad.com/role/EarningsLossPerShareTables 51 false false R52.htm 9954502 - Disclosure - Earnings (Loss) Per Share (Details) Sheet http://www.bio-rad.com/role/EarningsLossPerShareDetails_1 Earnings (Loss) Per Share (Details) Details http://www.bio-rad.com/role/EarningsLossPerShareTables 52 false false R53.htm 9954503 - Disclosure - Other Income, Net (Details) Sheet http://www.bio-rad.com/role/OtherIncomeNetDetails Other Income, Net (Details) Details http://www.bio-rad.com/role/OtherIncomeNetTables 53 false false R54.htm 9954504 - Disclosure - Income Taxes (Details) Sheet http://www.bio-rad.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bio-rad.com/role/IncomeTaxes 54 false false R55.htm 9954505 - Disclosure - Segment Information (Details) Sheet http://www.bio-rad.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.bio-rad.com/role/SegmentInformationTables 55 false false R56.htm 9954506 - Disclosure - Segment Information (Details) Sheet http://www.bio-rad.com/role/SegmentInformationDetails_1 Segment Information (Details) Details http://www.bio-rad.com/role/SegmentInformationTables 56 false false R57.htm 9954507 - Disclosure - Leases (Details) Sheet http://www.bio-rad.com/role/LeasesDetails Leases (Details) Details http://www.bio-rad.com/role/LeasesTables 57 false false All Reports Book All Reports bio-20240930.htm bio-20240930.xsd bio-20240930_cal.xml bio-20240930_def.xml bio-20240930_lab.xml bio-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bio-20240930.htm": { "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20240930", "dts": { "inline": { "local": [ "bio-20240930.htm" ] }, "schema": { "local": [ "bio-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bio-20240930_cal.xml" ] }, "definitionLink": { "local": [ "bio-20240930_def.xml" ] }, "labelLink": { "local": [ "bio-20240930_lab.xml" ] }, "presentationLink": { "local": [ "bio-20240930_pre.xml" ] } }, "keyStandard": 295, "keyCustom": 16, "axisStandard": 20, "axisCustom": 0, "memberStandard": 46, "memberCustom": 14, "hidden": { "total": 6, "http://fasb.org/us-gaap/2024": 1, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 297, "entityCount": 1, "segmentCount": 63, "elementCount": 577, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1169, "http://xbrl.sec.gov/dei/2024": 34, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.bio-rad.com/role/DocumentandEntityInformation", "longName": "0000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentTransitionReport", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentTransitionReport", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R3": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets Parenthetical", "shortName": "Condensed Consolidated Balance Sheets Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R5": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R6": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "longName": "9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement", "shortName": "Condensed Consolidated Statements of Stockholders' Equity Statement", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-17", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-63", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R8": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates", "longName": "9952157 - Disclosure - Basis of Presentation and Use of Estimates", "shortName": "Basis of Presentation and Use of Estimates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bio-rad.com/role/FairValueMeasurements", "longName": "9952158 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets", "longName": "9952159 - Disclosure - Goodwill and Other Purchased Intangible Assets", "shortName": "Goodwill and Other Purchased Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bio-rad.com/role/Inventory", "longName": "9952160 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformation", "longName": "9952161 - Disclosure - Supplemental Cash Flow Information", "shortName": "Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bio-rad.com/role/LongTermDebt", "longName": "9952162 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "9952163 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "shortName": "Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bio-rad.com/role/EarningsLossPerShare", "longName": "9952164 - Disclosure - Earnings (Loss) Per Share", "shortName": "Earnings (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bio-rad.com/role/OtherIncomeNet", "longName": "9952165 - Disclosure - Other Income, Net", "shortName": "Other Income, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bio-rad.com/role/IncomeTaxes", "longName": "9952166 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bio-rad.com/role/SegmentInformation", "longName": "9952167 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bio-rad.com/role/LegalProceedings", "longName": "9952168 - Disclosure - Legal Proceedings", "shortName": "Legal Proceedings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bio-rad.com/role/Leases", "longName": "9952169 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies)", "shortName": "Basis of Presentation and Use of Estimates (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables", "longName": "9954472 - Disclosure - Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "shortName": "Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables", "longName": "9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables)", "shortName": "Goodwill and Other Purchased Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bio-rad.com/role/InventoryTables", "longName": "9954475 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformationTables", "longName": "9954476 - Disclosure - Supplemental Cash Flow Information (Tables)", "shortName": "Supplemental Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bio-rad.com/role/LongTermDebtTables", "longName": "9954477 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bio-rad.com/role/EarningsLossPerShareTables", "longName": "9954479 - Disclosure - Earnings (Loss) Per Share (Tables)", "shortName": "Earnings (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bio-rad.com/role/OtherIncomeNetTables", "longName": "9954480 - Disclosure - Other Income, Net (Tables)", "shortName": "Other Income, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bio-rad.com/role/SegmentInformationTables", "longName": "9954481 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bio-rad.com/role/LeasesTables", "longName": "9954482 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "longName": "9954483 - Disclosure - Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "shortName": "Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:DeferredRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R36": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails", "longName": "9954484 - Disclosure - Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "shortName": "Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails", "longName": "9954486 - Disclosure - Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "shortName": "Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesDetails", "longName": "9954487 - Disclosure - Basis of Presentation and Use of Estimates (Details)", "shortName": "Basis of Presentation and Use of Estimates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-14", "name": "bio:RevenueAllocationPercentToLeaseElements", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "longName": "9954488 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:TradingSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:TradingSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R40": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "longName": "9954489 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-214", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-214", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "longName": "9954490 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R42": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "longName": "9954491 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)", "shortName": "Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "longName": "9954493 - Disclosure - Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details)", "shortName": "Fair Value Measurements and Investments Fair Value of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R44": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "longName": "9954494 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "longName": "9954495 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details)", "shortName": "Goodwill and Other Purchased Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1", "longName": "9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details)", "shortName": "Goodwill and Other Purchased Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R47": { "role": "http://www.bio-rad.com/role/InventoryDetails", "longName": "9954497 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails", "longName": "9954498 - Disclosure - Supplemental Cash Flow Information (Details)", "shortName": "Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R49": { "role": "http://www.bio-rad.com/role/LongTermDebtDetails", "longName": "9954499 - Disclosure - Long-Term Debt (Details)", "shortName": "Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherLongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherLongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954500 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-250", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R51": { "role": "http://www.bio-rad.com/role/EarningsLossPerShareDetails", "longName": "9954501 - Disclosure - Earnings (Loss) Per Share (Details)", "shortName": "Earnings (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-2", "name": "bio:ElectionPercentageForBoardOfDirectors", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "bio:ElectionPercentageForBoardOfDirectors", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1", "longName": "9954502 - Disclosure - Earnings (Loss) Per Share (Details)", "shortName": "Earnings (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R53": { "role": "http://www.bio-rad.com/role/OtherIncomeNetDetails", "longName": "9954503 - Disclosure - Other Income, Net (Details)", "shortName": "Other Income, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.bio-rad.com/role/IncomeTaxesDetails", "longName": "9954504 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bio-rad.com/role/SegmentInformationDetails", "longName": "9954505 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.bio-rad.com/role/SegmentInformationDetails_1", "longName": "9954506 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-288", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "unique": true } }, "R57": { "role": "http://www.bio-rad.com/role/LeasesDetails", "longName": "9954507 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20240930.htm", "first": true, "unique": true } } }, "tag": { "bio_A33SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "A33SeniorNotesDue2027Member", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.3%, Senior Notes due 2027", "label": "3.3%, Senior Notes due 2027 [Member]", "documentation": "3.3%, Senior Notes due 2027" } } }, "auth_ref": [] }, "bio_A37SeniorNotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "A37SeniorNotesDue2032Member", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.7%, Senior Notes due 2032", "label": "3.7%, Senior Notes due 2032 [Member]", "documentation": "3.7%, Senior Notes due 2032" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r73", "r951" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1134" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1107" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Defined Benefit Plans Adjustment", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r3", "r4", "r10", "r17", "r97", "r1084", "r1085", "r1086" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Net Unrealized Investment Gain (Loss)", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r195", "r196", "r197", "r199", "r206", "r207", "r1084" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r205", "r206", "r601", "r603", "r604", "r605", "r606", "r607" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "periodStartLabel": "Beginning balance, Accumulated other comprehensive income", "periodEndLabel": "Ending balance, Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r98", "r189", "r726", "r760", "r764" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r205", "r206", "r601", "r603", "r604", "r605", "r606", "r607" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r10", "r17", "r554", "r557", "r637", "r755", "r756", "r1084", "r1085", "r1086", "r1096", "r1097", "r1098", "r1100" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r2", "r10", "r17", "r95", "r96", "r206", "r207", "r603", "r604", "r605", "r606", "r607", "r1084" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r380", "r381", "r382", "r384", "r895" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1013" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in-capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r86", "r951", "r1250" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r774", "r1096", "r1097", "r1098", "r1100", "r1178", "r1252" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1026" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1026" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1026" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1026" ] }, "us-gaap_AdjustmentForAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortizationAbstract", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization [Abstract]", "label": "Amortization [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r47", "r48", "r468" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1059" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r985", "r995", "r1005", "r1037" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r988", "r998", "r1008", "r1040" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1060" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1026" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1033" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1033", "r1041", "r1045", "r1053" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Segment", "label": "Other Operating Segment [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r264", "r284", "r285", "r286", "r287", "r288", "r291", "r915", "r916" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1051" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r190", "r301", "r350", "r353", "r354", "r1215" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r190", "r301", "r350" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1134" ] }, "us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForLoanAndLeaseLossesWriteOffs", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance for Loan and Lease Losses, Write-offs", "label": "Allowance for Loan and Lease Losses, Writeoff", "documentation": "Amount of loans and leases that have been written off from both loan receivables and allowance reserve for credit loss." } } }, "auth_ref": [ "r155" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AmericasMember", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Americas [Member]", "label": "Americas [Member]" } } }, "auth_ref": [ "r1254", "r1255", "r1256", "r1257" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r379", "r386", "r923" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r255" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific [Member]", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1254", "r1255", "r1256", "r1257" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r380", "r381", "r382", "r383", "r384", "r1172" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition, Consideration Transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r937", "r1173", "r1174", "r1175" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r380", "r381", "r382", "r383", "r384", "r1172" ] }, "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer." } } }, "auth_ref": [] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed Securities [Member]", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r931", "r952", "r1120", "r1126", "r1127" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r140", "r153", "r183", "r222", "r259", "r267", "r286", "r290", "r339", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r545", "r547", "r595", "r722", "r818", "r915", "r916", "r951", "r976", "r1165", "r1166", "r1204" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r176", "r194", "r222", "r339", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r545", "r547", "r595", "r951", "r1165", "r1166", "r1204" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets, Fair Value Disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r573", "r574", "r938" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r308" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r309" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortized Cost", "totalLabel": "Total Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r305", "r358", "r720" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in more than five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1123" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in more than five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r314", "r716" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in one to five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1122" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in one to five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r313", "r715" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in less than one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1121" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in less than one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r312", "r714" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale", "totalLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r306", "r358", "r573", "r708", "r938", "r942", "r1111", "r1182", "r1183", "r1184" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1048" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1049" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1044" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1044" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1044" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1044" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1044" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1044" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1047" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1046" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1045" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1045" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r395", "r1217", "r1218" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r59", "r62", "r395", "r1217", "r1218" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Related Disclosures [Abstract]", "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time Deposits [Member]", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r149" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r539", "r1089" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r53", "r135", "r538", "r575", "r576", "r577" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r178", "r899" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r178" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1180", "r1181" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Cash, Cash Equivalents, and Restricted Cash", "periodEndLabel": "Ending Cash, Cash Equivalents, and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r117", "r221" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r117" ] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents [Member]", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r178" ] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r111" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1024" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1021" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1019" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r167", "r186", "r187", "r188", "r222", "r246", "r250", "r252", "r254", "r261", "r262", "r339", "r411", "r414", "r415", "r416", "r420", "r421", "r441", "r442", "r444", "r445", "r447", "r595", "r768", "r769", "r770", "r771", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r806", "r828", "r847", "r876", "r877", "r878", "r879", "r880", "r1063", "r1092", "r1101" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r186", "r187", "r188", "r261", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r768", "r769", "r770", "r771", "r929", "r1063", "r1092" ] }, "bio_ClinicalDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "ClinicalDiagnosticsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Diagnostics", "label": "Clinical Diagnostics [Member]", "documentation": "Clinical Diagnostics [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1025" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1025" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r129", "r410", "r971", "r972", "r973", "r974" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1252" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1252" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r967", "r968", "r969", "r971", "r972", "r973", "r974", "r1096", "r1097", "r1100", "r1178", "r1249", "r1252" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r85", "r806", "r824", "r1252", "r1253" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r85", "r725", "r951" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Voting Rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r40" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1030" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1029" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1031" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1028" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r54", "r137", "r202", "r204", "r209", "r710", "r733" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r94", "r208", "r709", "r731" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r151", "r224", "r259", "r269", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r411", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r915", "r916", "r1165", "r1166" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r151", "r224", "r259", "r269", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r411", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r915", "r916", "r1165", "r1166" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Debt Securities [Member]", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r931", "r933", "r938", "r952", "r965", "r1246" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r101", "r102", "r670" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships [Member]", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r51", "r1148", "r1150", "r1151", "r1152", "r1154", "r1155", "r1157", "r1158" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r75", "r76", "r141", "r143", "r224", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r924", "r925", "r926", "r927", "r928", "r949", "r1093", "r1160", "r1161", "r1162", "r1200", "r1201" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r78", "r423" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r924", "r925", "r926", "r927", "r928", "r949", "r1093", "r1200", "r1201" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r14", "r224", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r924", "r925", "r926", "r927", "r928", "r949", "r1093", "r1160", "r1161", "r1162", "r1200", "r1201" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r14", "r40", "r43", "r71", "r131", "r132", "r224", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r924", "r925", "r926", "r927", "r928", "r949", "r1093", "r1200", "r1201" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r428", "r439", "r609", "r610", "r611", "r925", "r926", "r949" ] }, "us-gaap_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecurities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities", "label": "Debt Securities", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r302", "r718", "r719", "r964", "r966" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1128" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r501", "r502", "r723" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r1081" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Current", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r1080" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r794", "r797", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r819", "r820", "r821", "r822", "r834", "r835", "r836", "r837", "r840", "r841", "r842", "r843", "r863", "r864", "r865", "r866", "r967", "r969", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1192", "r1193" ] }, "us-gaap_DerivativeForwardInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeForwardInterestRate", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Forward Interest Rate", "label": "Derivative, Forward Interest Rate", "documentation": "Stated rate on an interest rate forward or futures contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r60", "r63", "r64", "r138", "r794", "r797", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r819", "r820", "r821", "r822", "r834", "r835", "r836", "r837", "r840", "r841", "r842", "r843", "r863", "r864", "r865", "r866", "r906", "r967", "r969", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1192", "r1193" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1176", "r1177" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r12", "r55", "r56", "r57", "r58", "r61", "r63", "r65", "r66", "r67", "r560" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology Rights [Member]", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r134", "r1148", "r1150", "r1151", "r1152", "r1154", "r1155", "r1157", "r1158" ] }, "bio_DocumentAndEntityInformationParentheticalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "DocumentAndEntityInformationParentheticalAbstract", "lang": { "en-us": { "role": { "terseLabel": "Document and Entity Information (Parenthetical) [Abstract]", "label": "Document and Entity Information (Parenthetical) [Abstract]", "documentation": "Document and Entity Information (Parenthetical) [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r980" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1012" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1023" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per share basic attributable to Bio-Rad", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r210", "r233", "r234", "r235", "r236", "r237", "r238", "r244", "r246", "r252", "r253", "r254", "r258", "r533", "r544", "r570", "r571", "r711", "r734", "r908" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per share diluted attributable to Bio-Rad", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r210", "r233", "r234", "r235", "r236", "r237", "r238", "r246", "r252", "r253", "r254", "r258", "r533", "r544", "r570", "r571", "r711", "r734", "r908" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings per share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r243", "r255", "r256", "r257" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r600" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r504", "r936" ] }, "bio_ElectionPercentageForBoardOfDirectors": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "ElectionPercentageForBoardOfDirectors", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Election Percentage for Board of Directors", "label": "Election Percentage for Board of Directors", "documentation": "Election Percentage for Board of Directors" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r76" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r978" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r978" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r978" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1062" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r978" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r978" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r978" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r978" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1017" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1058" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1058" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1058" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r170", "r205", "r206", "r207", "r225", "r226", "r227", "r230", "r237", "r239", "r241", "r260", "r343", "r349", "r392", "r448", "r514", "r515", "r529", "r530", "r531", "r534", "r543", "r544", "r552", "r554", "r555", "r556", "r557", "r559", "r569", "r601", "r603", "r604", "r605", "r606", "r607", "r613", "r616", "r637", "r731", "r755", "r756", "r757", "r774", "r847" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r259", "r278", "r290", "r338", "r1078", "r1132" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r184", "r594", "r901" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain on Securities", "label": "Equity Securities, FV-NI, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r337" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity Securities, FV-NI, Unrealized Loss", "label": "Equity Securities, FV-NI, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r337" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r336" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1027" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r985", "r995", "r1005", "r1037" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r982", "r992", "r1002", "r1034" ] }, "bio_EscrowReceiptsForPreviousAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "EscrowReceiptsForPreviousAcquisition", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Escrow receipts on prior acquisition", "label": "Escrow Receipts for Previous Acquisition", "documentation": "Escrow Receipts for Previous Acquisition" } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe [Member]", "label": "Europe [Member]" } } }, "auth_ref": [ "r1254", "r1255", "r1256", "r1257" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1033" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r573", "r574", "r584", "r938" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r573", "r574", "r584", "r938" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r938", "r1180", "r1181", "r1192" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r575", "r576", "r942" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r68", "r69" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r430", "r460", "r461", "r462", "r463", "r464", "r465", "r572", "r574", "r575", "r576", "r577", "r583", "r584", "r586", "r641", "r642", "r643", "r925", "r926", "r931", "r932", "r933", "r938", "r942" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value by Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r573", "r574", "r575", "r577", "r938", "r1183", "r1194" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r579", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590", "r706", "r938", "r943" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r430", "r460", "r465", "r574", "r584", "r641", "r931", "r932", "r933", "r938" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r430", "r460", "r465", "r574", "r575", "r584", "r642", "r925", "r926", "r931", "r932", "r933", "r938" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r430", "r460", "r461", "r462", "r463", "r464", "r465", "r574", "r575", "r576", "r577", "r584", "r643", "r925", "r926", "r931", "r932", "r933", "r938", "r942" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r573", "r574", "r575", "r577", "r938", "r1183", "r1194" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r430", "r460", "r461", "r462", "r463", "r464", "r465", "r572", "r574", "r575", "r576", "r577", "r583", "r584", "r586", "r641", "r642", "r643", "r925", "r926", "r931", "r932", "r933", "r938", "r942" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r938", "r1180", "r1181", "r1182", "r1183", "r1184", "r1194" ] }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionChangesInFairValueGainLoss1", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings." } } }, "auth_ref": [ "r70" ] }, "us-gaap_FairValueOptionLoansHeldAsAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionLoansHeldAsAssetsAbstract", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Option, Loans Held as Assets [Abstract]", "label": "Fair Value, Option, Loans Held as Assets [Abstract]" } } }, "auth_ref": [] }, "bio_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "FinanceLeaseCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease Cost", "label": "Finance Lease Cost", "documentation": "Finance Lease Cost" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Interest Expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r619", "r624", "r950" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Interest Payment on Liability", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r621", "r626" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Liability", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r618", "r630" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r618" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r618" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Liability, Payment, Due", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r630" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due after Year Five", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, to be Paid, Year One", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Four", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Three", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Two", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1203" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finance Lease, Liability, Undiscounted Excess Amount", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r630" ] }, "bio_FinanceLeaseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "FinanceLeaseObligationsMember", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Obligations", "label": "Finance Lease Obligations [Member]", "documentation": "Finance Lease Obligations [Member]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Principal Payments", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r620", "r626" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-Of-Use Asset, Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": [ "r1067", "r1068" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r619", "r624", "r950" ] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-Of-Use Asset, before Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r1066" ] }, "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "label": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "documentation": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r629", "r950" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r628", "r950" ] }, "bio_FinanceLeasesandOtherDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "FinanceLeasesandOtherDebtMember", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases and Other Debt", "label": "Finance Leases and Other Debt [Member]", "documentation": "Finance Leases and Other Debt [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r351", "r352", "r355", "r356", "r357", "r359", "r360", "r361", "r438", "r446", "r560", "r591", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r732", "r921", "r938", "r940", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r952", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1128", "r1129", "r1130", "r1131", "r1179", "r1182", "r1183", "r1184", "r1191", "r1194" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r181", "r365", "r385", "r923" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r378", "r380", "r381", "r382", "r384", "r385", "r388", "r389", "r671", "r675", "r895" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Price", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r365", "r385", "r675", "r923" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r378", "r380", "r381", "r382", "r384", "r385", "r388", "r389", "r895" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r671", "r1155" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r671" ] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": [ "r573", "r574" ] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": [ "r573", "r574" ] }, "bio_ForeignCurrencyDerivativeUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "ForeignCurrencyDerivativeUnrealizedGainLoss", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain (Loss) on Derivatives", "label": "Foreign Currency Derivative, Unrealized Gain (Loss)", "documentation": "Foreign Currency Derivative, Unrealized Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange (gains) losses, net", "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r596", "r597", "r598", "r599", "r844" ] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange (gains) losses, net", "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r826", "r975", "r1196", "r1197", "r1251" ] }, "us-gaap_ForeignGovernmentDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Government Debt [Member]", "label": "Foreign Government Debt [Member]", "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity." } } }, "auth_ref": [ "r1113", "r1125" ] }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Government Obligations [Member]", "label": "Debt Security, Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": [ "r952", "r1169", "r1246" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1041" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1041" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1041" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1041" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1041" ] }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "auth_ref": [] }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "documentation": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1022" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, net", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r180", "r366", "r707", "r916", "r922", "r939", "r951", "r1137", "r1144" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Purchased Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1135", "r1147" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Foreign Currency Translation Gain (Loss)", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r373" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill, Gross", "documentation": "Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r368", "r375", "r922" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated impairment loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r368", "r375", "r922" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r922" ] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Period Increase (Decrease)", "label": "Goodwill, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r1136" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r99", "r103", "r152", "r222", "r339", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r595", "r910", "r915", "r1102", "r1103", "r1104", "r1105", "r1106", "r1165" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "In Process Research and Development [Member]", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1148", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r100", "r147", "r152", "r712", "r729", "r910", "r915", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r152", "r736", "r910", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r393", "r395", "r397", "r578", "r580", "r585", "r750", "r752", "r831", "r895", "r941", "r1219" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r395", "r397", "r578", "r580", "r585", "r750", "r752", "r831", "r895", "r941", "r1219" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r223", "r499", "r504", "r505", "r506", "r507", "r509", "r511", "r519", "r521", "r524", "r525", "r773", "r936" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Provision) benefit for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r159", "r165", "r240", "r241", "r259", "r275", "r290", "r503", "r504", "r520", "r737", "r936" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax payments, net", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r22", "r220", "r512", "r513" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in accounts payable and other current liabilities", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other." } } }, "auth_ref": [ "r1089" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in deferred income taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredLiabilities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of operating lease liabilities", "label": "Increase (Decrease) in Deferred Liabilities", "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r1089" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in other long term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r247", "r248", "r249", "r254", "r469" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r378", "r383", "r387", "r923" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r365", "r387", "r923" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r378", "r383", "r387", "r923" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1033", "r1041", "r1045", "r1053" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1051" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r981", "r1057" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r981", "r1057" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r981", "r1057" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r180" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased intangibles, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r378", "r1155", "r1156" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r259", "r267", "r271", "r277", "r290", "r608", "r915", "r916" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid, net", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r215", "r218", "r219" ] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Receivable, Current", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r362" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r126", "r903" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r191", "r900", "r951" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r126", "r905" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r126", "r904" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest and investment income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r107", "r108" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Owned, Balance, Shares", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r786", "r795", "r852", "r860", "r869", "r969" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r787", "r789", "r790", "r792", "r795", "r850", "r853", "r856", "r859", "r862", "r867", "r871", "r872", "r873", "r874", "r875", "r969" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r787", "r789", "r790", "r792", "r795", "r850", "r853", "r856", "r859", "r862", "r867", "r871", "r872", "r873", "r874", "r875", "r969" ] }, "bio_Investmentownershippercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "Investmentownershippercentage", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Investment ownership percentage", "label": "Investment ownership percentage", "documentation": "Investment ownership percentage" } } }, "auth_ref": [] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "bio_KnowHowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "KnowHowMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Know How [Member]", "label": "Know How [Member]", "documentation": "Know how [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1202" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": [ "http://www.bio-rad.com/role/LegalProceedings" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Proceedings", "label": "Legal Matters and Contingencies [Text Block]", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": [ "r127" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r623", "r631" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r623", "r631" ] }, "bio_LesseeOperatingAndFinanceLeasesRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "LesseeOperatingAndFinanceLeasesRemainingLeaseTerm", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Operating And Finance Leases Remaining Lease Term", "label": "Lessee Operating And Finance Leases Remaining Lease Term", "documentation": "Lessee Operating And Finance Leases Remaining Lease Term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lessee, Operating Lease, Liability, Payments, Due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1203" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r630" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.bio-rad.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r615" ] }, "bio_LesseeSupplementalBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "LesseeSupplementalBalanceSheetInformationTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Supplemental Balance Sheet Information", "label": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "documentation": "Lessee Supplemental Balance Sheet Information [Table Text Block]" } } }, "auth_ref": [] }, "bio_LesseeSupplementalCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "LesseeSupplementalCashFlowInformationTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Supplemental Cash Flow Information", "label": "Lessee Supplemental Cash Flow Information [Table Text Block]", "documentation": "Lessee Supplemental Cash Flow Information [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r75", "r76", "r77", "r80", "r81", "r82", "r83", "r222", "r339", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r546", "r547", "r548", "r595", "r805", "r909", "r976", "r1165", "r1204", "r1205" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r90", "r144", "r728", "r951", "r1094", "r1133", "r1195" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r77", "r177", "r222", "r339", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r546", "r547", "r548", "r595", "r951", "r1165", "r1204", "r1205" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Fair Value Disclosure", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r574", "r1180" ] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements [Member]", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r52", "r498", "r1148", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1171" ] }, "bio_LifeScienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "LifeScienceMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Life Science", "label": "Life Science [Member]", "documentation": "Life Sciences [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r74", "r79" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit, Current", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r75", "r141" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r14", "r143", "r429", "r440", "r925", "r926", "r949", "r1214" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total long-term debt, excluding leases and current maturities", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r1180", "r1182", "r1183", "r1184" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current maturities", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r185" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.bio-rad.com/role/LongTermDebt" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r128" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r179" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r14", "r1160", "r1161", "r1162" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r14", "r37", "r1160", "r1161", "r1162" ] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Marketable Securities, Unrealized (Gain) Loss", "terseLabel": "Marketable Securities, Unrealized Gain (Loss)", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r109" ] }, "us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gains) losses from change in fair market value of equity securities and loan receivable", "label": "Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "documentation": "Amount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI)." } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r285", "r288", "r291", "r915", "r916" ] }, "bio_MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities Of Lease Liabilities For Operating and Finance Leases", "label": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]", "documentation": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r466", "r496", "r577", "r669", "r749", "r751", "r765", "r796", "r797", "r851", "r855", "r857", "r858", "r868", "r893", "r894", "r920", "r929", "r934", "r942", "r943", "r947", "r948", "r961", "r1167", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1025" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1025" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r466", "r496", "r577", "r669", "r749", "r751", "r765", "r796", "r797", "r851", "r855", "r857", "r858", "r868", "r893", "r894", "r920", "r929", "r934", "r942", "r943", "r947", "r961", "r1167", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1044" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1169" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1052" ] }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MunicipalBondsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Municipal Obligations (Member)", "verboseLabel": "Municipal obligations [Member]", "label": "Municipal Bonds [Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1026" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r216" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r216" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "terseLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r117", "r118", "r121" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Bio-Rad", "terseLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r104", "r121", "r148", "r175", "r200", "r203", "r207", "r222", "r229", "r233", "r234", "r235", "r236", "r237", "r240", "r241", "r251", "r339", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r420", "r421", "r533", "r544", "r571", "r595", "r730", "r827", "r845", "r846", "r975", "r1165" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r228", "r229", "r230", "r231", "r232", "r235", "r242", "r258", "r298", "r299", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r391", "r392", "r396", "r514", "r515", "r516", "r517", "r518", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r592", "r593", "r612", "r613", "r614", "r632", "r633", "r634", "r635", "r636", "r637", "r672", "r673", "r674", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r766" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from external customers [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r26", "r168", "r169", "r170", "r171", "r172", "r173", "r228", "r229", "r230", "r231", "r232", "r235", "r242", "r258", "r298", "r299", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r391", "r392", "r396", "r514", "r515", "r516", "r517", "r518", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r540", "r541", "r542", "r543", "r544", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r592", "r593", "r612", "r613", "r614", "r632", "r633", "r634", "r635", "r636", "r637", "r672", "r673", "r674", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r766" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements Issued and to be Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1025" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r989", "r999", "r1009", "r1033", "r1041" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1016" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1015" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1033" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1052" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1052" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sold marketable securities and investments", "label": "Noncash or Part Noncash Acquisition, Accounts Receivable Acquired", "documentation": "The amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncompeteAgreementsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Noncompete Agreements [Member]", "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": [ "r50", "r1148", "r1150", "r1151", "r1152", "r1154", "r1155", "r1157", "r1158" ] }, "us-gaap_NotesAndLoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and notes payable", "label": "Notes and Loans Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r75", "r76" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Segment profit (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r152", "r910", "r1102", "r1103", "r1104", "r1105", "r1106" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r625", "r950" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r618" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r618" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r618" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r622", "r626" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r617" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in the carrying amount of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1090" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r629", "r950" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r628", "r950" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r291", "r915", "r916" ] }, "bio_OrdinaryVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "OrdinaryVotingSharesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary voting shares [Member]", "label": "Ordinary voting shares [Member]", "documentation": "Ordinary voting shares" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Use of Estimates", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r72", "r122", "r123", "r136" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r139", "r182", "r721", "r916", "r976" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r193", "r951" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r3", "r4", "r10", "r97", "r98", "r137" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r206", "r601", "r604", "r607", "r731", "r1084" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r731" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss) net of tax", "terseLabel": "Total other comprehensive income (loss) net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r11", "r13", "r201", "r204", "r208", "r237", "r601", "r602", "r607", "r709", "r731", "r1084", "r1085" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r10", "r137", "r201", "r204", "r237" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r5", "r205", "r208", "r503", "r522", "r523", "r601", "r605", "r607", "r709", "r731" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized holding gains (losses) on available-for-sale investments net of tax expense", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r195", "r198", "r335" ] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r9", "r36", "r105" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNet" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income, Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r1069", "r1170" ] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments [Member]", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r76", "r951" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r81" ] }, "us-gaap_OtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebt", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-term Debt", "label": "Other Long-Term Debt", "documentation": "Amount of long-term debt classified as other." } } }, "auth_ref": [ "r14", "r143", "r1214" ] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Long-Term Debt, Current", "label": "Other Long-Term Debt, Current", "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r75", "r76", "r804" ] }, "bio_OtherLongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "OtherLongTermDebtMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-Term Debt", "label": "Other Long-Term Debt [Member]", "documentation": "Other Long-Term Debt" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Nonoperating (Income)", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r211" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 }, "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/OtherIncomeNetDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r110" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1025" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r987", "r997", "r1007", "r1039" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r990", "r1000", "r1010", "r1042" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r990", "r1000", "r1010", "r1042" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1014" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for purchases of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r115" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r20" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax payments from net share settlement", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r214" ] }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for acquired in-process research and development", "label": "Payments to Acquire in Process Research and Development", "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination." } } }, "auth_ref": [ "r19" ] }, "bio_PaymentsToAcquireInProcessResearchAndDevelopmentOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "PaymentsToAcquireInProcessResearchAndDevelopmentOperatingActivities", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development", "label": "Payments to Acquire in Process Research and Development, Operating Activities", "documentation": "Payments to Acquire in Process Research and Development, Operating Activities" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for purchases of marketable securities and investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r113" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r114" ] }, "us-gaap_PaymentsToSuppliersAndEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToSuppliersAndEmployees", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid to suppliers and employees", "label": "Payments to Suppliers and Employees", "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided." } } }, "auth_ref": [ "r217", "r1087", "r1088" ] }, "bio_Paymentsforproceedsfromderivativeinstrumentsoperatingactivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "Paymentsforproceedsfromderivativeinstrumentsoperatingactivities", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from forward foreign exchange contracts, net", "label": "Payments for (proceeds from) derivative instruments, operating activities", "documentation": "Payments for (proceeds from) derivative instruments, operating activities" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1024" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1024" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1016" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1033" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1026" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1015" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1017" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1061" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1016" ] }, "bio_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "PreferenceSharesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Preference shares [Member]", "label": "Preference shares [Member]", "documentation": "Preference shares" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Par or Stated Value Per Share", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r84", "r441" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r806" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r84", "r441" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Value, Issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r724", "r951" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r192", "r363", "r364", "r902" ] }, "us-gaap_ProceedsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCustomers", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from customers", "label": "Proceeds from Customers", "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services." } } }, "auth_ref": [ "r119" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Issuance of Common Stock", "negatedTerseLabel": "Proceeds from Issuance of Common Stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities and investments", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r212", "r213", "r1112" ] }, "us-gaap_ProceedsFromOtherOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromOtherOperatingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment proceeds and miscellaneous receipts, net", "label": "Proceeds from Other Operating Activities", "documentation": "Amount of cash inflow from operating activities classified as other." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Sale of Debt Securities, Available-for-sale", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r18", "r212", "r303", "r334" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from dispositions of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r112" ] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warranty accrual, beginning of period", "periodEndLabel": "Warranty accrual, end of period", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": [ "r142", "r404", "r406", "r409" ] }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Actual warranty costs", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for warranty", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": [ "r408" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r1068", "r1159" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1014" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1014" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r459", "r466", "r492", "r493", "r494", "r496", "r577", "r644", "r653", "r669", "r749", "r751", "r765", "r796", "r797", "r851", "r855", "r857", "r858", "r868", "r893", "r894", "r920", "r929", "r934", "r942", "r943", "r947", "r948", "r961", "r969", "r1163", "r1167", "r1183", "r1207", "r1208", "r1209", "r1210", "r1211" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r459", "r466", "r492", "r493", "r494", "r496", "r577", "r644", "r653", "r669", "r749", "r751", "r765", "r796", "r797", "r851", "r855", "r857", "r858", "r868", "r893", "r894", "r920", "r929", "r934", "r942", "r943", "r947", "r948", "r961", "r969", "r1163", "r1167", "r1183", "r1207", "r1208", "r1209", "r1210", "r1211" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net realized (gain) loss on investments", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r735" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r206", "r601", "r606", "r607", "r731", "r1084" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r207" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r207" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r207" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r34", "r35" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r34", "r35" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r982", "r992", "r1002", "r1034" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on long-term borrowings", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r116", "r771" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r497", "r895", "r915", "r1212" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r983", "r993", "r1003", "r1035" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r984", "r994", "r1004", "r1036" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r991", "r1001", "r1011", "r1043" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r178" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Current", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1077", "r1091" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Noncurrent", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r160", "r1079", "r1091" ] }, "bio_RestrictedInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "RestrictedInvestmentMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted investment [Member]", "label": "Restricted investment [Member]", "documentation": "Restricted investment" } } }, "auth_ref": [] }, "us-gaap_RestrictedInvestmentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedInvestmentsAtFairValue", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Investments, at Fair Value", "label": "Restricted Investments, at Fair Value", "documentation": "The aggregate value of all restricted investments." } } }, "auth_ref": [ "r854", "r861", "r870", "r882", "r883" ] }, "us-gaap_RestrictedInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedInvestmentsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted investments", "label": "Restricted Investments, Current", "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions." } } }, "auth_ref": [ "r717", "r882", "r883" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "verboseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r87", "r133", "r727", "r759", "r764", "r772", "r807", "r951" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r170", "r225", "r226", "r227", "r230", "r237", "r239", "r241", "r343", "r349", "r392", "r514", "r515", "r529", "r530", "r531", "r534", "r543", "r544", "r552", "r555", "r556", "r559", "r569", "r613", "r616", "r755", "r757", "r774", "r1252" ] }, "bio_RevenueAllocationPercentToLeaseElements": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "RevenueAllocationPercentToLeaseElements", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesDetails", "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Allocation Percent To Lease Elements", "label": "Revenue Allocation Percent To Lease Elements", "documentation": "Revenue Allocation Percent To Lease Elements" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r150", "r151", "r259", "r268", "r269", "r284", "r290", "r293", "r295", "r297", "r457", "r458", "r670" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r166", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r896" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r124" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r627", "r950" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1052" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1052" ] }, "bio_SaberBioAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "SaberBioAcquisitionMember", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Saber Bio Acquisition", "label": "Saber Bio Acquisition [Member]", "documentation": "Saber Bio Acquisition" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r242", "r467", "r1064", "r1099" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r1198", "r1199" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class." } } }, "auth_ref": [ "r380", "r381", "r382", "r384", "r895" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of identifiable purchased intangible assets with definite lives", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r1149", "r1154" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r14", "r40", "r43", "r71", "r131", "r132", "r925", "r927", "r1095", "r1200" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Discussion of current derivative risk management", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r12", "r55", "r56", "r57", "r58", "r61", "r63", "r65", "r66" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r922" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes to goodwill by segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r922", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r15", "r91", "r92", "r93" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of other income (expense), net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Warranty Liability [Table Text Block]", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r38", "r39", "r40", "r41", "r42", "r43", "r130", "r131", "r132", "r133", "r186", "r187", "r188", "r261", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r768", "r769", "r770", "r771", "r929", "r1063", "r1092" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r27" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r977" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r979" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r259", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r297", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r390", "r398", "r399", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r912", "r915", "r916", "r922", "r963", "r1216", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1247", "r1248" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r295", "r296", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r788", "r791", "r793", "r853", "r856", "r862", "r871", "r881", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r897", "r930", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r962", "r969", "r1168", "r1216", "r1220", "r1221", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1247", "r1248" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r153", "r259", "r263", "r264", "r265", "r266", "r267", "r280", "r282", "r283", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r297", "r911", "r913", "r914", "r915", "r917", "r918", "r919" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r106" ] }, "us-gaap_SeniorLongTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorLongTermNotes", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes, Noncurrent", "label": "Senior Notes, Noncurrent", "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": [ "r14", "r951" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsandInvestmentsFairValueofLongTermDebtDetails", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ] }, "bio_ShareBasedPaymentArrangementSharesWithheldForSettlementOfEquityAwardsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "ShareBasedPaymentArrangementSharesWithheldForSettlementOfEquityAwardsAmount", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount", "label": "Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount", "documentation": "Share-Based Payment Arrangement, Shares Withheld for Settlement of Equity Awards, Amount" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r145", "r146", "r1083" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments [Member]", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r873", "r874", "r875", "r898" ] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date." } } }, "auth_ref": [ "r158" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Product Warranty, Policy", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r1164" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r174", "r259", "r264", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r297", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r390", "r394", "r398", "r399", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r912", "r915", "r916", "r922", "r963", "r1216", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1247", "r1248" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r167", "r186", "r187", "r188", "r222", "r246", "r250", "r252", "r254", "r261", "r262", "r339", "r411", "r414", "r415", "r416", "r420", "r421", "r441", "r442", "r444", "r445", "r447", "r595", "r768", "r769", "r770", "r771", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r806", "r828", "r847", "r876", "r877", "r878", "r879", "r880", "r1063", "r1092", "r1101" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r85", "r88", "r89", "r170", "r205", "r206", "r207", "r225", "r226", "r227", "r230", "r237", "r239", "r241", "r260", "r343", "r349", "r392", "r448", "r514", "r515", "r529", "r530", "r531", "r534", "r543", "r544", "r552", "r554", "r555", "r556", "r557", "r559", "r569", "r601", "r603", "r604", "r605", "r606", "r607", "r613", "r616", "r637", "r731", "r755", "r756", "r757", "r774", "r847" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r295", "r296", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r788", "r791", "r793", "r853", "r856", "r862", "r871", "r881", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r897", "r930", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r962", "r969", "r1168", "r1216", "r1220", "r1221", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1247", "r1248" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r225", "r226", "r227", "r260", "r616", "r670", "r767", "r785", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r819", "r820", "r821", "r822", "r823", "r825", "r829", "r830", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r847", "r970" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Statement, Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r242", "r467", "r1064", "r1065", "r1099" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r225", "r226", "r227", "r260", "r300", "r616", "r670", "r767", "r785", "r798", "r799", "r800", "r801", "r802", "r803", "r806", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r819", "r820", "r821", "r822", "r823", "r825", "r829", "r830", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r847", "r970" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r986", "r996", "r1006", "r1038" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": [ "r11", "r45", "r84", "r85", "r133" ] }, "bio_StockRepurchasedDuringPeriodExciseTaxAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "StockRepurchasedDuringPeriodExciseTaxAmount", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock Repurchased During Period, Excise Tax, Amount", "label": "Stock Repurchased During Period, Excise Tax, Amount", "documentation": "Stock Repurchased During Period, Excise Tax, Amount" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Total Stockholders' Equity", "periodEndLabel": "Total Stockholders' Equity", "terseLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r88", "r89", "r125", "r808", "r824", "r848", "r849", "r951", "r976", "r1094", "r1133", "r1195", "r1252" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events, Policy", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1032" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income and other taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r75", "r76" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1024" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1031" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable and Allowance for Credit Losses", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r154", "r156", "r157", "r1108", "r1109", "r1110" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Trade Names [Member]", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r49", "r1148", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1051" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1053" ] }, "us-gaap_TradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingSecurities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r145", "r184", "r901" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r438", "r446", "r560", "r591", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r732", "r938", "r940", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r952", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1128", "r1129", "r1130", "r1131", "r1179", "r1182", "r1183", "r1184", "r1191", "r1194" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1054" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1055" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1055" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1053" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1053" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1056" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1054" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Common", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r45" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r45" ] }, "us-gaap_TreasuryStockReissuedAtLowerThanRepurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockReissuedAtLowerThanRepurchasePrice", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Reissuance of treasury stock", "label": "Treasury Stock Reissued at Lower than Repurchase Price", "documentation": "In cases when treasury stock is reissued at a price lower than the cost to repurchase, the excess difference between the selling price and cost to repurchase is charged against retained earnings (assuming that all APIC arising from treasury stock transactions has first been exhausted)." } } }, "auth_ref": [ "r11", "r44", "r85", "r133" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r45", "r46", "r85", "r88" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r11", "r45", "r133" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryAndGovernmentMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "US Government Sponsored Agencies [Member]", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r713", "r931", "r952", "r965", "r1246" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US Treasury Securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r907", "r931", "r933", "r938", "r1213" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1050" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r500", "r508", "r935" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r28", "r29", "r30", "r161", "r162", "r163", "r164" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r510" ] }, "bio_ValueAppreciationRightsUnrecognizedUnrealizedAppreciationDepreciationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20240930", "localname": "ValueAppreciationRightsUnrecognizedUnrealizedAppreciationDepreciationNet", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net", "label": "Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net", "documentation": "Sartorius Loan value appreciation rights - Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1020" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r245", "r254" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r244", "r254" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1018" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "30", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-10" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/230/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r959": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r960": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r961": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r962": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r963": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r964": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r965": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r966": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1022": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1023": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1025": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1026": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1027": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1028": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1029": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1030": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1031": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1032": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1033": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1036": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1037": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1040": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1041": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1042": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1043": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1044": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1045": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1046": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1047": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1048": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1049": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1050": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1051": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1052": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1053": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1054": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1055": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1056": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1057": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1058": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1059": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1060": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1061": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1062": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1063": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1064": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1065": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 78 0000012208-24-000063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-24-000063-xbrl.zip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